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INTEGRIN LIGANDS 
1.1 Targeting integrins 
1.1.1 Introduction 
Integrins are the major family of adhesion receptors in the Animalia kingdom. This family 
was first recognized around 25 years ago 1  and since then have become attractive 
pharmacological targets2. In the last decade research focused on the discovery and 
development of integrin antagonists for clinical applications because of their roles in 
pathological conditions.3 A turning point for class-selective or promiscuous integrin inhibitor 
was provided by rational design based on the discovery of the structural basis of the 
integrin-ligand recognition. This aim has been achieved by means of studies on short 
amino acid sequences 4  and crystallographic, electron microscopy, computational 
analysis5 on selected integrin subfamilies. 
Integrins are involved in the regulation of many aspects of cell behavior, 6  in cell 
adhesion to the ECM proteins, they provide anchorage for endothelial cells and they 
make transmembrane connections between the ECM and the cytoskeleton, mediating 
dynamic linkages. In addition, they activate many intracellular signaling pathways. 
Moreover in vertebrates, these proteins play a role in mediating cell-cell adhesion 
processes. Thanks to their involvement in all these functions, integrins are involved both in 
physiological processes and pathological conditions. These receptors and their ligands 
play a key role in pathogenesis of inflammatory diseases, leukocyte traffic, aggregation, 
tumor progression, osteoporosis and macular degeneration. 
 
  
                                                          
1 Hynes, R. O., Cell 1987, 48, 549-554 
2 Millard, M.; Odde, S.; Neamati, N., Theranostics 2011, 1, 154-188 
3 (a) Shimaoka, M.; Springer, T. A., Nature Rev. Drug. Discov. 2003, 2, 703-716; (b) Gottschalk, E.-K.; Kessler, H., Angew. Chem. Int. Ed. 2002, 41, 3767-3774; (c) Miller, W. H.; Keenan, R. M.; Willette, R. N.; Lark, M. W., Drug Discovery Today 2000, 5, 397-408; (d) Ojima, I., Bioorg. Med. Chem. 1995, 3, 337-360 
4 (a) Rouslahti, E., Matrix Biol. 2003, 22, 459-465; (b) For a review on the isoDGR-motif see: Rouslahti, E., Annu. Rev. Cell. Dev. Biol. 1996, 12, 967-715 
5 (a) Xiong, J. P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D. L.; Joachimiak, A.; Goosman, S. L.; Amaout, M. A., Science 2001, 294, 339-345; (b) Xiong, J. P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D. L.; Joachimiak, A.; Goosman, S. L.; Amaout, M. A., Science 2002, 296, 151-155; (c) Chen, W.; Chang, C.; Gilson, M. K., J. Am. Chem. Soc. 2006, 128, 4675-4684; (d) Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H., J. Med. Chem. 2005, 48, 4204-4207; (e) Marinelli, L.; Gottschalk, K.-E.; Meyer, A.; Novellino, E.; Kessler, H., J. Med. Chem. 2004, 47, 4166-4177; (f) Xiao, T.; Tagaki, J.; Coller, B. S.; Wang, J.-H.; Sprinmger T. A., Nature 2004, 432, 59-67; (g) Springer, T. A.; Zhu, J.; Xiao, T., J. Cell. Biol. 2008, 182, 791-800; (h) You, T. J.; Maxwell, D. S.; Kogan, T. P.; Chen, Q.; Li, J.; Kassir, J.; Holland, G. W.; Dixon, R. A. F., Biophys. J. 2002, 82, 447-457 
6 Barczyk, M.; Carracedo, S.; Gullberg, D., Cell Tissue Res. 2010, 339, 269-280 
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1.1.2 Integrins: family, structure, function 
1.1.2.1 Integrins structure and subfamilies 
Integrins are a heterodimeric membrane glycoproteins composed by non-covalently 
associated - and subunits (Figure 1.1). In mammals 18  and 8  subunits, giving rise to 
24 different heterodimers, are present but their diversity varies among species.7  
 
 
Figure 1.1 – Mammalian integrins subunits and their associations 
Selectivity for ECM proteins, cell surface molecules, plasma proteins, or microorganism is 
determined by the combination between the - and the -chain.8 Although some integrins 
recognize primarily a single ECM protein ligand, others can bind several ligands (e.g., V3 
binds vitronectin, fibronectin, fibrinogen, denatured or proteolyzed collagen, and other 
matrix proteins).8b,9 
  
                                                          
7 Hynes, R. O., Cell 2002, 110, 673-687 
8 (a) Loftus, J. C.; Smith, J. W.; Ginsberg, M. H., J.Biol. Chem. 1994, 269, 25235-25238; (b) Plow. E. F.; Haas, T. A.; Zhang, L.; Loftus, J. C.; Smith, J. W., J. Biol. Chem. 2000, 275, 21785-21788; (c) Van der Flier, A.; Sonnenberg, A., Cell. Tissue Res. 2001, 305, 285-298 
9 (a) Humphries, J. D.; Byron, A.; Humphries, M. J., J. Cell Sci. 2006, 119, 3901-3903; (b) Pankov, R.; Yamada, K. M., J. Cell Sci. 2002, 115, 3861-3863  
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Each subunit consists of an extracellular domain, a single transmembrane region and a 
short (30-40 amino acids) cytoplasmic region (Figure 1.2, V3 integrin). The N-terminus of 
the -subunit consists of a -propeller, which is a domain made of seven repeated 
sequences of 60 amino acids each.10 Between the Thigh and Calf-1 domains is present a 
highly flexible region. In addition, in half of the -subunits the I-domain, 200 additional 
amino acids, is inserted between the second and third repeated sequences in the -
propeller.11 In integrins with an I-domain, this region is a major binding-site for ligands 
whereas in all the other integrins the -propeller is the binding-site.12 Cytoplasmic tail 
domains of individual -subunits are well-conserved across species boundaries. 13  This 
subunit has also a flexible “knee” region, formed by the hybrid domain and the first EGF-
like repeats.12 In the  subunit the N-terminus region consist of a Cys-rich region 
(plexinsemaphorin-integrin domain). This domain has a C-terminus evolutionary conserved 
I-like domain flanked on either side by hybrid domains (immunogloblulin folds). These 
cytoplasmic tails in the -chain play key roles in regulating integrin activity.5b A metal ion-
dependent adhesion site (MIDAS), which is important in the ligand-protein interaction14, is 
present across their extracellular / subunits interface. 
 
Figure 1.2 – V3 integrin structure 
 
  
                                                          
10 Springer, T. A., Proc. Natl. Acad. Sci. USA 1997, 94, 65-72 
11 Humphries, M. J., Biochem. Soc. Trans. 2000, 28, 311-339 
12 Shimaoka, M; Takagi, J; Springer A. T., Annu. Rev. Biophys. Biomol. Struct. 2002, 31, 485-516 
13 Fagerholm, S. C.; Hilden, T. J.; Gahmberg, C. G., Trends Biochem. Sci. 2004, 29, 504-512 
14 Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W., J. Biol. Chem. 2000, 275, 21785-21788 
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1.1.2.2 Integrins action mechanism 
Integrins are not constitutively active15 and their activation status is regulated by a 
delicate balance. The interaction between integrins and ligands is regulated by 
conformational changes. 16  Signal transfer is allosterically coupled to three major 
equilibrium conformational states, including the 1) inactive bent state, 2) intermediate 
extended state with a closed headpiece, and 3) active extended form with an open 
headpiece. 17  Recognition ligand-integrin, and consequently integrin activation, is 
mediated by peptidic sequences contained in the ligands. Many integrins recognize the 
RDG sequence (Aspartic acid, Glycine, Arginine) in their endogenous or exogenous 
ligands. (while other integrins recognize alternative short peptide sequences). 
 
Figure 1.3 - Representation of integrin activation states 
Integrins are defined bidirectional receptor because they mediate both the outside-in 
signaling and the inside-out signaling17 to promote cell adhesion, motility, and migration. 
As a consequence, their activation status is regulated both by extra- and intra-cellular 
stimuli (Figure 1.3).7,16a Extracellular factors that influence integrin activation are ligand 
binding, divalent cation concentration (since integrins bind to their ligands in a divalent 
cation-dependent manner18), chemokine signaling, and mechanical stress. When a signal 
is transmitted to the cell interior, the organization of the cytoskeleton is regulated, kinase 
signaling cascades are activated, and the cell cycle and gene expression are modulated. 
The out-in signaling, following ligand binding, and the consequent switch from the inactive 
to active state is accompanied by an outwards movement of the -hybrid domain, 
characterized by a swing-out angle varying between 10° and 80°.19 In the inside-out 
signaling, intracellular events alter the tertiary and quaternary structure of the extracellular 
region, making the integrin ligand-competent. 
  
                                                          
15 Moser, M.; Legate, K. R.; Zent, R.; Fässler, R., Science 2009, 324, 895-899 
16 (a) Arnaout, M. A.; Mahalingam, B.; Xiong, J. P., Annu. Rev. Cell Dev. Biol. 2005, 21, 381-410; (b) Luo, B. H.; Carman, C. V.; Springer, T. A., Annu. Rev. Immunol. 2007, 25, 619-647 
17 For a review see: Asakai, J. A.; Buckley, P. A.; Mould, A. P.; Humphries, M. J., J. Cell. Sci. 2009, 122, 165-170 
18 (a) Smith, J. W.; Piotrowicz, R. S.; Mathis, D., J. Biol. Chem. 1994, 269, 960-967; (b) Mould, A. P.; Akiyama, S. K.; Humphries, M. J., J. Biol. Chem. 1995, 270, 26270-26277 
19 (a) Puklin-Faucher, E.; Gao, M.; Schulten, K.; Vogel, V., J. Cell Biol. 2006, 175, 349-360; (b) Puklin-Faucher, E.; Vogel, V., J. Biol. Chem. 2009, 284, 36557-36568; (c) Provasi, D.; Murcia, M.; Coller, B. S.; Filizola, M., Proteins Struct. Funct. Genet. 2009, 77, 477-489 
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There is a strong similarity between many integrins stimulated pathways and those 
triggered by growth factors. Moreover, there is a significant cross-talk in the regulation of 
angiogenesis between integrin operated pathways and growth factors operated 
pathways (e.g.: VEGF route20). In adhesion dependent cells, an ECM privation results in 
anoikis and apoptotic cell death5f,21 because the signal generated from focal adhesions 
have been shown to promote cell survival, differentiation, and proliferation (Figure 1.4).22  
 
Figure 1.4 – Integrin signaling 
Integrins behave as mechanochemical transducers. For the whole receptor family 
(except for 64), the linkage is to the actin-based microfilament system. 
Since these receptors serve as a site for docking of various kinases and related adaptor 
proteins, among which focal adhesions, integrin ligation is essential to block apoptosis (via 
PI3-kinase and Akt) and to stimulate cell cycle progression (e.g., via ERK and cyclin D) in 
normal cells.7 As a consequence, prolonged integrin inhibition prevents cells from survival. 
So pharmacological inhibition of integrin ligation is of great interest for the therapy of 
numerous diseases resulting from aberrant integrin mediated signaling. 
  
                                                          
20 Reynolds, A. R.; Hart, I. R.; Watson, A. R.; Welti, J. C.; Silva, R. G.; Robinson, S. D.; Da Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M. C.; Jones, D. T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F. J. C.; Tucker, G. C.; Hodivala-Dilke, K. M., Nat. Med. 2009, 15, 392-400 
21 Desgrosellier, J.; Cheresh, D., Nat. Rev. Cancer. 2010, 10, 9-22 
22 Legate, K.; Wickström, S.; Fässler, R., Genes Dev. 2009, 23, 397-418 
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1.1.2.3 Integrins functions 
As mentioned before, integrins are involved in a number of physiological and 
pathological situations (Table 1.1)23.  
Integrin class Clinically target in Main ligands* 
4-Family 
41 MS, autoimmune, Chron’s, IBD VCAM-1, FN 
47 MS, autoimmune, Chron’s, arthritis Mad-CAM-1 
91 Cancer VCAM-1, Opn, VEGF-C, D 
Leukocyte cell adhesion 
L2 Inflammation, psorisasis, stroke, ischemia, fibrosis ICAM-1, -2, -3 
M2 Inflammation, autoimmune iC3b, Fbg 
X2 Inflammation iC3b, Fbg 
D2 Inflammation ICAM-3, VCAM-1 
E7 Inflammation E-cadherin 
RGD-binding 
gpIIbIIIa Thrombosis, stroke, myocardial ischemia Fbg, vWf 
51 Cancer, AMD FN 
81 None Npn, FN, VN 
V1 Cancer VN, FN 
V3 Cancer, osteoporosis VN, Opn, vWf, FN, Fbg** 
V5 Cancer VN 
V6 Fibrosis, transplant rejection, cancer FN, TGF-b1, -3 
V8 Cancer FN, TGF-b1, -3 
I domain: collagen binding 
11 Fibrosis, cancer Col 
21 Fibrosis, cancer Col 
11, 111 None Col 
LN binding 
31 None LN-5 
61, 71 None LN-1, -2 
64 None LN-2, -4, -5 
Table 1.1 – Integrin subfamilies cluster major therapeutic indications and main ligands (* = see the list of abbreviations for acronyms; ** = among many other ligands) 
As an example, the growth of new blood vessels (angiogenesis) from pre-existing 
vasculature promotes embryonic development, wound healing, the female reproductive 
cycle but it has also a key role in various pathological events such as development of solid 
tumor cancers, hemangiomas, diabetic retinopathy, age-related macular degeneration, 
psoriasis, gingivitis rheumatoid arthritis, and possibly osteoarthritis and inflammatory bowel 
                                                          
23 Teicher, B. A.; Ellis, L. M.; Eds., Antiangiogenic Agents in Cancer Therapy, HumanPress, 2008, 3, 49-71 
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disease.24 A deep analysis of all these different profiles is beyond the scope of this thesis 
and only the aspects concerning tumor growth and metastasis spreading will be taken 
into consideration. As previously mentioned, VEGF is a growth factor that induces blood 
vessel growth and it is strictly connected with integrins. Angiogenesis is known to play a 
major role in tumor growth and so inhibiting angiogenesis can inhibit tumor progression 
and metastasis. 
 
Figure 1.5 – Angiogenesis promoted by secreted growth factors and chemokines 
A second key factor for tumor growth and metastasis spreading is adhesion to the ECM. 
As a matter of fact, formation of new vasculature requires endothelial cell attachment 
and migration on ECM proteins. Among all the ECM proteins, fibronectin in particular is 
associated with proliferation.25 As already explained, integrins are critical for the cell to 
bind ECM and in regulating vascular growth. Since proliferating endothelial cells 
overexpress integrins that are not expressed in quiescent vessels (e.g., V326) a selective 
inhibition of these ones is interesting from a therapeutical point of view. Antibody or 
peptide antagonists of V3 were proved to block angiogenesis and tumor growth in 
animal models and to stimulate tumor regression related to apoptosis.27  
Also 51 integrins are up-regulated in tumor angiogenesis (mice and humans) but not 
in quiescent endothelium. Also in this case, tumor regression23 in chicks and mice is 
induced by 51-antagonist (through the activation of protein kinase A and caspase-8) as 
a consequence of angiogenesis inhibition and induced apoptosis.28 These antagonists 
suppress signal transduction for cell survival, cell migration on vitronectin, but not 
attachment to vitronectin. These data show a dependence of the migration process and 
cell survival from 51-antagonists but not a relation to integrin receptors for vitronectin.23,28 
                                                          
24 Carmeliet, P., Nat. Med. 2003, 9, 653-660 
25 Kim, S.; Bell, K.; Mousa, S. A.; Varner, J. A., Am. J. Pathol. 2000, 156, 1345-1362 
26 Brooks, P.C.; Clark, R. A.; Cheresh, D. A., Cell, 1994, 270, 1500-1502 
27 Brooks, P.C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A., Cell, 1994, 270, 1500-1502 
28 Kim, S; Bakre, M.; Yin, H.; Varner, J. A., J. Clin. Invest. 2002, 110, 933-941 
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The 3D structure of the ligand-binding site of 51 complexed with fibronectin was 
determined.29 Integrins V5 are closely related to V3 for what concern the structure. 
Differences were found in the 3 subunit (residues 159-188) and explains why a few V3 
inhibitor display selectivity over V55e, 30  but specific inhibitors of V3 have not been 
described yet. 
 
1.1.2.4 RGD recognition motif 
The RGD sequence (Figure 1.6) is a tripeptide sequence composed by Aspartic acid, 
Glycine and Arginine identified as the endogenous recognition motif for cell attachment 
to proteins. This recognition motif was discovered in fibronectin in 1984.31 Among the large 
amounts of recognized proteins, such as fibrinogen, vitronectin, and thrombospondin, it 
recognizes and binds numerous integrin subfamilies.31 
 
Figure 1.6 – The RGD sequence 
Naturally RGD-ligands have a varied selectivity and potency in targeting RGD-
recognized integrins. The structure of these compounds was analyzed and it seems that in 
order to inhibit integrins, a proper restriction of the RGD flexibility is required.32 In the ligand 
recognition the RGD sequence is primary involved while the flanking residues are 
important for the selectivity.8a,b The binding mode of RGD sequence to integrins was 
deeply studied (Figure 1.7), thanks to the crystal structure of extracellular segment of the 
V3 complexed with the cyclic pentapeptide Cyclo[N-MeVal-D-Phe-Arg-Gly-Asp] 
(Cilengitide) (Figure 1.8). 33  The analysis revealed for this compound a conformation 
featuring an inverse -turn centered on Asp and an ectodomain receptor conformations 
of a distorted II’-turn with Gly and Asp at the i+1 and i+2 positions respectively. The 
measured distance C(Arg)-C(Asp) was around 8.9 Å, that accounts for an almost 
extended RGD sequence conformation. 
                                                          
29 Takagi, J.; Strokovich, K.; Springer, T. A.; Waltz, T., EMBO J. 2003, 22, 4607-4615 
30 Meyer, A.; Auernheimer, J.; Modlinger, A.; Hessler, H., Curr. Pharm. Des. 2006, 12, 2723-2747 
31 Pierschbacher, M. D.; Ruoslahti, E., Nature 1984, 309, 30-33 
32 (a) Swenson, S.; Ramu, S.; Markland, F. S., Curr. Pharm. Des. 2007, 13, 2860-2871; (b) Calvete, J. J.; Marcinkiewicz, C.; Monleόn, D.; Esteve, V.; Celda, B.; Juárez, P.; Sanz, L., Toxicon 2005, 45, 1063-1074; (c) Fujii, Y.; Okuda, D.; Fujimoto, Z., J. Mol. Biol. 2003, 332, 1115-1122; (d) Gould, R. J.; Polokoff, M. A.; Friedman, P. A.; Huang, T. F.; Holt, J. C.; Cook, J. J.; Niewiarowski, S., Proc. Soc. Exp. Biol. Med. 1990, 195, 168-171 
33 Xiong, P. J.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M; Goodman, S. L.; Arnaout, M. A., Science 2002, 296, 151-155 
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The main interactions involve the guanidinium group of the 
with the Asp218 and Asp150
carboxylic group of the Asp 
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NGR (Asn-Gly-Arg) and DGR (Asp-Gly-Arg) motifs, as well as other integrin recognition 
sequences,4b contain Asp or Asn that can spontaneously undergo post-translational 
modifications to form isoAsp (both in vitro and in vivo35). Evidences show the formation of 
this non-standard -amino acid during tissue aging in the ECM and in proteins with a slow 
turn over.35b,36 Even if usually this reaction causes a loss of the protein activity (it might 
cause a change in the charge or the length of the peptide bond), in the case of 
fibronectin a gain of function was observed: the switch creates a new binding-site for 
integrins because the resulting isoDGR motif can mimic RGD and recognize the RGD-
binding site.37 For example, it has been suggested that at the NGR site of FN-I5, a naturally 
occurring reaction leads to the formation of the isoDGR and the DGR, activating a latent 
V3-integrin-binding site. It has also been proposed that the isoAsp formation can provide 
a sort of molecular indicator of protein damage because the switch (which might occur 
faster in proteins that have a lost their structural integrity) is able to activate selective 
degradation mechanisms.35,36,38 
The formation of isoAsp in proteins is obtained by a non-enzymatic Asn deamidation or 
Asp isomerization reactions (Scheme 1.1).37,38b, 39 , 40  Asn deamidation occurs by a 
nucleophilic attack of the backbone NH center at the carbonyl group of Asn side chain, 
which leads to formation of a succinimide ring. The succinimide ring is also the first 
intermediate formed in the Asp isomerization. Both carbonyl groups of the succinimide ring 
are susceptible to hydrolysis, that leads a mixture of Asp and isoAsp residues (ratio of 
approximately 1:3). Racemization and hydrolysis of the succinimide intermediate can also 
lead to the formation of Asp and isoAsp in D-configuration. However the resulting Asp and 
isoAsp in L-configuration are more relevant because the formation of the D-isomers occur 
with much lower efficiency.39,41 These deamidation and isomerization reactions can take 
hours, days or even years, depending on several factors (the presence of secondary or 
tertiary or quaternary structural elements38b, 42 , the pH, the ionic strength, and the 
temperature38b). For example, NGR deamidation in the FN-I5 fragment is very rapid,37 
probably because a Gly residue follows the Asn, and because of the position of the Asn 
side chain that is favorable to a nucleophilic attack.43 Notably, isoDGR can be converted 
into succinimide intermediate by protein-L-isoAsp-O-methyltransferase (PIMT), which 
catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to the free carboxyl 
                                                          
35 (a) Reissner, K. J.; Aswald, D. W., Cell Mol. Life Sci. 2003, 60, 1281-1295; (b) Weber, D. J.; McFadden, P. N., J. Protein Chem. 1997, 16, 269-281 
36 (a) Lanthier, J.; Desrosiers, R. R., Exp. Cell Res. 2004, 293, 96-105; (b) Linder, H.; Helliger, W., Exp. Gerontol. 2001, 36, 1551-1563; (c) Weber, D. J.; McFadden, P. N., J. Protein Chem. 1997, 16, 269-281 
37 Curnis, F.; Longhi, R.; Crippa, L.; Cattaneo, A.; Dondossola, E.; Bachi, A.; Corti, A., J. Biol. Chem. 2006, 281, 36466-36476 
38 (a) Robinson, N. E.; Robinson, A. B., Proc, Natl. Acad. Sci. USA 2001, 98, 94-949; (b) Weintraub, S. J.; Deverman, B. E., Sci. STKE 2007, 2007, re7 
39 Geiger, T.; Clarke, S., J. Biol. Chem. 1987, 262, 785-794 
40 Takahashi, S.; Leiss, M.; Moser, M.; Ohashi, T.; Kitao, T.; Heckmann, D.; Pfeifer, A.; Kessler, H.; Takagi, J.; Erickson, H. P.; Fässler, R., J. Cell Biol. 2007, 178, 167-178 
41 (a) Stephenson, R. C.; Clarke, S., J. Biol. Chem. 1989, 264, 6164-6170; (b) Tyler-Cross, R.; Schirch, V., J. Biol. Chem. 1991, 266, 22549-22556 
42 (a) Robinson, N. E., Proc. Natl. Acad. Sci. USA 2002, 99, 5283-5288; (b) Robinson, N. E.; Robinson, Z. W.; Robinson, B. R.; Robinson, A. L.; Robinson, J. A.; Robinson, M. L.; Robinson, A. B., J. Pept. Res. 2004, 63, 426-436 
43 Di Matteo, P.; Curnis, F.; Longhi, R.; Colombo, G.; Sacchi, A.; Crippa, L.; Protti, M. P.; Ponzoni, M.; Toma, S.; Corti, A., Mol. Immunol. 2006, 43, 1509-1518 
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group of D-Asp and L-isoAsp residues38a. The resulting methyl ester can then form the cyclic 
succinimide intermediate that could generate the DGR motif, inactivating the isoDGR 
site.40 
 
Scheme 1.1 – Naturally occurring pathways for isoAsp generation 
It has been suggested that both NGR and DGR sequences can function as a latent 
integrin-binding site, that is differentially activated depending on its molecular context and 
conditions, because they can be converted into isoDGR by the isomerization of Asp. As a 
matter of facts, isoDGR containing peptides can recognize only some members of the 
RGD-dependent integrin family, such as V3, V5, V6, V8, and 51.44 The affinity and 
specificity of the interaction depend on the molecular scaffold of isoDGR.44 Also in that 
case, the context (flanking residues and 3D presentation) influences activity and selectivity 
for integrins. A marked loss of binding affinity is caused by the replacement of isoAsp with 
Asp or with D-isoAsp, indicating the highly selective and stereospecific interactions.40,44 
NMR structure analysis of correspondent cyclic isoDGR-, RGD-, DGR-, and NGR- peptides 
showed that isoDGR but not DGR and NGR fit into the RGD-binding pocket interacting 
favorably with integrins (Figure 1.10).34,40 
                                                          
44 Curnis, F.; Cattaneo, A; Longhi, R.; Sacchi, A.; Gasparri, A. M.; Pastorino, F.; Di Matteo, P.; Traversari, C.; Bachi, A.; Ponzoni, M.; Rizzardi, G.-P.; Musco, G., J. Biol. Chem 2010, 285, 9114-9123 
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Figure 1.10 – Model for the interaction of isoDGR and RGD-binding site of V3 integrin 
The isoDGR sequence mimics the RGD sequence and it docks in the RGD integrin 
binding-site in an inverted orientation with respect to the RGD sequence, thus allowing the 
formation of the classic electrostatic clamp as for the RGD motif.45 The binding mode to 
the integrin pocket of V3 is maintained: the acid and basic residues are at the correct 
distance and orientation to generate stabilizing interactions with the polar region of 
integrins. Also for the isoDGR sequence, the isoAsp carboxylic side chain interacts with 
MIDAS, Asn215, Tyr122, and Arg214 while the guanidinium group of the Arg interacts with 
Asp218, Asp150, and Gln180. Further stabilizing interactions are present and involve the Gly 
residue: it recognizes the receptor via polar interactions and, thanks to its amide group, 
forms an H-bond with the carbonyl of Arg216. 
Although isoDGR and RGD-containing ligands share the same integrin binding-site, they 
might act in different ways on integrins because RGD-ligands and isoDGR ligands could 
activate different conformational changes (regulating integrin activation).46 Even if the 
binding affinity of the two classes of ligands is similar, the kinetic data of binding might 
differ. Since this is an important parameter for biological properties, kinetics analysis are 
needed to define the extent to which isoDGR differs from or mimics RGD.46 For instance, 
the MolMed group discovered that the isoDGR ligand CisoDGRC can block the integrin in 
the bent, inactive conformation acting as a true antagonist.47 
  
                                                          
45 Spitalieri, A.; Mari, S.; Curnis, F.; Traversari, C.; Longhi, R.; Bordignon, C.; Corti, A.; Rizzardi, G.-P.; Musco, G., J. Biol. Chem. 2008, 283, 19757-19768 46 Corti, A., Curnis, F.; J. Cell Sci. 2011, 124, 515-522 
47 Ghitti, M.; Spitalieri, A.; Valentinis, B.; Mari, S.; Asperti, C.; Traversari, C.; Rizzardi, G.-P.; Musco, G., Angew. Chem. Int. Ed. 2012, 51, 7702-7705 
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1.2 RGD- and isoDGR-integrin ligands 
Nowadays, many linear or cyclic peptidic and peptidomimetic integrin ligands have 
been developed and a few potent compounds are in different phases of clinical trials as 
anticancer drugs or in clinical use for antithrombotic therapy.48 
 
1.2.1 RGD-integrin ligands 
1.2.1.1 Linear RGD-integrin ligands 
Examples of linear RGD-containing integrin ligands are present in the literature. 49 
However they have shown lower activity than the correspondent cyclic derivatives.49 This 
low activity is probably due to the reduced rigidity (since the RGD sequence requires a 
proper conformation to interact optimally with the receptor) and also to an increase of 
the degradation compared to cyclic correspondent ligands.50 In fact it is know in the 
literature that cyclization increases stability towards in vivo enzymatic peptide 
degradation. 51  In addition, the Asp residue, known to be susceptible to chemical 
degradation, in the linear derivative is less protected.52 
 
1.2.1.2 Cyclic RGD-integrin ligands 
Many cyclic peptides and peptidomimetics RGD-containing integrin ligands have been 
developed. In these compounds different flanking residues are present and they are 
characterized by different 3D presentation of the RGD sequence.48c Semipeptidic V3 
inhibitors, bearing a non-peptidic and rigid turn-inducing scaffold to appropriately 
constrain the RGD motif, and various peptides are validating their use as preferred 
conformation-inducing scaffolds.53 
In 1991, Kessler and co-workers identified RGD-based cyclic peptide, c(RGDfV) (Figure 
1.11), an early example of V3 integrin ligands (V3 IC50 = 3.2 ± 1.3 nM, value calculated 
as the concentration required for 50% inhibition of biotinylated vitronectin binding as 
estimated by GraphPad Prism software).54 This derivative targets selectively V3 integrins 
                                                          
48 (a) Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A., Nat. Rev. Cancer 2008, 8,604–617; (b) D’Andrea, L. D.; Del Gatto, A.; Pedone, C.; Benedetti, E., Chem. Biol. Drug Des. 2006, 67, 115–126; (c) Auzzas, L.; Zanardi, F.; Battistini, L.; Burreddu, P.; Carta, P.; Rassu, G.; Curti, C.; Casiraghi, G., Curr. Med. Chem. 2010, 17, 1255–1299 
49 Samenen, J.; Ali, F.; Romoff, T.; Calvo, R.; Sorenson, E.; Vasko, J.; Storer, B.; Berry, D.; Bennett, D.; Strohsacker, M.; Powers, D.; Stadel, J.; Nichols, A., Bioorg. Med. Chem. 2014, 14, 4158-4181 
50 Bogdanowich-Knipp, S. J.; Chakrabarti, S.; Williams, T. D.; Dillman, R. K.; Siahaan, T. J., J. Peptide Res. 1999, 53, 530-541 
51 (a) Hruby, V. J., Life Sci. 1982, 31, 189-199; (b) Cody, W. L.; Mahoney, M.; Knittel, J. J.; Hruby, V.J.; Castrucci, A. M. De L.; Hadley, M. E., J Med. Chem. 1985, 28, 583-588; (c) Hruby, V. J., Epilepsia 1989, S42-S50; (d) Hadley, M. E.; Marwan, M. M.; Hruby, F.; Castrucci, A. M., Pigment Cell Res. 1989, 2, 478-484 
52 (a) Clarke, S., Int. J. Peptide Protein Res. 1987, 30, 808-821; (b) Geiger, T.; Clarke, S., J. Biol. Chem. 1987, 262, 785-794; (c) Manning, M.C.; Patel, K; Borchardt, R. T., Pharm. Res. 1989, 6, 903-918 
53 (a) Hanessian, S.; Auzzas, L., Acc. Chem. Res. 2008, 41, 1241-1251; (b) Trabocchi, A.; Scarpi, D.; Guarna, A., Amino Acids 2008, 34, 1-24; (c) Cowell, S. M.; Lee, Y. S.; Cain, J. P.; Hruby, V. J., Curr. Med. Chem. 2004, 11, 2785-2798 
54 Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H., FEBS Lett. 1991, 291, 50-54 
 Page 16    
and is commercially available thus providing an useful reference standard compound. 
Later, the same group developed a potent V3 RGD-containing integrin ligand (the N-
methylated derivative) named Cilengitide (EMD121974, Figure 1.8)3b,55. This ligand opened 
the era of investigation of integrin inhibitor as anticancer and antiangiogenic agents. 
 
Figure 1.11 – c(RGDfV) integrin ligand  
In Kessler’s research group also azabicycloalkane and spyrocyclic systems, traditionally 
known as -inducers, were to be inserted into RGD cyclic peptidomimetics were 
developed.56 The most active and less constrained compound of the series was a fully 
promiscuous antagonist (Figure 1.12) with IC50 43 nM on V3 and 550 nM on IIb3. 
 
Figure 1.12 – Kessler’s RGD- azabicycloalkane ligand  
Kessler inserted also an amino pyrrolidinone-based scaffold in a RGD cyclic 
peptidomimetics (Figure 1.13).56 Both these derivatives showed a nanomolar affinity for 
V3 integrins, but the most active (a) was also the less selective towards IIb3 integrins 
while ligand b was more selective but with higher IC50. The main difference between the 
two ligands is the orientation of the lactam bond that is rotated by 180° in the two isomers. 
This amide bond was proved to be involved in an H-bond with the receptor. As a 
consequence the interaction is different in the two cases. 
 
Figure 1.13 – Kessler’s RGD- azabicycloalkane ligand 
                                                          
55 (a) Schaffner, P.; Dard, M. M., Cell. Mol. Life Sci. 2003, 60, 119.132; (b) Dechantsreiter, M.; Planker, E.; Mathä, B.; Lohof, E.; Hӧlzelmann, G.; Jonczyk, A.; 
Goodman, S. L.; Kessler, H., J. Med. Chem. 1999, 42, 3033-3040 
56 Haubner, R.; Schmitt, W.; Hӧlzemann, G.; Goodmann, S. L.; Jonczyk, A.; Kessler, H., J. Am. Chem. Soc. 1996, 118, 7881-7891 
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Kessler and Overhand have inserted pyranoid and furanoid sugars as scaffolds in the - 
and -amino acid-based cyclic compounds (representative members of the class are 
shown in Figure 1.14).57 These molecules have a high flexibility which cancel selectivity 
towards the different integrin subfamilies (Pyranoid-derivative: V3 25 nM, V5 >104, IIb3 
13.4 nM; furanoid-derivative: V3 1.4 M, V5 0.38 M), as confirmed by conformational 
analysis. 
 
Figure 1.14 – Pyranoid and furanoid RGD-peptidomimetics 
In a similar approach, Casiraghi and coworkers synthesized -amino acid, generating 
four stereoisomeric 14-membered macrocycles (representative members of the family are 
depicted in Figure 1.15).58 The activity was slightly improved compared to the previous 
sugar derivatives (V3 IC50: a = 5.6 ± 0.1 nM, b = 7.2 ± 0.07 nM and V5 IC50: a = 4.56 ± 0.13 
nM, b = 13.1 ± 0.05 nM). In these ligands the distance C(Asp)-C(Arg) is in the range of 8.0-
8.4 Å. The conformation, according to NMR, is a -turn centered on the Asp residue. 
Analogue c was the best candidate (IC50 = 1.5 nM vs V3 and 0.59 nM vs V5). 
 
Figure 1.15 – Casiraghi’s compounds 
The same research group used the 4-amino proline (Amp) as scaffold in cyclic RGD 
peptidomimetics (Figure 1.16).59 All the synthesized compounds displayed a really high 
affinity towards V3 and V5 integrins (nanomolar values and picomolar values in the high 
affinity status of the integrin). In all the cyclic derivatives the C(Asp)-C(Arg) distance was 
measured with values in the range of 7.8-8.2 Å. All the key interactions were maintained in 
the most active analogues and if R is an hydrogen, a further H-bonding between this NH 
and the Tyr178 is present. On the other hand, alkyl and acyl chains provided additional 
                                                          
57 (a) Van Well, R. M.; Marinelli, M.; Altona, C.; Erkelens, K.; Siegal, G.; Van Raaij, M.; Liamas-Saiz, A. L.; Kessler, H.; Novellino, E.; Lavecchia, A.; Van Boom, J. H.; Overhand, M., J. Am. Chem. Soc. 2003, 125, 10822-10829; (b) Van Well, R. M.; Overkleeft, H. S.; Van der Marel, G. A.; Bruss, D.; Thibault, G.; De Groot, P. G.; Van Boom, J. H.; Overhand, M., Bioorg. Med. Chem. Lett. 2003, 13, 331-334; (c) Lohof, E.; Planker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M. A.; Haubner, R.; Wester, H.-J.; Schwaiger, M.; Hӧlzemann, G.; Goodman, S.L.; Kessler, H., Angew. Chem. Int. Ed. 2000, 39, 2761-2764 
58 Casiraghi, G.; Rassu, G.; Auzzas, L.; Burreddu, P.; Gaetani, E.; Battistini, L.; Zanardi, F.; Curti, C.; Nicastro, G.; Belvisi, L.; Motto, I.; Castorina, M.; Giannini, G.; Pisano, C., J. Med. Chem. 2005, 48, 7675-7687 
59 Zanardi, F.; Burreddu, P.; Rassu, G.; Auzzas, L.; Battistini, L.; Curti, C.; Sartori, A.; Nicastro, G.; Menchi, G.; Cini, N.; Bottoncetti, A.; Raspanti, S.; Casiraghi, G., J. Med. Chem. 2008, 51, 1771-1782 
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contacts in an aromatic rich hydrophobic hollow of the receptor. NMR conformational 
analysis detected a preferred inverse -turn motif centered on Asp for macrocycles 
containing a cis-disposed -amino acid. On the contrary, more flexibility is associated with 
trans--amino acids. 
 
Figure 1.16 – Cyclic RGD containing the Amp scaffold 
Pepidomimetics developed by Sewald, Reiser, and co-workers are very close to this 
class. These 16-membered cyclic peptidomimetics contain a cis--
aminocyclopropanecarboxylic acid as scaffolds, and the RGDV (Arg-Gly-Asp-Val) 
sequence. These compounds will be treated in Chapter 4. 
Guarna and coworkers have replaced the N-Me-Val moiety of Cilengitide with D- and 
L-morpholines (Figure 1.17). 60  Derivative a showed a ten time higher affinity for V5 
integrins (IC50 = 15.1 nM) versus V3 integrins (IC50 = 157 nM), while derivative b has 
nanomolar IC50 values for both the integrin families (32.6 nM for V3 and 21 nM for V5). 
The two cyclic derivatives show distinct structural arrangements because of the D-Phe-
morpholine peptide bond which has different conformations in the two derivatives. 
According to the docking analysis, ligand b has a cis conformation in which the RGD 
sequence adopts an arrangement comparable to the one of the RGD-complexed 
Cilengitide. 
 
Figure 1.17 – Morpholine-based RGD ligands 
The group of Scolastico, synthesized and tested a library of RGD cyclopentapeptides 
incorporating a 5,6- and 5,7-fused azabicycicloalcane amino acid (Figure 1.18).61 The most 
active one, ST1646 (15-membered cycle), has a low nanomolar affinity for V3 and V5 
integrins (3.8 ± 0.9 nM and 1.39 ± 0.2 nM respectively, tested in a solid-phase receptor 
                                                          
60 Sladojevich, F.; Trabocchi, A.; Guarna, A., J. Org. Chem. 2007, 72, 4254-4257 
61 (a) Belvisi, L.; Bernardi, A.; Colombo, M.; Manzoni, L.; Potenza, D.; Scolastico, G.; Giannini, G.; Marcellini, M.; Riccioni, T.; Castorina, M.; LoGiudice, P.; Pisano C., Bioorg. Med. Chem. 2006, 14, 169-180; (b) Manzoni, L.; Belvisi, L.; Arosio, D.; Civera, M.; Pilkington-Miksa, M.; Potenza, D.; Caprini, A.; Araldi, E. M. V.; Monferrini, E.; Mancino, M.; Podestà, F.; Scolastico, C., ChemMedChem 2009, 4, 615-632 
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assay for their ability to compete for the binding of [125I]echistatin to either purified V3 or 
V5) and it is selective towards IIB3 and 51 integrins. In vitro cell tests on this compound 
demonstrated the inhibition of endothelial cells proliferation indicator of an 
antiangiogenic activity.62 Docking studies, showed a -turn conformation centered on the 
Asp residue, maintaining the main contacts already seen in the X-ray for Cilengitide. 
 
Figure 1.18 – Scolastico’s RGD-azabicycloalkane ligands  
Tests performed on these compounds were indicative of a strong dependence of the 
activity on the lactam ring size and on the stereochemistry as these parameters influence 
the overall conformation. Conformational studies performed on the library showed for 
ST1646 a C(Arg)-C(Asp) distance of 8.8 Å and the same interactions found in the 
complexed structure of Cilengitide.63 
Sewald and coworkers examined the application of -amino acids in the design of 
cyclic peptides. The insertion of these amino acids allows the control of the peptide 
backbone conformation such that these non-native building blocks clearly prefer to 
adopt Ψ-turns. Among the various cyclic RGD-containing peptides studied, the 13-
membered derivative depicted in Figure 1.19 resulted a selective V3 nanomolar 
antagonist (IC50 V3 = 63 nM; IC50 IIb3 > 300 nM).64 
 
Figure 1.19 – Sewald’s best ligand  
                                                          
62 Belvisi, L.; Riccioni, T.; Marcellini, M.; Vesci, L.; Chiarucci, I.; Efrati, D.; Potenza, D.; Scolastico, C.; Manzoni, L.; Lombardo, K.; Stasi, M. A.; Orlandi, A.; Ciucci, A.; Nico, B.; Ribatti, D.; Giannini, G.; Presta, M.; Carminati, P.; Pisano, C., Mol. Cancer Ther. 2005, 4, 1670-1680 
63 Arosio, D.; Belvisi, L.; Colombo, L.; Invernizzi, D.; Manzoni, L.; Potenza, D.; Serra, M.; Castorina, M.; Pisano, C.; Scolastico, C., ChemMedChem 2008, 3, 1589-1603 
64 Schumann, F.; Müller, A.; Koksch, M.; Müller, G.; Sewald, N., J. Am. Chem. Soc. 2000, 122, 12009-12010 
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The synthesis of a library of 17-membered ring cyclic peptidomimetics containing a 
diketopiperazine scaffold has already been reported by our research group. 65  These 
compounds will be deeply considered in Chapter 2. 
 
1.2.2 isoDGR-integrin ligands 
A few examples of constrained cyclic peptides or pseudo-peptides containing the 
isoDGR sequence can be found in the literature.66 Early evidences of the interest of this 
family of molecules date back to 2006.37 Corti and co-workers discovered the first ligand of 
the class (Figure 1.20, compound a)34 and then a derivative of this (Figure 1.20, compound 
b) was prepared in the same research group. This second compound showed an 
increased affinity towards the majority of integrins tested.44 However the competitive 
binding test has been performed against a weak V3 ligand and so the data obtained 
cannot be compared to all the previous ones. 
 
Figure 1.20 – Corti’s isoDGR ligands 
A further attempt has been pursued by Kessler’s research group working on the 
retrosequence of c(RGDfV), thus synthesizing for example c(VfisoDGR). Results were not 
significant. A more interesting result was obtained with compounds depicted in Figure 
1.21.66b In these derivatives have been highlighted an interesting selectivity towards 
integrins V3 and IIb3 (a: 51 = 83 nM, V3 = 410 nM; b: 51 = 19 nM, V3 > 103 nM; c: 
51 = 57 nM, V3 = 753 nM; d: 51 = 406 nM, V3 = 89 nM). This example furnished an idea 
of how much the effects of a isoDGR-flanking aromatic moiety is important. However, 
                                                          
65 (a) Resurreiçao, A. S. M.; Vidu, A.; Civera, M.; Belvisi, L.; Potenza, D.; Manzoni, L.; Ongeri, S.; Gennari, C.; Piarulli, U., Chem. Eur. J. 2009, 15, 12184-12188; (b) Marchini, M.; Mingozzi, M.; Colombo, R.; Guzzetti, I.; Belvisi, L.; Vasile, F.; Potenza, D.; Piarulli, U.; Arosio, D.; Gennari, C., Chem. Eur. J. 2012, 18, 6195-6207 
66 (a) Spitaleri, A.; Ghitti, M.; Mari, S.; Alberici, L.; Traversari, C.; Rizzardi, G.-P.; Musco, G., Angew. Chem. Int. Ed. 2011, 50, 1832–1836; (b) Frank, A. O.; Otto, E.; Mas-Moruno, C.; Schiller, H. B.; Marinelli, L.; Cosconati, S.; Bochen, A.; Vossmeyer, D.; Zahn, G.; Stragies, R.; Novellino, E.; Kessler, H., Angew. Chem. Int. Ed. 2010, 49, 9278–9281 
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none of these first isoDGR-containing ligands showed an high affinity for V3 integrins in 
competitive binding assays.66 
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Figure 1.21 – isoDGR ligands 
The synthesis and biological evaluation of cyclic peptidomimetics containing a 
bifunctional diketopiperazine scaffold (DKP2 and DKP3) was already reported by our 
research group 67  and the library was recently extended with two more members 
(containing the DKP5 and DKP7).68 These compounds will be deepened in Chapter 2. 
  
                                                          
67 Mingozzi, M.; Dal Corso, A.; Marchini, M.; Guzzetti, I.; Civera, M.; Piarulli, U.; Arosio, D.; Belvisi, L.; Potenza, D.; Pignataro, L.; Gennari, C., Chem. Eur. J. 2013, 19, 3563–3567 
68 Panzeri, S.; Zanella, S.; Arosio, D.; Vahdati, L.; Dal Corso, A.; Pignataro, L.; Paolillo, M.; Schinelli, S.; Belvisi, L.; Gennari, C.; Piarulli, U., Chem. Eur. J. 2015, 21, 6265 – 6271 
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1.3 RGD- and isoDGR-integrin ligands mode of action 
1.3.1 Receptor pharmacology: general definitions 
Drugs that bind to physiological receptors and mimic the regulatory effects of the 
endogenous signaling compounds are termed agonists. Agents that are only partly as 
effective as agonists no matter the amount employed (even at saturating concentrations) 
are termed partial agonists. Drugs that bind to receptor without regulatory effect but only 
blocking the binding of the endogenous ligand (for example by competition for agonist-
binding site) are called antagonists and those who stabilize the receptor in its inactive 
conformation are termed inverse agonists (Figure 1.22). 69  Inverse agonism may be 
measured only in systems where an equilibrium between the active and inactive receptor 
state in absence of drugs exists, and this is not the case of integrins which are constitutively 
in the inactivated state.15 The whole concept is much more clear as depicted in Figure 
1.22. Named D the studied drug and R the receptor, Ra is the active receptor state, Ri is the 
inactive receptor state and DRa/DRi is the complex ligand-receptor. 
 
Figure 1.22 – Regulation of the activity of a receptor with conformation-selective drugs 
 
1.3.2 Cilengitide  pharmacological activity 
Cilengitide (Figure 1.8) is a 15-membered cyclic RGD-pentapeptide (c-RGD-(D-Phe)-N-
Methyl-Val) developed by Kessler and coworkers3b,55. It is a potent V3/V5 binder (IC50 
V3 = 0.6 nM, IC50 IIb3 = 860 nM). As mentioned before, the crystal structure of this 
compounds complexed with integrins has already been studied.34 The calculated 
distance C(Asp)-C(Arg) is around 9 Å, thus allowing an extended conformation of the 
RGD sequence that guarantee an optimal ligand-receptor interaction. 
                                                          
69 Brunton, L. L.; Lazo, J. S.; Parker, K. L. in “The Pharmacological Basis of Therapeutics – Goodman & Gilman’s” (11th edition), 2006, 23 
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Preclinical models have indicated a synergistic effect in combination with 
radiotherapy70  or with an alkylating agent. For example in a rat xenograft model, it 
potentiated the cytotoxic effects of radiation when the compound was administered prior 
to the radiation therapy (differently from classical radiosensitizers71).69a Cilengitide has 
demonstrated its potential as antiangiogenic agent in cancer therapy in various clinical 
trials (in different clinical phases according to the kind of cancer).72 For example phase I 
and phase II trials of Cilengitide as single-agent in glioblastoma multiforme demonstrated 
little toxicity and promising antitumor activity.73 In a phase I/IIa study, the addition of 
Cilengitide to the standard chemoradiotherapy for newly diagnosed glioblastoma 
multiforme demonstrated to be safe, well tolerated, and to improve progression-free 
survival and overall survival in patients with MGMT promoter methylation (status of the 
gene encoding for the repair enzyme O6-methylguanine-DNA methyltransferase). 74 
However, in a subsequent study, Cilengitide was not proven to alter the tumor 
progression75 and in a phase III clinical trial (CENTRIC) the addition of Cilengitide to the 
standard of care did not improve overall patient survival.76 
Cell studies on Cilengitide are controversial. This RGD-ligand was proven to induce 
anoikis and to inhibit FAK phosphorylation in glioblastoma and endothelial cells in the 
micromolar concentration range (1–80 m).77 On the other hand, the same compound 
showed, at nanomolar concentrations an agonist-like activity and adverse paradoxical 
integrin activation effects.20 Moreover, Cilengitide was shown to promote angiogenesis in 
human umbilical vein endothelial cells (HUVEC) at nanomolar concentrations while, in the 
same cellular model, it was reported to induce FAK phosphorylation at clinically-relevant 
concentration (i.e. 10 m).78 These different data seem to indicate that experimental 
conditions and cellular model affect the activity of Cilengitide. 
This evidenced paradoxical pro-angiogenic activity of RGD-mimetic agents at low 
concentrations have raised concerns about the efficacy of RGD compounds as true 
integrin antagonists and raise questions concerning the use of antiangiogenetic drugs as 
single therapy agent.20,47,79 In summary, one major problem with integrin inhibitors is their 
                                                          
70 (a) Mikkelsen, T; Brodie, C.; Finniss, S.; Berens, M. E.; Rennert, J. L.; Nelson, K.; Lemke, N.; Brown, S. L.; Hahn, D.; Neuteboom, B.; Goodman, S. L., Int. J. Cancer 2009, 124 (11), 2719-2727; (b) MacDonald, T. J.; Taga, T.; Shimada, H., et. al., Neurosurgery, 2001, 48, 151-157 
71 Miller R. A.; Woodburn, K.; Fan, Q.; Renschler, M. F.; Sessler, J. L.; Koutcher, J. A., Int. J. Radiat. Oncol. Biol. Phys. 1999, 45, 981-989 
72 Mas-Moruno, C.; Rechenmacher, F.; Kessler, H., Anti-Cancer Agents Med. Chem. 2010, 10, 753-768 
73 (a) Reardon, D. A.; Fink, K. L.; Mikkelsen, T.; Cloughesy T. F.; O'Neill, A.; Plotkin, S.; Glantz, M.; Ravin, P.; Raizer, J. J.; Rich, K. M.; Schiff., D.; Shapiro, W. R.; Burdette-Radoux, S.; Dropcho, E. J.; Wittemer, S. M.; Nippgen, J.; Picard, M.; Nabors, L. B., J. Clin. Oncol .2008, 26(34), 5610-5617; (b) Gilbert, M.; Lamborn, K.; Lassman, A., et. al, Preliminary data from NABTC protocol 03-02, presented at the 12th Annula Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007 (abstr. MA39); (c) Nabors, L. B.; Mikkelsen, T.; Rosenfeld, S. S., et. al, J. Clin. Oncol. 2007, 25, 1651-1657 
74 Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlege, U.; Clement, P. M. J.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P.-Y.; Pietsch, T.; Hicking, C.; Tonn, J.-C.; Diserens, A.-C-; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M., J. Clin. Oncol. 2010, 28(16), 2712-2718 
75 Eisele, G.; Wick, A.; Eisele, A.-C.; Clément, P.M.; Tonn, J.; Tabatabai, G.; Ochsenbein, A.; Schlegel, U.; Neyns, B.; Krex, D.; Simon, M.; Nikkhah, G.; Picard, M.; Stupp, R.; Wick, W.; Weller, M., J. Neurooncol. 2014, 117(1), 141-145 
76 Merck Group, CENTRIC trials (news release, March, the 24rd 2014) 
77 Oliveira-Ferrer, L.; Hauschild, J.; Fiedler, W.; Bokemeyer, C.; Nippgen, J.; Celik, I.; Schuch, G., J. Exp. Clin. Cancer Res. 2008, 27, 86–99 
78 Alghisi, G. C.; Ponsonnet, L.; Rüegg, C., PLoS ONE 2009, 4, e4449 
79 (a) Weiss, S. M.; Stupack, D. G.; Cheresh, D. A., Cancer Cell 2009, 15, 359-361; (b) Robinson, S. D.; Hodivala-Dilke, K. M., Curr. Opin. Cell Biol. 2011, 23, 630-637 
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potential to activate conformational changes, which can initiate unwanted signals that 
induce agonist-like activities and adverse paradoxical effects.3a,80 
 
1.3.3 isoDGR-integrin ligands act as true integrin antagonists 
In order to design new integrin blockers could be very useful to get information defining 
the receptor allosteric events induced by ligand binding. In this context, Musco and co-
workers exploited a combination of computational (all-atom MD simulations) and 
biochemical studies to describe the dynamic changes of V3 upon ligand binding.47 
Simulations were carried out on the V3 headpiece alone and in the presence of 
cyclopeptidic ligands: RGDf(NMe)V, CisoDGRC, and acCisoDGRC. Collected data showed 
that the three ligands anchor to the V and 3 domains through an electrostatic clamp. 
However, the three interaction patterns are similar but not identical (Figure 1.23).47 In 
particular, a relevant difference was registered in the coordination pattern of the second 
carboxylate oxygen. In the case of isoDGR-containing peptides (CisoDGRC and 
acCisoDGRC) this oxygen interacts with residue N2153, whereas the very same oxygen in 
RGDf(NMe)V stably binds to residues S1213-S1233. These interactions play a crucial role as 
the trigger of the integrins activation mechanism operated by endogenous ligands.81 
Remarkably, these interactions are barely present in the simulations with isoDGR-
containing cyclopeptides.47 
 
Figure 1.23 – Interactions patterns of the ligands tested 
The V3 binding pocket is in grey and the cyclopeptides ligands are depicted in green (blue = nitrogen, red = oxygen, yellow = sulfur). Sticks are used to represent V3 residues (one-letter code) directly coordinating the carboxylate groups of Asp/isoAsp residue of the ligand. MIDAS is represented as a yellow sphere. Dotted lines highlight the different ligand-receptor interaction patterns. 
  
                                                          
80 (a) Cox, D.; Brennan, M.; Moran, N., Nat. Rev. Drug. Discovery 2010, 9, 804-820; (b) Ahrens, I.; Peter, K., Thromb. Haemostasis 2008, 99, 803-804 
81 Zhu, J.; Zhu, J.; Negri, A.; Provasi, D.; Filizola, M.; Coller, B. S.; Springer, T. A., Blood 2010, 116, 5050-5059 
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As presented in paragraph 1.1.2.2 (Integrin action mechanism), the activation of 
integrins involves an outwards movement of the -hybrid domain. None of the movements 
for V3, either free or bound to isoDGR-containing ligands, matches the typical features of 
the swing-out movement. Therefore, it seems that isoDGR-containing cyclopeptides, unlike 
RGDf(NMe)V, do not induce the V3 headpiece-opening.47 
The same research group carried out a further investigation to see whether isoDGR-
containing cyclopeptides could also act as inhibitors of V3 allostery in receptors already 
bound to the cell surface. Receptor activation changes the conformation of the 3 
subunit47 resulting in the exposure of epitopes called ligand-induced binding sites (LIBS). 
These could be specifically recognized by LIBS-specific monoclonal antibodies (such as 
AP5mAb). As expected, only RGDf(NMe)V induces a significant exposure of LIBS on 
HUVEC. In contrast, CisoDGRC and acCisoDGRC fail to induce the exposure of these 
epitopes. All the data collected seem to indicate that isoDGR-containing cyclopeptides 
inhibit integrin activation unlike RGDf(NMe)V, which induces integrin activation.47 
Additional studies on V3-expressing HUVEC were carried out with the aim of 
investigating if the allosteric movement of V3 could influence the pathways usually 
triggered by ligand-induced V3 activation. Once again, the effect of RGDf(NMe)V was 
compared to the effect of isoDGR-containing cyclopeptides. Both acCisoDGR and 
CisoDGRC did not induce accumulation of V3 at the cell border while RGDf(NMe)V 
promoted the redistribution of V3 from focal adhesion to the cell periphery,77 an event 
critical for cell migration82. These data prove that V3 relocalization at the cell edge is 
induced by RGDf(NMe)V (Figure 1.24) and, as a consequence, that this RGD-containing 
ligand stimulates the conversion of an inactive integrin into a multifaceted signaling 
machine causing undesired receptor clustering, activation, and redistribution.47 All these 
experimental evidences support the hypothesis that isoDGR-containing cyclopeptides 
compete with the ligand binding without inducing integrin activation.83 
  
                                                          
82 Kiosses, W. B.; Shattil, S. J.; Pampori, N.; Schwartz, M. A., Nat. Cell Biol. 2001, 3, 316-320 
83 Caswell, P. T.; Vadrevu, S.; Norman, J. C., Nat. Rev. Mol. Cell Biol. 2009, 10, 843-853 
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Figure 1.24 – Localization of V3 integrin (green) and FAK (red) was monitored by immunoflorescence staining 
In this test, HUVEC were plated on fibronectin and treated with saturating amounts of RGDf(NMe)V, CisoDGR, or 
acCisoDGRC. Only RGDf(NMe)V caused disappearance of V3 (stained with focal adhesion kinase antibodies) from focal adhesion and promoted relocalization at the cell periphery. 
Summarizing, Musco and co-workers demonstrated that isoDGR-based cyclopeptides 
unexpectedly inhibit receptor allosteric activation acting as true antagonist of V3 
integrin. The intrinsic ability of the isoDGR motif to block receptor allosteric activation is 
interesting for drug development: isoDGR-based drugs represent promising integrin 
antagonist class, devoid of intrinsic paradoxical activation effects.78 
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DKP-INTEGRIN LIGANDS 
 
2.1 Aim of the project 
The aim of this project was the synthesis of a small collection of Cyclo[DKP-isoDGR] 
peptidomimetics active as integrin ligands. According to the evidences reported in 
Chapter 1.3, the isoDGR library was synthesized to see whether the new compounds 
maintain the affinity and selectivity of the RGD-ligands analogues with the advantage of 
pure antagonist activity on integrins. The synthesis was planned with a mixed solid 
phase/solution phase approach. 
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2.2 2,5-Diketopiprazines as privileged scaffolds 
2.2.1 Introduction 
2,5-Diketopiperazines (DKPs) (Figure 2.1) are biologically active constrained cyclic 
peptides84 with a wide spectrum of properties85 and applications. These compounds are 
six-membered heterocyclic scaffolds that differ for the substitution on up to four positions 
(N1, N4, C3, C6) and for the configuration at the two stereocenters (C3, C6). DKPs are 
formally derived from two -amino acids. 
 
Figure 2.1 – DKP general structure and numbering 
DKPs are characterized by a rigid structure embedding amide groups and, because of 
this, they are poorly soluble in organic solvents. The nitrogen atom of the -amino amide is 
constrained into a ring and therefore the susceptibility to bond cleavage is reduced, the 
physical properties are altered and conformational rigidity is induced. Because of their 
properties, DKPs can be used to circumvent some limitations of peptides.86 In addition, 
interactions with biological targets are supported by the presence of groups acting as 
donors and acceptors of hydrogen bonds. 
DKPs were once believed to be only protein artifacts or degradation products. 
Nowadays they are considered privileged structures87 in medicinal chemistry, in 
heterocyclic diversity-oriented synthesis and in combinatorial biomedical chemistry88, to 
provide high-affinity ligands to specific receptors and for the de novo design of proteins89. 
Moreover they find applications also in organocatalysis: they were used in the 
hydrocyanation of aldehydes,90 imines91 (even if the result in this last case was 
questioned92) and in the addition reaction of several aldehydes to -nitrostyrene and (E)-2-
(furan-2-yl)nitroethene.93 
                                                           
84 (a) Witiak, D. T.; Wei, Y. in: Progress in Drug Discovery (Ed.: E.Jucker, BirkhäuserVerlag: Basel), 1990, 35, 249–363; (b) González, J. F.; Ortín, I.; De la Cuesta, E.; Menéndez, J. C. Chem. Soc. Rev. 2012, 41, 6902-6915; (c) Martins, M. B.; Carvalho, I., Tetrahedron, 2007, 63, 9923-9932; (d) Liebscher, J.; Jin, S., Chem. Soc. Rev. 1999, 28, 251-259 
85 McCleland, K.; Milne, P. J.; Lucieto, F. R.; Frost, C.; Brauns, S. C.; Van De Venter, M.; Du Plessis, J.; Dyason, K. J., Pharm. Pharmacol. 2004, 56, 1143-1153 
86 Borthwick, A. D., Chem. Rev. 2012, 112, 3641-3716 
87 Evans, B. E.; Rittle, K. E.; Bock, M. G.; Di Pardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. G.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J., J. Med. Chem. 1988, 31, 2235–2246 
88 (a) Horton, D. A.; Bourne, G. T.; Smythe, M. L., Mol. Divers. 2000, 5, 289-304; (b) Spatola, A. F.; Romanovskis, P. in “Combinatorial Peptide and Nanopeptide Libraries” (Ed: G. Jung, VHC, Weinheim), 1996, 327-347 
89 Tuchscherer, G.; Mutter, M., J. Biotechnol. 1995, 41, 197-210 
90 (a) Oku, J. I.; Inoue, S., J. Chem. Soc., Chem. Commun. 1981, 229-230; (b) Kogut, E. F.; Thoen, J. C.; Lipton, M. A., J. Org. Chem. 1998, 63, 4604-4610 
91 Iyer, M. S.; Gigstad, K. M.; Namedev, N. D.; Lipton, M., J. Am. Chem. Soc. 1996, 118, 4910-4911 
92 Becker, C; Hoben, C.; Schollmeyer, D.; Scherr, G.; Kunz, H., Eur. J. Org. Chem. 2005, 1497-1499 
93 Durini, M.; Sahr, F. A.; Kuhn, M.; Civera, M.; Gennari, C.; Piarulli, U., Eur. J.Org. Chem. 2011, 20, 5599-5607 
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2.2.2 Applications to medicinal chemistry 
The DKP heterocycle can be found as part of complex molecules in natural 
products84c,94 (fungi95 or bacterial96 origin) or alone. They show various therapeutic 
properties97 and a widespread applications as biologically active compounds. Among all 
these activities, the most important are probably the inhibitor of plasminogen activator 
inhibitor-1 (PAI-1)98, the regulation of the P-glycoprotein activity, and the effects on 
cardiovascular and blood-clotting functions85. DKPs are also antitumor99, antifungal100, 
antibacterial101, antihyperglycaemic102, and antiviral agents103. It is well known their affinity 
for calcium channels and opioid receptors104, as well as for GABAergic105, for 
serotoninergic 5-HT1A106 and oxytocin receptors.107 Several example concerning 
pharmacologically active compounds (both synthetic or natural) containing DKPs can be 
found in the literature. In the following section will be discussed only some examples to 
give an idea of their wide spectrum of applications. 
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99 (a) Kanoh, K.; Kohno, S.; Katada; J., Takahashi, J.; Uno, I., J. Antibiot. 1999, 52, 134-141; (b) Nicholson, B.; Lloyd, G. K.; Miller, B. R.; Palladino, M. A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S. T. C., Anti-Cancer Drugs 2006, 17, 25-31; (c) Kanzaki, H.; Imura, D.; Nitoda, T.; Kawazu, K., J. Biosci. Bioeng. 2000, 90, 86-89 
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2.2.2.1 Examples of biological active compounds containing DKPs 
Acyl-CoA cholesterol transferase enzyme is the rate-limiting enzyme in the absorption of 
cholesterol and, because of this, its inhibition has a potential in moderating the effect of 
elevated cholesterol level. Gypsetin (Figure 2.2) was found to be a competitive acyl-CoA 
cholesterol transferase inhibitor with respect to oleoyl-CoA.108 
 
Figure 2.2 – Gypsetin 
Some examples of DKPs as antimicrobial active compounds (identified and isolated 
from microorganism) are depicted in Figure 2.3: a series of DD-DKPs (2.1 isolated from 
Pectenmaximus bacterial strains)102a, roquefortine (2.2)101e and 3,12-dihydroroquefortine 
(2.3)101e. 
 
Figure 2.3 – DKPs with antimicrobial activity 
It is also worth mentioning Pestalazine A (Figure 2.4), which presents inhibitory activity 
against HIV-1 replication.99c 
 
Figure 2.4 – Pestalazine A 
Several examples of DKP-containing compounds show cytotoxicity. In Figure 2.5 are 
reported some molecules as a representative set of derivatives with this action. For 
example, (-)-Phenylahistin (2.4) is a metabolite isolated from Aspergillus ustus which 
                                                          
108 Schkeryantz, J. M.; Woo, J. C. G.; Danishefsky, S. J., J. Am. Chem. Soc.1995, 117, 7025-7026 
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resulted cytotoxic for several lines of tumor cells.99a Diketopiperazine (2.5) is a synthetic 
analogue of 2.4 and it is a promising agent for cancer treatment. Both these molecules 
bind to microtubules. Compound 2.5 showed antitumor activity in vitro against human 
tumor cell lines from prostate, breast, lung, leukemia and colorectal tumors.99b Moreover 
2.5 is able to induce rapidly microtubule depolymerization already at low concentration in 
an in vitro model for vascular endothelial tumor cells. 
 
Figure 2.5 – Cytotoxic DKPs 
Another biological activity of DKPs is related to the inhibition of plasminogen activator 
inhibitor (PAI-1) and to alterations of cardiovascular and blood-clotting functions.98d In 
Figure 2.6 are depicted four molecules that were designed structurally based on DKPs as 
inhibitors of PAI-1.98 
 
Figure 2.6 – DKPs as PAI-1 inhibitors 
It seems that tumor malignant cells are protected from the host immunological system 
because of a fibrin coat stimulated by the same tumor cells (pro-coagulant activity). As a 
consequence, inhibition of tumor growth and circumvention of metastasis could be 
reached by targeting components of the blood-clotting system. Cyclo(L-His-L-Tyr) DKP 2.6 
(Figure 2.7) significantly increased clotting time, prevented platelet adhesion and 
 Page 34    
aggregation induced by adenosine diphosphate, and increased the heart rate in isolated 
rodent hearts. On the other hand, Cyclo(L-His-L-Phe) DKP 2.7 (Figure 2.7) showed antitumor 
activity by significantly reducing the viability of HeLa cells (from cervical carcinoma), 
WHCO3 cells (from oesophageal carcinoma) and MFC-7 cells (from mammary 
carcinoma) and it also decreased the cardiac output and the level of coronary blood 
flow.85 
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Figure 2.7– DKPs which interfere in cardiovascular and blood-coagulation functions 
 
2.2.2.2 Applications as templates 
DKPs have been used as templates in order to induce a defined secondary structure in 
peptide sequences. These constrained heterocyclic scaffolds were employed in the 
selective recognition of anions and small peptides, and in peptidomimetics as secondary 
structure-mimics (e.g., -turns, -hairpins, and -helices mimics). Thanks to their peptide 
functionalities (e.g., an amine and a carboxy groups) and their well-defined spatial 
properties, DKPs can reproduce the desired orientation in the growing peptide. 
Several examples in which DKPs are used as -turn inducers are reported in the 
literature. A -turn is a four residue turn showing a 10-membered intramolecular H-bonded 
ring (general structure in Figure 2.8). -turn inducers are grouped in three classes (Figure 
2.9): a) internal -turn mimics, b) -hairpin mimics (when a rigid scaffold, incorporated into 
a peptide or pseudo-peptide chain, causes a reversal of the chain.109), c) external -turn 
inducers (where a rigid template is used to constrain the backbone of a cyclic peptide in 
order to stabilize the peptide residue into a -turn conformation). 
 
Figure 2.8 – -turn structure 
                                                          
109 Robinson, A. J., Acc. Chem. Res. 2008, 41, 1278-1288 
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Figure 2.9 – -turn classes 
To mention some interesting applications in this field, Golebiowski and co-workers 
developed a solid-supported high-throughput synthesis of bicycle DKPs and synthesized a 
library to mimic type I -turn (2.8, Figure 2.10)110. A further example is the conformationally 
restricted -turn mimic 2.9 presented by Khan and co-workers (Figure 2.10).111 
 
Figure 2.10 - Examples of diketopiperazine-based β-turn mimics 
Burgess and co-workers synthesized antagonists for tropomysin C containing a DKP 
substituted at N1 and C3 (general structure in Figure 2.11) where these substituents, 
according to calculations, overlay with the side chains of the i+1 and i+2 of a type I -
turn.112 
 
Figure 2.11 – General structure of the tropomysin C antagonist of Burgess and co-workers 
  
                                                          
110 Golebiowski, A.; Klopfenstein, S. R.; Chen, J. J.; Shao, X., Tetrahedron Lett .2000, 41, 4841-4844 
111 Kim, H.-O.; Nakanishi, H.; Lee, M. S.; Khan, M., Org. Lett. 2000, 2, 301-302 
112 Liu, J.; Brahimi, F.; Saragovi, H. U.; Burgess, K., J. Med. Chem. 2010, 53, 5044-5048 
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As -hairpin inducers, the DKP scaffold can promote the formation of parallel or 
antiparallel -sheets depending whether the side chains contain the same or 
complementary functionalities. For example, a protected optically pure DKP scaffold 
(Figure 2.12) was synthesized by Gellerman and co-workers.113 
 
Figure 2.12 – DKP-based -turn mimic 
Examples of external -turn inducers, based on DKP scaffold, have been reported by 
Robinson and co-workers.114 The Pro-based DKP templates were used to stabilize turn and 
hairpin conformations in cyclic peptides containing the Asn-Pro-Asn-Ala sequence (which 
seemed important for immune recognition of the folded circumsporozoite surface protein 
in Plasmodium falciparum). The same scaffold was also introduced into a cyclic RGD-
containing peptidomimetic (Figure 2.13).114 Unfortunately, from 1H-NMR studies, emerged 
that the compound was present in more conformational states in aqueous solution 
because of the rapid interconversion of the peptide backbone. 
 
Figure 2.13 – DKP-based external -turn mimic 
  
                                                          
113 (a) Gellerman, G.; Hazan, E.; Brider, T.; Traube, T.; Albeck, A.; Shatzmiler, S., Int. J. Pept. Res. Ther. 2008, 14, 183-192; (b) Gellman, G.; Hazan, E.; Kovaliov, M.; Albeck, A.; Shatmiler, S., Tetrahedron 2009, 65, 1389-1396 
114 Bisang, C.; Weber, C.; Robinson, J. A., Helv, Chim. Acta 1996, 79, 1825-1842 
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Schafmeister and co-workers have synthesized a “molecular rod” (Figure 2.14) starting 
from a “bis-amino acid”, the 4-amino-4-carboxy Pro.115 Bis-peptide are defined as 
“synthetic oligomers assembled from cyclic, stereochemically pure monomers coupled 
through pairs of amide bonds to form rigid spiroladder oligomers with predefined and 
programmable three-dimensional structures”116. 
 
Figure 2.14 – Molecular rod 
 
2.2.2.3 DKPs as two armed receptors 
Two-armed receptors are structures composed of a central scaffold and two arms, 
generally symmetrical, that contain several binding sites that bind different kinds of guests 
(e.g., anions, cations, small molecules, amino acids and short peptides). The central 
scaffold has two roles: create a cleft with an adequate size to accommodate the guest 
and link two-side arms with correct geometry to tie up the guest with a sufficient number 
of binding points. DKPs, having a flat core and lateral chains of diverse size and nature, are 
suitable for this purpose. For example, Wennemers and co-workers synthesize a class of 
symmetrical DKP-based two-armed receptors derived from 4-aminoproline (five different 
molecules) with two tripeptide chains in cis relative configuration (Figure 2.15).117 In these 
structures, the scaffold avoids also intramolecular recognition between the two tripeptide 
arms and collapse of the receptor. The screening against a resin-bound tripeptide library 
revealed for each of the five structurally similar prototypes selectivity for different 
                                                          
115 Levins, G. C.; Schafmeister, C. E., J. Am. Chem. Soc. 2003, 125, 4702-4703 
116 Schafmeister, C. E.; Brown, Z. Z.; Gupta, S., Acc. Chem. Res. 2008, 41, 1387-1398 
117 (a) Wennemers, H.; Conza, M.; Mold, M.; Krattiger, P., Chem. Eur. J. 2001, 7, 3342-3347; (b) Conza, M.; Wennemers, H., J. Org. Chem. 2002, 67, 2696-2698 
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tripeptides.118 These two-armed receptors were evaluated also as selective and sensitive 
coatings for gravimetric gas sensors and to detect and differentiate simple alcohols.119 
 
Figure 2.15 - General structure of di-(2S,4R)-4-aminoproline DKP two-armed receptors 
 
2.2.2.4 Previous work of our group on DKPs field 
In 2008 our research group has reported the synthesis of a new class of DKPs.120 The 
bifunctional cis-DKP scaffold 2.10, can be seen as a -hairpin inducer and promoter of 
antiparallel -sheet. This compound seemed to have promising properties and it when 
inserted into several peptidomimetics (synthesis performed in solution with a Boc strategy). 
1H-NMR spectroscopy (chemical shift and NOE studies), IR spectroscopy, CD spectroscopy 
and molecular modeling were employed to clarify the conformation of the derivatives 
depicted in picture 2.16.120 These analysis revealed the formation of -hairpin mimics 
involving 10- and 18-membered H-bonded rings and a reverse turn of the growing peptide 
chain. The high stability of the -hairpin conformation and the turn-inducing ability of 2.10 
scaffold was demonstrated by NMR experiments and it was detected also in competitive, 
dipolar and even protic solvents on 2.11 and 2.12 (Figure 2.16).120  
 
Figure 2.16 - Bifunctional 2,5-DKP -hairpin mimic 
  
                                                          
118 (a) Ohlmeyer, M. H. J.; Swanson, R. N.; Dillard, L. W.; Reader, J. C.; Asouline, G.; Kobayashi, R.; Wigler, M. H.; Still, W. C., Proc. Nat. Acad. Sci. USA, 1993, 90, 10922-10926; (b) Nestler, H. P.; Bartlett, P.; Still, W. C., J. Org. Chem. 1994, 59, 4723-4724 
119 Emery, F.; Bisang, C.; Favre, M.; Jiang, L.; Robinson, A., Chem. Commun. 1996, 2155-2156 
120 Resurreiçao, A. S. M.; Bordessa, A.; Civera, M.; Belvisi, L.; Gennari, C.; Piarulli, U., J. Org. Chem. 2008, 73, 652-660 
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An evidence of the DKP1 turn-inducing ability arose also from investigations on the 
trimerBoc-(DKP1)3-NHnBu (Figure 2.17), and on the correspondent tetramer (Boc-(DKP1)4-
NHnBu).121 1H-NMR and CD spectroscopy of the trimeric structure in solution suggest the 
possible formation of two turns for the first and third residues. On the other hand, the 
tetramer is best described as a -bond ribbon conformation which means a succession of 
β-turns forming a linear peptide with a ribbon-like shape. 
 
Figure 2.17 – Boc-(DKP1)3-nBu trimer and Boc-(DKP1)4-nBu tetramer  
As already mentioned in Chapter 1, several cyclic peptides and peptidomimetics 
containing the RGD sequence or the isoDGR sequence active as integrin ligands have 
been synthesized and tested: if the ring-size and conformational properties of the cyclic 
ligand are properly chosen, nanomolar receptor binding affinities could be observed. 
From this point of view, DKPs have well-defined conformational properties which confer 
them unique feature as scaffolds to constrain cyclic ligands. Our research group has 
synthesized a collection of RGD-65 and isoDGR-67,68 cyclic peptidomimetics active as 
integrin ligands containing various DKPs as scaffolds to induce the proper RGD-/isoDGR- 
conformation. The whole topic will be further discussed in Paragraph 2.3. 
 
  
                                                          
121 Delatouche, R.; Durini, M.; Civera, M.; Belvisi, L.; Piarulli, U., Tetrahedron 2010, 51, 4278-4280 
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2.2.3 Synthesis 
In nature the 2,5-DKPs head-to-tail dipeptides are a common structural motif and, as a 
consequence, most of the biologically active DKPs can be isolated from natural sources. 
They are also common by-products/degradation products in oligopeptides synthesis. 
However DKPs can be easily accessed from commercial -amino acids through different 
synthetic pathways both in solid phase122 or in solution phase by conventional synthetic 
procedures123 or using microwave-assisted organic synthesis124. 
The main logical sites of disconnections of a 2,5-DKP ring are three (Figure 2.18): the 
amide bond (A) and the C−N bond (B), both frequently used, and the C−C bond (C), 
more recent as approach. Also tandem cyclizations forming N1−C2/C3−N4 (D) and 
C2−N1−C6 (E) bonds are mentioned in the literature but not commonly used. 
 
Figure 2.18 - Possible disconnections of the 2,5-DKP ring 
In addition, DKP formation in reactions involving amino acids is quite a common side 
reaction. For example, attempts to employ ethyl glycine chloride in the presence of a 
strong base to perform nucleophilic substitutions in pyrimidinic rings, resulted in the DKP 
produced by predominant auto-condensation of ethyl glycine.125 
Since a comprehensive review an DKPs synthesis is beyond the scope of this thesis, only 
some interesting conventional synthetic procedures will be shortly examined while more 
attention will be given to the synthetic pathway used for Cyclo[DKP-RGD] and Cyclo[DKP-
isoDGR] ligands. 
  
                                                          
122 (a) Li, W. R.; Yang, J. H., J. Comb. Chem. 2002, 4, 106-108; (b) For a review, see: Fischer, P. M., J. Pept. Sci. 2003, 9, 9-35 
123 Rodionov, I. L.; Rodionova, L. N.; Baidakova, L. K.; Romashko, A. M.; Balashova, T. A.; Ivanov, V. T., Tetrahedron 2002, 58, 8515-8523; (b) For a review on synthetic approaches to all three DKP isomers (2,3-, 2,5-, and 2,6-), see: Dinsmore, C. J.; Beshore, D. C., Tetrahedron 2002, 58, 3297-3312 and references therein 
124 (a) Lopez-Cobenas, A.; Cledere, P.; Sanchez, J. D.; Lopez-Alvaro, P.; Ramos, M. T.; Avendano, C.; Menendez, J. C., Synthesis 2005, 19, 3412-3422; (b) For a review, see: O’Neill, J. C.; Blackwell, H. E.; Comb. Chem. High Throughput Screening 2007, 10, 857-876 and references therein 
125 Ermolat’ev, D. S.; Babaev, E. V., Molecules 2003, 8, 467-471 
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2.2.3.1 Conventional synthetic procedures 
It is possible to prepare symmetrical DKPs simply by heating the free amino acid methyl 
esters (even with reactive chains) in a sealed tube. However, it is generally better to use 
protected precursors to avoid the formation of by-products (the corresponding 
pyrrolidone, piperidone and homopiperidone). For unsymmetrical DKPs, the oldest 
synthetic procedure consists in the dipeptide ester treatment with methanolic ammonia. 
Unfortunately this strategy can lead to epimerization because of the strong basic 
conditions. Boc-dipeptidyl methyl ester N-deprotection with formic acid followed by reflux 
of the dipeptidyl ester formate salt in 2-butanol/toluene (and removal of formic acid 
through azeotropic distillation is a method less prone to loss of stereointegrity. For many 
DKPs is enough the simple reflux the dipeptidyl methyl esters in low-boiling solvents, such as 
MeOH (Scheme 2.1).126 
 
Scheme 2.1 – Solution phase synthesis in refluxing MeOH 
DKPs can be synthesized also through a Ugi reaction with the advantage of possible 
direct substitutions on the secondary amino group (Scheme 2.2).88 
 
Scheme 2.2 – Ugi reaction mechanism and following cyclization 
An example is depicted in Scheme 2.3, a stereospecific synthesis proposed as an 
alternative in the preparation of trisubstituted DKPs. Unfortunately, the stereochemistry on 
the stereocenter located on the -carbon of the tertiary ammine which could not be 
controlled.127 
                                                          
126 Nitecki, D. E.; Halpern, B.; Westley, J. W., J. Org. Chem. 1968, 33, 864-866 
127 Sollis, S. L., J. Org. Chem. 2005, 70, 4735-4740 
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Scheme 2.3 – Example of Ugi-reaction type 
The Ugi-type reaction approach has been used to synthesize pharmacological active 
DKP-containing compounds such as the Aplaviroc (Figure 2.19).97d 
 
Figure 2.19 - Aplaviroc 
A different protocol employs the Gly cyclic dipeptide as starting material for the 
synthesis of substituted DKPs in solution.122a A similar strategy allowed to generate olefin 
derivatives of N-acetylated DKPs with exocyclic double bonds,128 as well as bis-epoxides. 
These molecules could serve as precursor to more complex DKPs.129 
An innovating strategy envisages the use of microwaves to couple peptides 
intramolecularly thus obtaining the symmetrical DKP without epimerization in the -position 
of the amino acids. An example of this application is depicted in Scheme 2.4 (synthesis of 
N-benzoyl-Arg(NO2)-Leu-NH2, a PAR-2 receptor antagonist): compared to conventional 
heating, the microwave synthesis produced the desired compounds in higher yields and 
shorter reaction times.130 In this example a Gly residue was introduced at the C-terminal 
end of the pharmacophore and activated for auto-condensation thus obtaining a 
cyclo(Gly-Gly) DKP substituted on the nitrogen with the pharmacophore. 
                                                          
128 Hayashi, Y.; Orisaka, S.; Tanaka, K.; Kanoh, K.; Kiso, Y., J. Org. Chem. 2000, 65, 8402-8405 
129 Ando, S.; Grote, A. L.; Koide, K., J. Org. Chem. 2011, 1155-1158 
130 Santagada, V.; Fiorino, F.; Perissutti, E.; Severino, B.; Terracciano, S.; Cirino, G.; Caliendo, G., Tetrahedron Letters 2003, 44, 1145-1148 
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Scheme 2.4 – Synthesis of N-benzoyl-Arg(NO2)-Leu-NH2 
However, symmetrical and unsymmetrical 2,5-DKPs can also be produced by a 
microwave-assisted stereoselective one-pot pathway starting from unprotected amino 
acids, through a phosphite-promoted one step coupling reaction (Scheme 2.5). Overall 
good yields, scalability (the reaction has been worked up simply by filtration through a 
pad of silica), and tolerance to several base-stable protecting groups have made this 
reaction an useful tool for DKPs synthesis.131 
 
Scheme 2.5 – One-pot stereoselective microwave-assisted DKPs synthesis 
Microwave irradiation has also been reported as a method to provide DKPs in excellent 
yields starting from the N-Boc-dipeptidyl-tert-butyl and -methyl esters through an aqueous 
in situ one-pot N-Boc-deprotection cyclization (Scheme 2.6).132 
 
Scheme 2.6 – One-pot aqueous microwave-assisted DKPs synthesis 
Phase-transfer catalysis has been suggested as another reliable method for the one-pot 
synthesis of symmetric 1,4-disubstituted-DKPs. The desired product is obtained through this 
strategy starting from a suitable amine and chloroacetyl chloride in presence of an 
aqueous base (example depicted in Scheme 2.7).133 
                                                          
131 Jainta, M.; Nieger, M.; Bräse, S., Eur. J. Org. Chem. 2008, 5418-5424 
132 Pérez-Picaso, L.; Escalante, J.; Olivo, H. F.; Rios, M. Y., Molecules 2009, 14, 2836-2849 
133 O’Reilly, E.; Pes, L.; Paradisi, F., Tetrahedron Letters 2010, 51, 1696-1697 
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Scheme 2.7 – One-pot DKPs synthesis through phase-transfer catalysis 
Another route that has to be mentioned is the O,N-acyl transfer, which is a valuable 
method for efficient synthesis of difficult peptide sequences with the advantage of 
allowing a racemization-free segment condensation. In this approach the first hindered 
amino acid, previously activated as ester, reacts with the free carboxylic acid of a second 
fragment. The generated mixed anhydride then undergoes spontaneous rearrangement 
and proceeds to the DKP product (Scheme 2.8). This approach is useful to produce 
oligomers and it was also employed in the synthesis of hexa- and pentasubstituted DKPs 
under mild conditions.134 
 
Scheme 2.8 – Synthesis of hexasubstituted DKPs via O,N-acyltransfer 
The synthetic routes presented so far are solution-phase methods. These present the 
advantage of requiring a limited number of steps to produce the substituted DKPs. 
However, solid-phase synthesis has been mostly used to obtain these products. In solid 
phase synthesis resin type, PGs and cleavage systems can be varied thus allowing a wider 
spectrum of possibilities. 
  
                                                          
134 Brown, Z. Z.; Schafmeister, C. E., Org. Lett. 2010, 12, 1436-1439 
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In scheme 2.9 a solid-phase protocol is depicted.135 This synthetic route employs the 
phenacyl ester bond to attach the carboxylic amino acid terminal to the resin. The linear 
precursor is then obtained by Boc-deprotection and amino acid coupling of the second 
amino acid. The subsequent steps of deprotection, cleavage and cyclization are required 
to obtain the DKP. A side-chain PG is required because the bound resin-first amino acid is 
susceptible to nucleophilic attack. 
 
Scheme 2.9 – Generic protocol for the solid phase synthesis of DKPs 
Reagent and conditions: a) BrCH2COBr, AlCl3, nitrobenzene/DCM (1:1); b) Boc-AA’-OH, Et3N, DMF; c) 1) 3.5 N HCl/AcOH; 2) Boc-AA’’-OH, HOBt, DCC, NMM, DMF; d) 1) 10% DIPEA/EtOAc; 2) 5% Et3N/THF-H2O (8:1). 
To solve this problem, it has been suggested to attach the peptide to the resin via a 
safety-catch technique (Scheme 2.10). In this approach the stable resin-first AA bond is 
activated only after ending the peptide synthesis, allowing the cleavage and cyclization 
(usually a safety catch is an acyl sulfonamide that is easily hydrolyzed after methylation). 
 
Scheme 2.10 – DKPs solid-phase synthesis by safety-catch approach 
Reagents and conditions: a) Boc-AA’-OH, DIC, DIPEA; b) Boc-based solid-phase peptide synthesis; c) TFMSA, TFA; d) DIPEA. 
                                                            
135 Wang, D.-X.; Liang, M.-T.; Tian, G.-J.; Lin, H.; Liu, H.-Q., Tetrahedron Lett. 2002, 43, 865-867 
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2.2.3.2 Synthesis via ester cyclization 
This synthetic approach is widely used because it is effectively simple: dipeptide 2.15 is 
generated by the coupling between an -amino acid protected at the amino group 
(2.14) and an α-amino ester (2.13). A large number of coupling reagents are suitable for 
that reaction. Lactamization of the resulting dipeptide 2.15 is spontaneous after 
deprotection of the terminal amine and generates the 2,5-DKP 2.16 (Scheme 2.11).86 
 
Scheme 2.11 - Dipeptide ester cyclization 
The amide bond is known to be planar with a partial double bond character and in 
polypeptides it is generally present in the trans-conformation. Trans/cis isomerism 
activation barrier in the order of 15-20 kcal/mol) is relevant to DKP formation because the 
intramolecular attack of the amino group on the carboxylic group is possible only from a 
folded conformation containing a cis peptide bond. If the amide bond is not in cis-
conformation (because of sterical hindrances or electronical interferences), the rate of 
cyclization is lower than when it is in a cis-conformation. When the cyclization is difficult, 
some expedients can be used (e.g., heating in acidic136 or basic137 medium, heating to 
reflux in high boiling solvents138) to improve the yield. Reactions conditions have to be 
carefully chosen to limit racemization.  
 
Luthman et al. described a new general solution-phase synthesis using microwaves 
(heating for 10 min using water as solvent).139 This new strategy is efficient, affording 
moderate to excellent yield (63%-97%), with no dependence on the amino acid sequence 
and no epimerization. Polysubstituted 2,5-piperazinedione derivatives124a and indolyl 2,5-
DKP analogues140 were synthesized directly by microwave irradiation of N-Boc dipeptide 
esters under solvent-free conditions in an efficient manner. 
 
                                                          
136 Suzuki, K.; Sasaki, Y.; Endo, N.; Mihara, Y., Chem. Pharm. Bull. 1981,29, 233 
137 Depew, K. M.; Marsden, S. P.; Zatorska, D.; Zatorski, A.; Bornmann, W.G.; Danishefsky, S. J., J. Am. Chem. Soc. 1999, 121, 11953-11963 
138 See, for instance: (a) Bull, S. D.; Davies, S. G.; Moss, W. O., Tetrahedron: Asymmetry 1998, 9, 321-327; (b) Woodard, R. W., J. Org. Chem. 1985, 50, 4796-4799 
139 Tullberg, M.; Grotli, M.; Luthman, K., Tetrahedron 2006, 62, 7484-7491 
140 Pandey, S. K.; Awasthi, K. K.; Saxena, A. K., Tetrahedron 2001, 57, 4437-4442 
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2.2.3.3 Previous work in the group 
Our research group has previously described the synthesis of a small library of 
bifunctional DKP scaffolds (Figure 2.20), formally derived from 2,3-diaminopropionic acid 
and aspartic acid or glutamic acid in the case of DKP8 (2.23, Figure 2.20).65,120 These 
scaffolds could also be seen as formed by two -amino acids (in particular a 2- and a 3-
amino acids, following Seebach’s nomenclature141). These DKPs, differing for the 
configuration of the two stereocenters and for the substitution at the endocyclic nitrogens, 
were synthesized using the ester cyclization pathway86.65 Depending on the relative 
configuration of the two stereocenters, the synthesized derivatives can be used as 
secondary structures inducers in linear or cyclic peptides. 
 
Figure 2.20 - DKPs library 
For DKPs bearing a benzyl group at nitrogen N4 (DKP1 2.10, DKP2 2.17 and DKP3 2.18) 
the serine ligation strategy (Scheme 2.12) was selected. Starting from either (R)- or (S)-Ser 
and (S)- or (R)-Asp, (R)- or (S)-N-benzylserine methyl ester 2.26 and (R)- or (S)-N-(tert-
butoxycarbonyl)aspartic acid β-allyl ester 2.29 were easily prepared according to 
literature procedure142. The direct coupling of 2.26 and 2.29 generated the isopeptides 
2.30 in high yield (72%). Among the various possibilities, the direct coupling of 2.26 and 2.29 
was chosen in order to avoid the introduction of further protecting groups. After the Boc-
deprotection of 2.30 and the cyclization, the introduction of the azide group was carried 
out through a Mitsunobu-type reaction. The azido derivative 2.32 was converted into the 
NHBoc-compound 2.33 in an one-pot Staudinger reduction-Boc protection followed by 
de-allylation (via a Pd(0) catalyzed Tsuji-Trost reaction) to give the final product 2.17 and 
                                                          
141 The subscripted number after  specifies the position of the side chain on the corresponding β-amino acid, see: Hintermann, T.; Seebach, D., Synlett 1997, 437-438 
142 For the benzyl-serine: Thompson, C. M.; Frick, J. A.; Green, D. L. C., J. Org. Chem. 1990, 55, 111-116; for he -allyl ester: Webster, K. L.; Maude, A. B.; O’Donnell, M. E.; Mehrotra, A. P.; Gani, D., J. Chem. Soc., Perkin Trans. 1 2001, 1673-1695 
 Page 48    
2.18. With the same procedure, allyl deprotection was performed directly on the azido 
derivative 2.32 to obtain the final scaffold 2.34 and 2.35 necessary for the Fmoc-SPPS, 
which does not allow the use of Boc-derivatives. 
 
Scheme 2.12 - Synthesis of DKP1, DKP2/DKP*2 and DKP3/DKP*3 
Reagents and conditions: a) CH3COOH, CH3OH, reflux; b) Et3N, PhCHO, then NaBH4, under N2; c) CH3COCl, Allyl alcohol, reflux; d) Et3N, Boc2O, 1:1 H2O/THF, r.t.; e) EDC, DMAP cat., DCM, 0°C to r.t., under N2; f) 1) TFA/DCM, 1:1; 2) DIPEA, iPrOH, r.t.; g) PPh3, DIAD, H3N.tol, -20°C, under N2; h) PPh3, BOC-ON, THF, -20°C to r.t., under N2; i) [Pd(PPh3)4], PPh3, pyrrolidine, DCM, 0°C, under N2; j) [Pd(PPh3)4], PPh3, pyrrolidine, DCM, 0°C, under N2. 
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Isopetide 2.30 was detected instead of the expected dipeptide 2.36 the synthesis. The 
mechanism of this isopeptide formation was deeply studied in our research group 
(Scheme 2.13).143 NMR spectra were measured (Figure 2.21) and confirmed the 
mechanism via O,N-acyl transfer144 (“depsipepeptide technique”145 or “O-acyl isopeptide 
methodology”146). The peptidic sequence is extended via functionalization of the -
hydroxy group of an N-protected Ser or Thr residue and the native peptide is restored after 
the final coupling and Ser/Thr deprotection thanks to the O,N-acyl transfer. As a matter of 
fact, selective O-acylation of the unprotected -hydroxyl group of N-benzylserine methyl 
ester is preferred over the formation of the tertiary amide and the resulting ester bond is 
stable in solution to O,N-acyl transfer. Boc cleavage and base treatment trigger the O,N-
acyl migration and promote the simultaneous cyclization. 
 
Scheme 2.13 – Isopeptide formation mechanism 
                                                          
143 Marchini, M.; Mingozzi, M.; Colombo, R.; Gennari, C.; Durini, M.; Piarulli, U., Tetrahedron 2010, 66, 9528-9531 
144 Coin, I., J. Pept. Sci. 2010, 16, 223-230 
145 Carpino, L. A.; Krause, E.; Sferdean, C. D.; Schumann, M.; Fabian, H.; Bienert, M.; Beyermann, M., Tetrahedron Lett. 2004, 45, 7519-7523 
146 (a) Mutter, M.; Chandravarkar, A.; Boyat, C.; Lopez, J.; Dos Santos, S.; Mandal, B.; Mimna, R.; Murat, K.; Patiny, L.; Saucede, L.; Tuchscherer, G., Angew. Chem. Int. Ed. 2004, 43, 4172-4178; (b) Sohma, Y.; Sasaki, M.; Hayashi, Y.; Kimura, T.; Kiso, Y., Chem. Commun. 2004, 124-125; (c) Kiewitz, S. D.; Kakizawa, T.; Kiso, Y.; Cabrele, C., J. Pept. Sci. 2008, 14, 1209-1215  
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Figure 2.21 - NMR spectra of isopetides 2.30 (on the right isopeptide of cis-scaffold and on the left isopeptide of trans-scaffold) 
The conversion of compound 2.31 into 2.32 was successfully achieved through a 
Mitsunobu reaction (Scheme 2.14). In the case of our DKPs, this resulted in a crucial 
reaction since the C6 acid proton could be easily extracted and then the activated 
hydroxyl functionality could undergo -elimination before reacting with the hydrazoic acid 
(which acts as nucleophile). The -elimination was particularly competitive in the case of 
the cis-derivative, which also required a more complex purification than the trans 
derivatives. 
 
Scheme 2.14 – Mitsunobu-type reaction, mechanism 
The following step (the conversion of 2.32 into 2.33) involved a one-pot Staudinger-Boc 
protection. The mechanism is reported in Scheme 2.15: the azide reacts with a phosphine 
to generate phosphazide which then looses N2 forming an iminophosphorane. In a 
classical Staudinger reaction, the hydrolysis of this last intermediate leads to the amine 
and the very stable phosphine oxide. However in this one-pot Staudinger-Boc protection, 
the iminophosphorane reacts directly with 2-(tert-butoxycarbonyloxyimino)-2-
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phenylacetonitrile (Boc-ON) affording the desired Boc-protected amine in very good 
yield. 
 
Scheme 2.15 – One-pot Staudinger-Boc protection reaction 
The final deallylation on 2.32 or on 2.33 was performed in the presence of a catalytic 
amount of Palladium tetrakis(triphenylphosphine), [Pd(PPh3)4], and pyrrolidine as 
nucleophile (which is necessary as allyl scavenger). Such methodology is of special interest 
for peptide synthesis because the deprotection conditions are usually mild enough to be 
compatible with the presence of labile tBu and Boc protections.147 The final amino acid 
derivatives have been obtained in good yields. The mechanism of this reaction is reported 
in Scheme 2.16. 
 
Scheme 2.16 – Deallylation mechanism 
For DKPs benzylated on N4 (Figure 2.1 for numbering; 2.19 and 2.21), a different 
synthetic pathway was developed (Scheme 2.17).65b The synthesis was accomplished 
starting from L- or D- Ser and D- or L-Asp. The aspartate residue was protected on both 
carboxylic groups as methyl ester and then coupled to the Boc-Ser-N3 moiety, which was 
previously activated as symmetric anhydride. Notably, the Mitsunobu reaction was directly 
performed on the Boc-Ser-O-Mehydroxyl group, thus deleting the problem of -elimination, 
avoiding the use of a further PG and allowing a scale-up of the synthesis. The coupling 
step (80% yield) has been followed by Boc-deprotection and cyclization (yield almost 
                                                          
147 David, C.; Bischoff, L.; Meudal, H.; Mothé, A.; De Mota, N.; Da Nascimento, S.; Lorens-Cortes, C.; Fournié-Zaluski, M.-C.; Roques, B. P., J. Med. Chem. 1999, 42, 5197-5211 
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quantitative). The azide was then catalytically reduced and Boc protected. The methyl 
ester hydrolysis finally afforded the desired products. 
 
Scheme 2.17 – DKP4 and DKP6 synthesis 
Reagents and conditions: a) CH3COCl, CH3OH, reflux; b) Boc2O, H2O/THF 1.1, r.t.; c) HN3, DIAD, PPh3, THF, -20°C, under N2 d) 1) LiOH, H2O/THF 1:1;2) DCC, DCM; e) CH3COCl, MeOH, reflux; f) PhCHO, Et3N, NaBH(AcO)3, r.t, under N2; g) DCC, rt; h) 1) TFA/DCM 1:2, Et2SiH, r.t.; 2) DIPEA, iPrOH, r.t.; i) 1) H2, Pd/C (10%), THF, r.t.;2) Boc2O, THF, r.t.; j) LiOH, H2O/THF 1:1, r.t.. 
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For solid phase purposes with a Fmoc strategy the Boc-derivatives are not suitable, so a 
small library of azido-acid DKPs (DKPs*) was synthesized (Figure 2.22).67,68 
 
Figure 2.22 – DKP* library 
The synthesis of scaffolds the 2.45 and 2.47 (as well as the synthesis of 2.20 and 2.22) 
could be in principle performed starting from the benzylation of the second DKP nitrogen 
of the azide-intermediate in the synthesis of either DKP2 and DKP4 or, DKP3 and DKP6 
respectively (Scheme 2.18). This strategy avoided the use of further protecting groups 
since the azide is stable in the reaction conditions thus behaving as PG. 
 
Scheme 2.18 – Possible retrosynthesis for DKP5 and DKP7 
A previous synthesis performed in our group started from 2.43 (Scheme 2.19).65b The final 
compounds were obtained by deprotonation of the azido esters with KHMDS (which 
prevent elimination being an hindered base) followed by alkylation with benzyl bromide 
keeping the temperature between -70°C and -40°C. Conversion into the –NHBoc 
derivative and deprotection of the carboxylic acid were performed with the same 
procedure used for DKP4 and DKP6. 
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Scheme 2.19 – DKP5 and DKP7 synthesis starting from DKP4 and DKP6 
Reagents and conditions: a) KHMDS, BnBr, THF/DMF 7:3, -70°C to -40°C, under N2; b) PPh3, Boc-ON, tol, -20°C to r.t., under N2; c) LiOH, H2O/THF 1:1, r.t.. 
In a subsequent synthetic approach, compounds 2.32, intermediates in the synthesis of 
2.34 and 2.35, respectively, were used as starting materials for the preparation of 2.45 and 
2.46 (Scheme 2.20).68 Also in this case, the azido esters were synthesized with the same 
reactions used for derivatives DKP5 and DKP7 (Scheme 2.20). The only difference is in the 
last deprotection step since an allyl ester is present as PG in the carboxylic acid instead of 
a methylester. As a consequence, deprotection was accomplished by treatment with 
[Pd(PPh3)4] and N-methyl aniline. 
 
Scheme 2.20 – DKP5 and DKP7 synthesis 
Reagents and conditions: a) KHMDS, BnBr, THF/DMF 7:3,  -70°C to -40°C, under N2; b) [Pd(PPh3)4], PPh3, N-methyl aniline, DCM, under N2,0°C to r.t., 1h (70%). 
DPK8 (2.23, Figure 2.20) was synthesized using a mixed procedure starting from (S)-Ser 
and (R)-glutamic acid -methyl ester (Scheme 2.21).65b The synthetic pathway of DKP1-2-3 
was followed to synthesize the –NHBoc methyl ester 2.50, which was then deprotected as 
DKP4 and DKP6. 
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Scheme 2.21 – DKP8 (2.23) synthesis 
In order to prepare cyclic RGD-peptidomimetics to be used in drug targeting, after 
conjugation with different payloads (e.g., cytotoxic agents148, VEGFR ligands149 and 
nanoparticles, see Chapter 3), four functionalized DKPs (DKPf) bearing a p-
aminomethylenbenzyl substituent on N1 or N4 were synthesized as both stereoisomers at 
C3 and C6, namely: 3R,6S and 3S,6R148 Trans-monobenzylated scaffolds were selected 
according to the binding data collected on unconjugated Cyclo[DKP-RGD] 
peptidomimetics (see paragraph 2.3). The selected linker for the DKPf bears two different 
functionalities: an aldehyde (for successive reductive amination) and an amino group (as 
moiety for the conjugation). 
 
Figure 2.23 – DKPf library 
  
                                                          
148 Colombo, R.; Mingozzi, M.; Belvisi, L.; Arosio, D.; Piarulli, U.; Carenini, N.; Perego, P.; Zaffaroni, N.; De Cesare, M.; Castiglioni, V.; Scanziani, E.; Gennari, C., J. Med. Chem. 2012, 55, 10460−10474 
149 Zanella, S.; Mingozzi, M.; Dal Corso, A.; Fanelli, R.; Arosio, D.; Cosentino, M.; Schembri, L.; Marino, F.; De Zotti, M.; Formaggio, F.; Pignataro, L.; Belvisi, L.; Piarulli, U.; Gennari, C., ChemistryOpen 2015, 4, 633-641 
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The synthetic pathway depicted in Scheme 2.22 refers to DKPf2 (2.51) and DKPf3 (2.52) 
and was developed following the same approach of the unfunctionalized scaffolds. The 
only difference was the aldehyde used in the reductive amination step which bore the 
linker with the –NH2 moiety suitable for further functionalization. According to the 
applications for which was developed the scaffold, Mtr was selected as PG on the amine 
functionality on the aldehyde. The overall yield (60%) is high and, thanks to the small 
number of chromatographic purifications, it is a suitable route for multi-gram scale 
synthesis. 
 
Scheme 2.22 – DKPf2 and DKPf3 synthesis 
Reagents and conditions: a) CH3COCl, Allyl alcohol, reflux; b) Boc2O, TEA, dioxane/water 1:1, r.t.; c) LiAlH4, dry THF, reflux, under N2; d) Mtr-Cl, DIPEA, THF, r.t.; e) MnO2, THF, r.t.; f) CH3COCl, MeOH, reflux; g) (2.58), NaBH(OAc)3, Et3N, MeOH, r.t.; h) HATU, HOAt, DIPEA, DMF, 0°C to r.t.; i) 1) TFA/DCM (1:2), 0°C to rt 2) DIPEA, iPrOH, DMF, r.t., under N2; l) H3N in toluene, DIAD, Ph3P, DCM/toluene 1:3, -20°C, under N2; m) Me3P, Boc-ON, THF, -20°C to rt; n) pyrrolidine, Ph3P, [Pd(Ph3P)4], DCM, r.t.. 
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Also DKPf4 (2.53) and DKPf6 (2.54) were prepared following a synthetic pathway 
patterned after the corresponding DKP4/DKP6 synthetic route (Scheme 2.23)65b,67,68 As for 
2.51 and 2.52, the aldehyde 2.58 was used instead of the benzyl aldehyde in the reductive 
amination to give the isopeptide 2.65. 
 
Scheme 2.23 – DKPf4 and DKPf6 synthesis 
Reagents and conditions: a) CH3COCl, MeOH, reflux; b) Boc2O, TEA, dioxane-water, r.t.; c) HN3.tol, DIAD, Ph3P, dry THF -20 °C, under N2; d) 1)LiOH, H2O/THF 1:1, 0°C; 2) DCC, DCM, r.t., e) CH3COCl, MeOH, reflux; f) 2.58, NaBH3(CN), MeOH, r.t.; g) DCM, r.t.; h) 1) TFA, Et3SiH, DCM, r.t.; 2) DIPEA, iPrOH, r.t.; i) 1) H2, 10% Pd/C, THF, r.t.; 2) Boc2O, DIPEA, DCM, r.t. i) LiOH, H2O/THF 1:1, 0°C. 
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2.3 DKP integrin ligands 
As already presented in Chapter 1, several RGD- and isoDGR integrin ligands have 
been synthesized and tested. Thanks to their conformational properties, DKPs are suitable 
scaffolds to build peptidomimetics with different conformational properties. 
 
2.3.1 Cyclo[DKP-RGD] integrin ligands 
The RGD sequence is a recognition motif for integrins widely used in peptidomimetics 
active as ligands for these receptors. The DKPs library synthesized in our group was then 
used for the synthesis of cyclic RGD-peptidomimetics (Figure 2.24).65 
 Figure 2.24 - Library of Cyclo[RGD-DKP] integrin ligands 
 
2.3.1.1 Synthesis 
A solution phase synthesis with Boc-protecting group strategy was adopted for the 
synthesis of the Cyclo[DKP-RGD] integrin ligands library (Scheme 2.24).65b The synthesis was 
accomplished starting from Boc-Arg(Mtr), Gly-OBn and Cbz-Asp(OtBu)-OH. Each step 
consisted on the Boc- deprotection of the first moiety and the coupling to the second one, 
previously activated at the carboxylic acid group. Once the linear peptidomimetics Cbz-
Asp(OtBu)-DKP-Arg(Mtr)-Gly-OBn (2.76) was obtained, it was deprotected by 
hydrogenolysis (Cbz and Bn). The linear deprotected derivative (2.77) was subjected to 
macrolactamization. Several methodologies were screened for the ring closure and the 
best yields were obtained by the literature procedure reported61a,150 in Scheme 2.24. A final 
side-chain deprotection afforded the desired compounds that were purified by 
preparative HPLC. 
                                                          
150 Luo, J.-M.; Dai, C.-F.; Lin, S.-Y.; Huang, P.-Q., Chem. Asian. J. 2009, 4, 328-335 
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Scheme 2.24 - Cyclo[DKPs-RGD] ligands synthesis 
Reagents and conditions: a) 1) CsCO3, MeOH; 2) BnBr, DMF; b) 1) TFA/DCM 1:2; 2) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2; c) 1) TFA/DCM 1:2; 2) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2; d) 1) TFA/DCM 1:2; 2)Cbz-Asp(OtBu)-OH, HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2 e) 1) TFA/DCM 1:2; 2) H2, Pd/C, THF/H2O 1:1, r.t.; f) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2; g) TFA/thianisole/ethanedithiol/anisole 90:5:3:2. 
Cyclic derivatives 2.72 and 2.74 containing the dibenzylated DKPs (DKP5 and DKP7) 
can exist as two different separable conformers (planar chirality) due to hindered rotation 
of one ring around the other. In the case of derivative 2.72 containing the DKP5 scaffold, 
only one diastereomer formed (either because it was formed exclusively/predominantly 
and the minor one was not detected/isolated). On the contrary, in the case of derivative 
2.74, containing DKP7, two diastereomers were detected. The two diastereomers were 
formed in the macrolactamization step, and, after side-chain deprotection, they could be 
separated, analyzed and tested separately (integrin affinity). 
 
2.3.1.2 Biological evaluation 
The library was examined in vitro for the ability to inhibit biotinylated vitronectin binding 
to the purified V3 and V5 receptors.65 The cis-derivative (Cyclo[DKP-1-RGD] 2.68) 
showed IC50 in a range of micromolar concentration, while trans-derivatives 2.69-2.75 
ranged from submicro- to subnanomolar concentrations (Table 2.1), very similar to each 
other.
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Structure Compound number V3 IC50 [nM] V5 IC50 [nM] 
Cyclo[DKP1-RGD] 2.68 3898±418 >104 
Cyclo[DKP2-RGD] 2.69 3.2±2.7 114±99 
Cyclo[DKP3-RGD] 2.70 4.5±1.1 149±25 
Cyclo[DKP4-RGD] 2.71 7.6±4.3 216±5 
Cyclo[DKP5-RGD] 2.72 12.2±5.0 131±29 
Cyclo[DKP6-RGD] 2.73 2.1±0.6 79±3 
Cyclo[DKP7-RGD]-major 2.74 a 220.2±82.3 >104 
Cyclo[DKP7-RGD]-minor 2.74 b 0.2±0.09 109±15 
Cyclo[DKP8-RGD] 2.75 7.5±0.6 >103 
c(RGDfV) / 3.2±1.3 7.5±4.8 
ST1646 / 1.0±0.5 1.4±0.8 
Table 2.1 – Inhibition of biotinylated vitronectin binding to V3 and V5 receptors 
IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean ± SD of triplicate determination. 
Moreover, the trans-compounds (except for 2.74 a) showed a higher selectivity 
compared to the reference compounds. Interestingly, the behavior of 2.74 a is peculiar 
taking into account that the diastereoisomer (2.74 b) is the most potent ligand if the series. 
 
2.3.1.3 NMR characterization and conformational studies 
1H-NMR studies (in particular chemical shift dependence on temperature and 
concentration to detect intramolecular hydrogen bonds, as well as NOESY to investigate 
both sequential and long-range contacts),computational studies (MC/SD simulations151, by 
using the implicit water GB/SA solvation model152 and the OPLS_2001 force field153), and 
docking studies (starting from the representative conformations obtained from the MC/SD 
simulations) were performed with the aim of rationalizing the affinity of these compounds 
for the V3 receptor at a molecular level. Among the data collected, the ones regarding 
2.70 will be deeply considered as this compound has been further investigated. This ligand 
is apparently characterized by conformational mobility, with a similarity to 2.68 for what 
concerns the NMR data and, consequently, of the detected conformation. Since these 
two ligands contain DKPs scaffolds with opposite configuration which should impart a 
different stereochemical orientation to the side arms, this similarity is quite surprising. This 
conformational similarity can be interpreted in terms of a quasienantiomeric structure                                                           
151 Guarneri, F.; Still, W. C., J. Comput. Chem. 1994, 15, 1302-1310 
152 Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T., J. Am. Chem. Soc.1990, 112, 6127-6129 
153 (a) Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J., J. Am. Chem. Soc.1996, 118, 11225-11236; (b) The OPLS_2001 force field, among several commonly used force fields, provided the highest correlation between calculated and experimental conformational preferences within the series of cyclic RGD peptidomimetics containing diketopiperazine scaffolds with different stereochemistry and substitution at the piperazinic nitrogen atoms. 
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(excluding the configuration of the remote RD amino acid side chains). In any case, the 
preferred conformation of 2.70 presents an extended arrangement of the RGD sequence 
with a distance of around 8.8 Å between the C(Arg) and the C(Asp) in the MC/SD 
simulation.65 
 
Figure 2.25 – Conformational analysis of 2.70 
Preferred intramolecular hydrogen-bonded pattern proposed on the basis of spectroscopic data (NOE contacts are indicated by an arrow). 
Further docking studies on H-bonding patterns with a C(Arg)-C(Asp) distance ≥ 8.8 Å 
taking as a reference model the crystal structure of the extracellular segment of integrin 
v3 complexed with the cyclic pentapeptide Cilengitide, showed top-ranked poses 
conserving all the important interactions of the X-ray complex (Figure 2.26).65 
 
Figure 2.26 – Docking studies on 2.70 
As an example is represented the best pose of 2.74 b (atom color tube representation) into the crystal structure of the extracellular domain of V3 integrin (α unit red and  unit blue wise representation) overlaid on the bound conformation of Cilengitide (green tube representation). Only selected integrin residues involved in the interaction with the ligand are shown. The metal ion in the MIDAS region is represented by a magenta sphere. Nonpolar hydrogen atoms were removed for clarity. 
The micromolar affinity of RGD peptidomimetics 2.68 and 2.74 b for V3 can be 
explained in terms of their low pre-organization for binding. In fact, as determined by the 
computational and NMR spectroscopy studies, in solution these compounds mainly 
feature non-extended RGD conformations, which according to the docking results, are 
not able to properly fit into the V3 receptor. On the contrary, the nanomolar affinity of 
2.70 (and of all the other trans-RGD-ligands of the series) for V3 can be attributed to their 
high structural pre-organization. 
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2.3.2 Cyclo[DKP-isoDGR] integrin ligands 
The DKPs library synthesized in our group has later been used also as scaffold for cyclic 
isoDGR integrin ligands. For this, four derivatives, namely Cyclo[DKP2-isoDGR] 2.76, 
Cyclo[DKP3-isoDGR] 2.77, Cyclo[DKP5-isoDGR] 2.78 and Cyclo[DKP7-isoDGR] 2.78 (Figure 
2.27) were prepared.67,68 The conformational properties of the cyclic ligands 2.76 and 2.77 
were investigated as well as their affinity to V3 and V5 integrin receptors. 
 
Figure 2.27 - Cyclo[DKP-isoDGR] integrin ligands 
 
2.3.2.1 Synthesis 
A SPPS protocol was used for the synthesis of these compounds, and it was carried out 
using SasrinTM resin as solid support (Scheme 2.25).67,68 The SPPS was chosen based on a 
successful synthesis of a DKP-containing decapeptide.154 
Each coupling step consisted in: 
i) activation of the Fmoc-protected amino acid, 
ii) addition of the activated amino acid to the resin to effect the coupling 
reaction and, after the scaffold coupling, reduction of the azide 
iii) capping and Fmoc-deprotection (except after the azide reduction and Cbz-
Asp(OtBu)-OH coupling). 
Cleavage from the resin was accomplished in weakly acidic conditions. The linear 
cleaved precursor (2.80) was deprotected in presence of Pd/C 10% in THF. The linear 
deprotected precursor 2.81 was cyclized, deprotected and purified by semi-preparative 
HPLC. Fmoc-orthogonal PGs were selected for the lateral chains of the amino acids (Arg 
was protected as -Mtr and Asp as -tBu). 
                                                          
154 Marchini, M., PhD thesis, University of Milan 
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 Scheme 2.25 - Cyclo[DKP-isoDGR] integrin ligands synthesis 
Reagents and conditions: a)Fmoc-Gly-OH, DIC, DMAP cat., DMF; b) 25% piperidine in DMF or DBU 2% in DMF, piperidine 2% in DMF; c) Fmoc-Asp(OtBu)-OH, DIC, HOAt, DMF; d) 25% piperidine in DMF or DBU 2% in DMF, piperidine 2% in DMF; e) DKP-N3, HOAt, DIC, DMF; f) PMe3, dioxane/water 4:1; g) Fmoc-Arg(Mtr)-OH, HOAt, DIC, DMF; h) 1% TFA in DCM; i) H2, 10% Pd/C, THF/water 1:1; j) HATU, HOAt, DIPEA, 1.4 mM, DMF; k) TFA/thioanisole/ethanedithiol/anisole 90:5:3:2. 
Interestingly and differently from the RGD series, in the case of compound 2.79, 
containing the DKP7 scaffold, no trace of two diastereoismers was detected in the 1H-NMR 
of the final cyclic compound. 
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2.3.2.2 Biological evaluation 
Cyclo[DKP-isoDGR] peptidomimetics were examined in vitro in competitive binding 
assays with biotinylated vitronectin to purified V3 and V5 receptors (Table 2.2).67,68 2.77 
showed a low nanomolar affinity for V3 integrins. These compounds compared well also 
with the corresponding RGD ligands65 and much better than other isoDGR-ligands (Table 
2.2)155. 
Structure Compound number V3 IC50 [nM] V5 IC50 [nM] 
Cyclo[DKP2-isoDGR] 2.76 46.7±18.2 220±84 
Cyclo[DKP3-isoDGR] 2.77 9.2±1.1 312±21 
Cyclo[DKP5-isoDGR] 2.78 490±77 9100±800 
Cyclo[DKP7-isoDGR] 2.79 255±140 5100±400 
Cyclo[DKP3-RGD] 2.70 4.5±1.1 149±25 
Cyclo[RGDfV] / 3.2±1.3 7.5±4.8 
Cyclo[GisoDGRphg] / 89 ± 19* n.d. 
Cilengitide / 0.6±0.1** 11.7±1.5** 
 Table 2.2 – Inhibition of biotinylated vitronectin binding to V3 and V5 receptors 
IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding. Screening assays were performed by incubating the immobilized integrins V3 and V5 with increasing concentrations (10-12-10-15M of the ligands in the presence of biotinylated vitronectin (1 mg/mL) and measuring the concentration of bound vitronectin in the presence of the competitive ligands67; * = determined by a solid phase binding assay by using supported vitronectin, soluble V3 integrin, specific primary and secondary antibodies155e; the IC50 value of this compound can be compared with the IC50 values of 2.76 and 2.77 notwithstanding that the binding assays were realized by using two different protocols. In fact, i) vitronectin is used as competitive natural ligand in both assays, and ii) Cilengitide gives the same IC50 value for V3 integrin with both assays, 155e and 55b respectively; ** = calculated as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding156 
In particular, 2.77 is the most potent ligand of the class. It is ten-times more potent in 
binding integrin V3 than Cyclo[GisoDGRphg],155e recently synthesized by Kessler and co-
workers as part of a library of isoDGR-cyclopentapeptides. 2.77 is only 2–3-times less potent 
than the correspondent RGD ligands 2.70 and Cyclo[RGDfV], and fifteen-times less potent 
than the powerful RGD-ligand Cilengitide. 
The isoDGR library showed very different IC50 values depending on the scaffold. 
Interestingly the RGD library differs under this aspect because all the IC50 values for 
peptidomimetics containing trans-scaffold are very similar (e.g., 2.70: V3 = 4.5 ±1.1, V5 = 
149 ±25; 2.72: V3 = 12.2 ± 5.0, V5 = 131 ± 29). 
  
                                                          
155 (a) Müller, G.; Gurrath, M.; Kessler, H., J. Comput.-Aided Mol. Des. 1994, 8 (6), 709-730; (b) Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H., J. Am. Chem. Soc. 1996, 118, 7461-7472 
156 Mas-Moruno, C.; Beck, J. G.; Doedens, L.; Frank, A. O.; Marinelli, L.; Cosconati, S.; Novellino, E.; Kessler, H., Angew. Chem. Int. Ed. 2011, 50, 9496–9500 
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2.3.2.3 NMR and conformational studies 
As for the RGD library, the preferred conformations of 2.76 and 2.77 were investigated 
by 1H-NMR spectroscopy (one dimensional 1H-NMR to detect intramolecular hydrogen 
bonds, NOESY spectra to investigate both sequential and long-range NOE signals that 
provide evidences of preferred conformations), by computational methods (restrained 
mixed-mode Metropolis Monte Carlo/stochastic dynamics (MC/SD) simulations,151 using 
the implicit water GB/SA solvation model152) and by docking analysis with the aim of 
rationalizing the affinity of these compounds for the V3 receptor at a molecular level. All 
the collected data confirm that the isoDGR sequence of 2.77 can fit into the RGD binding 
pocket of Vβ3 integrin, establishing the same electrostatic clamp as well as additional key 
interactions. According to the collected data, compound 2.76 is characterized by a high 
conformational flexibility with approximately 50% of the conformations arrangement of the 
isoDGR sequence characterized by a pseudo--turn at DKP-isoAsp and a C(Arg)-C(Asp) 
average distance of 8.6 Å (Figure 2.28). 
 
Figure 2.28 – Conformational studies on 2.76 
Left: preferred intramolecular hydrogen-bonded pattern proposed on the basis of spectroscopic data (NOE contacts are indicated by an arrow); right: MC/SD simulations based on experimental distance information after energy minimization (Pseudo--turn at DKP-Asp, C(Arg)-COO-(Asp) distance = 8.8 Å).   On the other hand, 2.77 exists in two preferred conformations: a -turn conformation 
and pseudo--turn motif similar to that observed for compound 2.76. Approximately 80% of 
the conformations sampled during the simulations adopted an extended arrangement of 
the isoDGR sequence, characterized by a pseudo--turn at DKP-isoAsp with the formation 
of a distorted -turn at Gly-Arg, was observed for 10% of the simulations. A C(Arg)-C(Asp) 
average distance of 10.8 Å was obtained during the MC/SD calculations for 2.77 (Figure 
2.29 and 2.30). 
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Figure 2.29 – NMR conformational studies on 2.77 
Preferred intramolecular hydrogen-bonded pattern proposed on the basis pf spectroscopic data. NOE contacts are indicated by an arrow. a) -turn at Gly-Arg; b) pseudo--turn at DKP-isoAsp. 
 
Figure 2.30 – MC/SD simulations based on experimental distance information after energy minimization 
a) Distorted -turn at Gly-Arg, populated for 10% of the simulations, C(Arg)-COO-(Asp) distance = 10.7 Å; b) Pseudo--turn at DKP-Asp, populated for 80% of the simulations, C(Arg)-COO-(Asp) distance = 10.8 Å. 
The crystal structure of the extracellular segment of integrin V3 complexed with 
Cilengitide was taken as a reference model.33 Docking calculations were performed 
starting from the pseudo--turn DKP-isoAsp geometries of 2.76 and from the distorted -turn 
Gly-Arg conformations of 2.77. Calculations produced top-ranked poses conserving the 
key electrostatic interactions but lacking further stabilizing hydrogen bond interactions 
with the -subunit for 2.76. On the other hand, calculations for 2.77 produced top-ranked 
poses conserving all the important interactions of the X-ray complex Cilengitide-V3 
(Figure 2.31). 
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Figure 2.31 – Docking studies 
Best pose of 2.77 (atom color tube representation, pseudo--turn at DKP-isoAsp) into the crystal structure of the extracellular domain of V3 integrin (α unit pink and  unit blue wise representation) overlaid on the bound conformation of Cilengitide (green tube representation). Only selected integrin residues involved in the interaction with the ligand are shown. The metal ion in the MIDAS region is represented by a magenta sphere. Nonpolar hydrogen atoms were removed for clarity. 
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2.4 Biological evaluation of Cyclo[DKP3-RGD] (2.70) and 
Cyclo[DKP3-isoDGR] (2.77) integrin ligands 
2.4.1 Cyclo[DKP3-RGD] (2.70) as angiogenesis inhibitor 
The activity of ligand 2.70 as an angiogenesis inhibitor has recently been investigated in 
HUVEC.157 HUVEC have been chosen because they provides a valid model of the 
intracellular events leading to neovascularization in response to inflammation and hypoxia 
in cancer, ischemic events, and in embryogenesis.158 HUVEC express integrins V3 and 
V5159 and as a consequence these cells represent a suitable model to study agents 
acting on such targets. As already mentioned, competitive binding studies performed on 
2.70 showed IC50 values of 4.5 ± 1.1 nM and 149 ± 25 nM to V3 and V5 integrins 
respectively65 and it was chosen as reference compound of the RGD library because it is 
the easier to synthesize. 
2.70 demonstrated an angiogenesis inhibition activity without affecting cell viability, 
apoptosis or proliferation. As a matter of facts, its antiangiogenic activity is independent 
from cytotoxicity, differently from the majority of anti-angiogenic compounds acting 
through the inhibition of integrin function (e.g. Cilengitide, Figure 1.2). Since the lack of 
cytotoxic effects of this integrin ligand has also been observed in several different cell-lines 
(ovarian carcinoma, IGROV-1 or SKOV3, human pancreatic carcinoma and MIA-PaCa2, 
human osteosarcoma U2-OS148), it can be considered a general feature of ligand 2.70. 
Since neoangiogenesis is a key step also in other pathological conditions (e.g., 
atheromatous plaque vulnerability160) where cytotoxicity could represent a risk for adverse 
effects, these class of antagonists have a potential widespread applications. In any case, 
further studies are required to establish whether this lack of cytotoxicity is suggestive of 
reduced toxicity and increased tolerability in vivo. However, the data collected suggested 
a possible application of 2.70 as a candidate modulator of angiogenesis (not only in 
tumors), hopefully without the adverse effects of cytotoxic analogues (complete 
toxicological assessment are currently ongoing). 
 
A deep investigation of the specific mechanisms of action of 2.70 has not still been 
performed but the compound has been shown not to affect the mRNA levels for the 
integrin subunits V, 3 and 5. However a significant inhibition of Akt phosphorylation was 
observed, as a consequence of disruption of endothelial cell–extracellular matrix 
                                                          
157 Fanelli, R.; Schembri, U.; Piarulli, U.; Pinoli, M.; Rasini, E.; Paolillo, M.; Galiazzo, M. C.; Cosentino, M.; Marino, F., Vascular Cell 2014, 6, 11 
158 Xu, Y.; Zhou, Y.; Lin, H.; Hu, H.; Wang, Y.; Xu, G., Int. J. Mol. Med. Mar. 2013, 31, 555-560 
159 Baranska, P.; Jerczynska, H.; Pawlowska, Z.; Koziolkiewicz, W.; Cierniewski, C. S., Cancer Genomics Proteomics 2005, 2, 265-270 
160 Moreno, P. R.; Purushothaman, M.; Purushothaman, K. R., Ann. NY Acad. Sci. 2012, 1254, 7–17 
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 Similarly, a marked inhibition of FAK phosphorylation 
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In our experiments, 2.70 proved to be an inhibitor of angiogenesis induced by the 
growth factors VEGF, EGF, IGF-I and FGF2, as well as by IL-8 (Figure 2.34 and 2.35). 2.70 
seems to block common mechanisms since all these proangiogenic agents act through 
distinct membrane receptors (the stimulated intracellular cascades finally activate 
common effector molecules, such as NF-κB or HIF-1163),163,164. A further confirmation is given 
by recent evidences indicating that direct interactions may occur between integrin 
activated pathways and VEGFr165/EGFr signaling166. 
 
Figure 2.34 – Antiangiogenic effect of 2.70 
Phase contrast micrographs of HUVEC plated on Matrigel in basal conditions or in stimulated conditions with 2.70 at different concentration. 
                                                          
163 Waugh, D. J. J.; Wilson, C., Clin. Cancer Res. 2008, 14, 6735–6741 
164 Brooks, A. N.; Kilgour, E.; Smith, P. D., Clin.Cancer Res. 2012, 18, 1855–1862 
165 Paesler, J.; Gehrke, I.; Poll-Wolbeck, S. J.; Kreuzer, K. A., Eur. J. Haematol. 2012, 89, 373–384 
166 Hu, B.; Wie, Y. Q.; Tian, L.; Zhao, X.; Lu, Y.; Wu, Y-; Yao. B.; Liu, J. Y.; Niu, T.; Wen, Y. J.; He, Q. M.; Su, J. M.; Huang, M. J.; Lou, Y. Y.; Luo, Y.; Kann, B., J. Immunother. 2005, 28, 236–244 
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Figure 2.35 - Effect of 2.70 on HUVEC angiogenesis 
Effect on HUVEC angiogenesis induced by VEGF, EGF, IGF-1 and FGF2 in the upper panels or by IL-8 in the lower panels. Angiogenesis has been evaluated as both number of loops (A) and length of branches (B). Empty symbols = basal conditions; filled symbols = stimulated conditions. Data are means ± SEM of 3-5 separate experiments; # = P<0.01 vs basal conditions, * = P<0.01 vs respective control. 
 
2.4.2 Comparison between 2.70 and 2.77 
Whether RGD ligands have an agonist/antagonist activity on integrins depending on 
the concentration is controversial. Taking into account that IC50 on V3 integrins of 
Cyclo[DKP3-isoDGR]67,68 is comparable to the value measured for Cyclo[DKPs-RGD] 
ligands,65 Cyclo[1a-RGD]161 and considering biological data on HUVEC157 and on 
glioblastoma cells161 presented before, an interesting outlook for anticancer activity of 
these compounds has been disclosed. 
 
Considering the structural correlation of 2.70 with 2.77 (the most potent isoDGR ligand 
of the library), it was selected for a comparison study. The aim of these experiments was 
the comprehension of the ligand-receptor interaction to see if one or both of these ligands 
act as pure antagonists on integrins.68  
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Figure 2.36 – ELISA assay, nucleosome content after 72h treatment
Data are expressed as percent of control (100%), in ordinate the nucleosome content (% of control); A = 2.77; ** = calculated probability value P>0.005
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Figure 2.37 – Infiltration assay 
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After treatment with both ligands a decrease of both FAK and Akt phosphorylation was 
observed and it was particularly evident after 24h treatment (Figure 2.39).68 
 
Figure 2.39 - FAK and Akt phosphorylation assays 
A = 2.70, B = 2.77; Densiometric analysis, * = calculated probability value P>0.5, ** = calculated probability value P>0.005, *** = calculated probability value P>0.001. 
From these data, it seems that 2.70 and 2.77 inhibit tumor cells infiltration processes and 
this process could be mediated by inhibition of the FAK and Akt signaling cascade.68 
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2.5 Conclusions and outlooks 
Cyclo[DKP3-isoDGR] 2.77 is the first isoDGR ligand found to be active in the inhibition of 
FAK/Akt integrin activated transduction pathway and on integrin-mediated cell infiltration 
processes. From the collected data, consistent with other isoDGR-containing 
cyclopeptides results47, an antagonist activity can be attributed to this compound.68 
For what concerns 2.70, results are consistent with literature data obtained for other 
RGD ligands at comparable concentrations (e.g., cyclo[1a-RGD]161) and with data 
obtained for the same compound on human endothelial cells.157 As a matter of facts, 
cellular effects of this ligand are consistent with an antagonist profile.68 
Unfortunately the comparison with Cilengitide activity profile is not well defined. 
According to already presented analysis of literature data (Chapter 1), a comparison of 
these cyclic ligands with Cilengitide is not appropriate because of the different 
experimental settings and cell types. 
Further in vitro and in vivo studies will be performed on 2.70 and on 2.77 to better 
understand their mechanism of action and to obtain a complete toxicity profile. 
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2.6 Experimental section 
2.6.1 Materials and methods 
All manipulations requiring anhydrous conditions were carried out in flame-dried 
glassware, with magnetic stirring and under a nitrogen atmosphere. All commercially 
available reagents were used as received. Anhydrous solvents were purchased from 
commercial sources and withdrawn from the container by syringe, under a slight positive 
pressure of nitrogen. The reactions were monitored by analytical TLC using silica gel 60 F254 
pre-coated glass plates (0.25 mm thickness). Visualization was accomplished by irradiation 
with a UV lamp and/or staining with a potassium permanganate alkaline solution or 
ninhydrin. Flash column chromatography was performed according to the method of Still 
and co-workers169 using Chromagel 60 ACC (40-63 m) silica gel. Proton NMR spectra were 
recorded on a spectrometer operating at 400.16 MHz. Proton chemical shifts are reported 
in ppm () with the solvent reference relative to TMS employed as the internal standard. 
The following abbreviations are used to describe spin multiplicity s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of doublet, ddd = 
doublet of doublet of doublet, ddt = doublet of doublet of triplet. Carbon NMR spectra 
were recorded on a spectrometer operating at 100.63 MHz, with complete proton 
decoupling. Carbon chemical shifts are reported in ppm () relative to TMS with the 
respective solvent resonance as the internal standard. ESI-MS spectra were recorded on 
the ion trap mass spectrometer Finnigan LCQ Advantage. 
 
RP-HPLC purification 
The HPLC purifications were performed on a Dionex Ultimate 3000 instrument equipped 
with a Dionex RS Variable Wavelenght Detector (column: Atlantis Prep T3 OBDTM 5 TM 19 x 
100 mm).The crude reaction mixture was dissolved in water and the solution was filtered 
(polypropylene, 0.45 m, 13 mm ø, PK/100) and injected in the HPLC, affording purified 
products. 
 
RP-HPLC analysis 
Purity analysis for each of the compounds was carried out on a Dionex Ultimate 3000 
instrument equipped with a Dionex RS Variable Wavelenght Detector (column: Atlantis 
Prep T3 OBDTM 5TM 19 x 100 mm). 1 mg of purified product was dissolved in 1 mL of H2O 
and was injected using the same gradient used in the purification step. The analysis of the 
integrals and the relative percentage of purity was performed with the software 
Cromeleon 6.80 SR11 Build 3161. 
                                                          
169 Still, W. C.; Kahn, M.; Mitra, A., J. Org. Chem. 1978, 43, 2923-2925 
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Freeze-drying 
The product was dissolved in water and frozen with dry ice: the freeze-drying was carried 
out at least for 48 h at -50 °C using the instrument 5Pascal Lio5P DGT. 
 
2.6.2 General procedures for SPPS 
The SPPS was accomplished using the semi-automatic synthesizer Biotage® InitiatorTM 
assisted by microwaves. The programs “Tasks” used in the SPPS instrument are reported in 
the General Procedures. Each task can be modified in every parameter and it is 
performed under mechanical stirring at 1000 rpm. A Fmoc strategy was selected and the 
SASRINTM Resin (200-400 mesh, loading: 1.02 mmol/g) were used. 
Solutions and solvents 
In order to execute the programs set, the synthesizer required two solutions and two 
solvents: 25% Ac2O in DMF (v/v), 25% piperidine in DMF (v/v), MeOH and DMF. MeOH was 
used only as washing solvent, DMF was used for washes and reactions (coupling, capping 
and deprotection). 
Resin preparation and storage 
The resin was weighted in a 10 mL vial and processed with the swelling task (GP1). At the 
end of this operation the resin was ready for the SPPS. When necessary, beads were stored 
at 4 °C under nitrogen after being washed several times with DCM and dried at the high 
vacuum pump. 
Kaiser test 
GP0: Phenol (80% solution in ethanol), ninhydrin (6% solution in ethanol) and pyridine (two 
drops) were added to a small sample of the resin and then heated in a boiling water bath 
for 60 sec. If the colour of the solution maintained yellow, quantitative coupling was 
achieved. In the case of a slight blue colour, the coupling step was not fully completed 
and had to be repeated. 
Swelling task 
GP1: DMF (3.0 mL) was added to the resin: the swelling was accomplished at r.t. in 30 min. 
At the end of the swelling step, the vial was empty. 
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Activation, loading of the first amino acid and capping of the resin 
GP2: To a solution of the first Fmoc-AA-OH in DMF, DIC and DMAP were added at 0 °C, 
under stirring and inert atmosphere. After 25 min, the reaction mixture was added to the 
resin at the synthesizer and a cycle of coupling (single or double-capping-deprotection-
washing) was effected. 
Activation of the Fmoc-AA-OH/DKP and coupling task 
GP3: To a solution of the desired Fmoc-AA-OH or N3-DKP-COOH in DMF, DIC, HOAt were 
added at 0 °C, under stirring and inert atmosphere. After 25 min, the reaction mixture was 
added to the resin at the synthesizer and a cycle of coupling (single or double-capping-
deprotection-washing) was effected. The activated Fmoc-AA-OH/DKP scaffold was 
added to the beads and the coupling reaction assisted by microwaves started was 
carried out at 70 °C under inert atmosphere for 12 min. The beads were washed six times 
with DMF (2.5 mL × 20 s for every wash). Activation and coupling step involving 
commercial AA, were performed twice. At the end of the coupling task, a Kaiser test was 
performed. At the end of each step, the vial was empty. 
Capping task 
GP4: The solution 25% Ac2O in DMF (3 mL) was added to the resin: the capping step was 
performed at r.t. under inert atmosphere for 15 min. The beads were washed six times with 
DMF (2.5 mL × 20 s for every wash). At the end of each step, the vial was empty. 
Fmoc-deprotection task 
GP5: Two deprotection steps were carried out adding the solution 25% piperidine in DMF 
(3.0 mL for each step) to the beads: the reaction was performed at r.t. under inert 
atmosphere for 5 min and 7 min for the first and the second deprotection step 
respectively. The beads were washed twice with DMF, MeOH, DMF, MeOH and DMF (3.0 
mL × 20 s for every wash; 3.0 mL × 20 s for the last washes in MeOH and DMF). At the end of 
each step, the vial was empty. 
Azide reduction on resin 
GP6: Azidopeptidyl resin (1 eq.) was suspended in a 4:1 mixture of dioxane/water. 
Trimethylphosphine (1M solution in toluene, 6 eq.) was added and the reaction vessel was 
shaken for 40 min. The resin was then washed with dioxane (3 x) and the conversion was 
checked by Kaiser test. 
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Cleavage from the resin 
GP7: The resin was thoroughly washed with DCM (10 x) and then treated with 1% TFA in 
DCM (2 mL) for 2-5 min. The mixture was filtered off with a N2pressure into a vial containing 
0.2 mL of 12% of Py in MeOH. The presence of the peptide was monitored by TLC 
(DCM/MeOH 9:1): after 5-8 cycles the peptide was completely cleaved from the resin. The 
fractions were collected and concentrated at reduced pressure. The mixture was then 
diluted with AcOEt and washed with 1 M KHSO4 (4 x). The organic layer was dried over 
Na2SO4 and concentrated affording a white solid. The crude compounds were purified by 
flash chromatography on silica gel (gradient: DCM/MeOH 95:5 to 8:2) to give the desired 
products. 
 
2.6.3 General procedures for solution-phase synthesis 
Cbz hydrogenolytic cleavage 
GP8: Protected compound (1 eq.) was dissolved in a mixture of THF/H2O (1:1) and Pd/C 
10% (0.1 eq.) was added. The reaction mixtures were subjected to three 
vacuum/hydrogen cycles and then left stirring overnight at room temperature under 1 bar 
of hydrogen. The mixture was filtered through Celite, and the cake was washed thoroughly 
with THF/H2O (1:1). The filtrate was concentrated and dried.  
Macrolactamization 
GP9: HATU (4 eq.), HOAt (4 eq.) and DIPEA (6 eq.) were added successively to a solution of 
deprotected linear compound (1.4 mm; 1 eq.) in DMF, under a nitrogen atmosphere at 
0°C. After stirring the reaction mixture at 0°C for 1 h, it was allowed to reach room 
temperature and stirred overnight. DMF was then removed under reduced pressure. 
Mtr AND OtBu ester removal 
GP10: Protected macrolactam was treated for 2h with TFA, in the presence of ion 
scavengers: thioanisole (5%), EDT (3%), anisole (2%). After TFA removal under reduced 
pressure, the residue was dissolved in a 1:1 mixture of diisopropyl ether/water. Phases were 
separated and the aqueous layer was washed several times with diisopropyl ether. The 
aqueous phase was concentrated under reduced pressure to give the crude product, 
which was purified by HPLC. 
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2.6.4 Synthesis 
N3-(3R,6S)-DKP-COOAllyl 2.32 a, N3-(3S,6R)-DKP-COOAllyl 2.32 b, N3-(3R,6S)-DKP-COOAllyl 
2.34 (DKP*2), N3-(3S,6R)-DKP-COOAllyl 2.35 (DKP*3), Cyclo[DKP2-isoDGR] 2.76 and 
Cyclo[DKP3-isoDGR] 2.77 were synthesized according to literature procedure (Mingozzi, 
M.; Dal Corso, A.; Marchini, M.; Guzzetti, I.; Civera, M.; Piarulli, U.; Arosio, D.; Belvisi, L.; 
Potenza, D.; Pignataro, L.; Gennari, C., Chem. Eur. J. 2013, 19, 3563-3567) and their 
analytical data were in agreement with those already published. 
N3-(3R,6S)-DKP-COOAll (2.49 a) and N3-(3S,6R)-DKP-COOAll (2.49 b) 
 
The reaction was performed in a flame-dried flask under nitrogen atmosphere. KHMDS (111 
mg, 0.55 mmol, 1.1 eq.) was dissolved in dry toluene to give a 0.5 M solution. The solution 
was cooled to -70°C and 2.32 a or 2.32 b (180 mg, 0.5 mmol, 1 eq.), previously dissolved in 
dry THF (9.9 mL), was added drop wise. The mixture was stirred under these conditions for 
30 minutes, then benzyl bromide (0.30 l, 2.5 mmol, 5 eq.) and DMF (4.2 mL) were 
sequentially added under these conditions. The reaction was allowed to reach -40°C and 
it was stirred under these conditions for 5 hours. After this time, a saturated solution of 
NH4Cl was added and the mixture was extracted three times with EtOAc (3 x 40 mL). 
Organic layers were reunited, washed with brine and dried over Na2SO4 anhydrous. 
Volatiles were removed under reduced pressure then the crude was purified by flash 
chromatography on silica gel eluting hexane: EtOAc (from 7:3 to 6:4). The product was 
recovered as a transparent oil (134 mg, 66%). 
Rf=0.4 (Hexane/AcOEt 6:4); 1H-NMR (400 MHz, CDCl3, T = 298K)  7.37 – 7.27 (10 H, m), 5.87-
5.77 (1H, m), 5.36 (2 H, dd, J 16, 8), 5.29 (3H, s), 5.23 (1H, d, J 12), 4.50 (2H, dq, J 44, 12, 8), 
4.24 (1H, s), 4.18– 4.15 (2 H, m), 4.09 (2 H, d, J 12), 3.74 (1 H, dd, J 12, 4), 3.30 (1 H, dd, J 16, 
4), 2.92 (1 H, dd, J 20, 8); 13C-NMR (101MHz, CD2Cl2, T = 298K)  169.5, 166.1, 164.9, 135.3, 
131.8, 128.8, 128.8, 128.6, 128.1, 128.0, 127.9, 127.8, 127.8, 127.3, 126.6, 118.4, 103.7, 65.6, 
58.4, 55.0, 51.4, 47.1, 47.0, 34.8; MS (ESI) m/z calcd. for [C24H24N5O4Na]+: 447.19; [M+Na]+; 
found: 470.4. 
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N3-(3R,6S)-DKP-COOH 2.45 (DKP*5) and N3-(3S,6R)-DKP-COOH 2.46 (DKP*7) 
 
N3-(3R,6S)-DKP-COOAll (2.49 a) or N3-(3S,6R)-DKP-COOAll (2.49 b) (120 mg, 0.27 mmol, 1 
eq.) was dissolved in DCM (2.7 mL) under a nitrogen atmosphere, and the mixture was 
cooled to 0°C. [Pd(PPh3)4] (94 mg, 0.08 mmol, 0.3 eq.) and freshly distilled N-methyl aniline 
(35 μl, 0.32 mmol, 1.2 eq.) were added successively. The mixture was then allowed to 
reach room temperature. After 1 h of stirring, the mixture was diluted with EtOAc (40 mL) 
and extracted with aqueous NaHCO3 (4 x 20 mL). The combined aqueous phases were 
acidified to pH 2 by adding KHSO4 (1M solution) and then extracted with DCM (4 x 20 mL). 
The resulting organic phase was dried over Na2SO4 and the solvent was evaporated to 
afford the desired product as a slightly yellow solid (77 mg, 70%) which was used without 
further purification. 
Rf=0.20 (Hexane/AcOEt 1:1); 1H-NMR (400 MHz, CDCl3, T = 298K)  7.41 – 7.25 (10 H, m), 5.47 
(2 H, dd, J 48, 16), 4.25 (1H, s), 4.14 – 4.06 (3H, m), 4.02 (1 H, d, J 16), 3.77 (1 H, dd, J 12, 2), 
3.37 (1 H, dd, J 20, 4), 2.97 (1 H, dd, J 20, 4); 13C-NMR (101MHz, CDCl3, T = 298K)  173.8, 
166.1, 165.3, 134.8, 134.4, 129.1, 129.0, 128.2, 128.1, 127.9, 127.8, 58.2, 54.3, 51.4, 47.1, 46.9, 
34.2; MS (ESI) m/z calcd for [C21H20N5O4Na]+: 429.40 [M+Na]+; found: 430.1020. 
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Cbz-Arg(Mtr)-(3R,6S)-DKP-isoAsp(OtBu)-Gly-OH (2.80 a) and Cbz-Arg(Mtr)-(3S,6R)-DKP-
isoAsp(OtBu)-Gly-OH (2.80 b) 
 
The resin was prepared and swelled (GP1). Fmoc-Gly-OH was activated and coupled to 
the resin (GP2). After a capping step (GP4) and a Fmoc deprotection step (GP5), Fmoc-L-
Asp(OH)-OtBu was activated and coupled (GP3). Then a capping step (GP4) and a Fmoc 
deprotection step (GP5) were performed. DKP-N3 scaffold was activated and coupled to 
the resin (GP3); the coupling was followed by the azide reduction (GP6). Fmoc-Asp(OtBu)-
OH was activated and coupled (GP3). After the Fmoc deprotection step (GP5), the linear 
precursor was cleaved from the resin (GP7). The desired products were obtained as white 
foams (2.80 a: 157 mg, 71%; 2.80 b: 90 mg, 81%). 
 
Compound 2.80 a: 
Rf=0.15 (9:1 DCM/MeOH); 1H-NMR (400 MHz, CD3OD)  7.43-7.20 (m, 15H), 6.63 (s, 1H), 5.39 
(d, J = 15.4 Hz, 1H), 5.14-4.99 (m, 3H), 4.57 (t, J = 6.2 Hz, 1H), 4.38 (s, 1H), 4.32 (dd, J =15.5, 6.9 
Hz, 2H), 4.09 (s, 1H), 4.03 (s, 1H), 3.80 (s, 5H), 3.74 (s, 2H), 3.19-3.04 (m, 3H), 2.90 (dd, J = 16.9, 
4.5 Hz, 1H), 2.72-2.64 (m, 5H), 2.59 (s, 3H), 2.10 (s, 3H), 1.68 (s, 1H), 1.58-1.38 (m,12H). 13C-
NMR (101 MHz, CD3OD)  178.2, 175.4, 172.1, 171.5, 171.1, 168.7, 167.8, 159.9,158.4, 158.2, 
139.5, 138.1, 137.9, 137.1, 136.8, 134.8, 130.0, 130.0, 129.5, 129.4, 129.0, 128.9,125.7, 112.8, 
83.2, 67.9, 59.8, 56.8, 56.3, 56.0, 51.6, 44.5, 40.5, 38.6, 36.4, 30.1, 28.3, 24.4, 18.9,12.1.; MS (ESI) 
m/z calcd. for [C55H70N9O14S]+: 1112.5 [M+H]+; found: 1112.5. 
Compound 2.80 b: 
Rf=0.15 (9:1 DCM/MeOH); MS (ESI) m/z calcd. for [C55H70N9O14S]+: 1156.4 [M+2Na-H]+;found: 
1156.6. 
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Exact amounts of the AA and coupling reagents used for SPPS are reported in Table 2.3 for 
Cyclo[isoDGR-3R,6S)-DKP] (2.76) and in Table 2.4 for Cyclo[isoDGR-3S,6R)-DKP] (2.77). 
Table 2.3 
Reagents Eq. or concentration mmol Amounts 
SASRINTM resin 1 eq. 0.2 200 mg 
Fmoc-Gly-OH* 4 eq. 0.8 238 mg 
DIC 4 eq. 0.8 124 L 
DMAP 0.1 eq. 0.02 2.4 mg 
DMF 0.27 M / 3 mL 
Fmoc-L-Asp(OH)-OtBu* 3 eq. 0.6 247 mg 
DIC 3 eq. 0.6 93 L 
HOAT 3 eq. 0.6 82 mg 
DMF 0.20 M / 3 mL 
N3-(3R,6S)-DKP-COOH 2.45 2.3 eq. 0.46 185 mg 
DIC 2.3 eq. 0.46 71 L 
HOAT 2.3 eq. 0.46 63 mg 
DMF 0.15 M / 3 mL 
Cbz-L-Arg(Mtr)-OH . CHA* 2.5 eq. 0.5 310 mg 
DIC 2.5 eq. 0.5 77 L 
HOAT 2.5 eq. 0.5 68 mg 
DMF 0.17 M / 3 mL 
* a double coupling step is performed. 
Table 2.4 
Reagents Eq. or concentration mmol Amounts 
SASRINTM resin 1 eq. 0.1 100 mg 
Fmoc-Gly-OH* 4 eq. 0.4 119 mg 
DIC 4 eq. 0.4 62 L 
DMAP 0.1 eq. 0.01 1.2 mg 
DMF 0.27 M / 1.5 mL 
Fmoc-L-Asp(OH)-OtBu* 3 eq. 0.3 124 mg 
DIC 3 eq. 0.3 47 L 
HOAT 3 eq. 0.3 41 mg 
DMF/DCM 0.20 M / 1.5 mL 
N3-(3S,6R)-DKP-COOH 2.46 2.3 eq. 0.23 93 mg 
DIC 2.3 eq. 0.23 36 L 
HOAT 2.3 eq. 0.23 32 mg 
DMF/DCM 0.15 M / 1.5 mL 
Cbz-L-Arg(Mtr)-OH · CHA* 2.5 eq. 0.25 155 mg 
DIC 2.5 eq. 0.25 39 L 
HOAT 2.5 eq. 0.25 34 mg 
DMF 0.17 M / 1.5 mL 
* a double coupling step was performed. 
 Page 84    
H-Arg(Mtr)-(3R,6S)-DKP-isoAsp(OtBu)-Gly-OH (2.81 a) and H-Arg(Mtr)-(3S,6R)-DKP-
isoAsp(OtBu)-Gly-OH (2.81 b) 
 
Compound 2.80 a or 2.80 b (2.80 a: 145 mg, 0.14 mmol, 1 eq; 2.80 b: 90 mg, 0.08 mmol, 1 
eq) was treated with10% Pd/C (2.80 a: 14 mg, 0.014 mmol, 0.1 eq; 2.80 b: 8 mg, 0.008 
mmol, 0.1 eq) under the conditions described in GP8. The product was obtained as a 
white solid (2.81 a: 134 mg, 98%; 2.81 b: 80 mg, quantitative yield) and it was used without 
further purification. 
 
Compound 2.81 a: 
1H-NMR (400 MHz, CD3OD)  7.44-7.15 (m, 10H), 6.64 (s, 1H), 5.45 (d, J = 15.4 Hz, 1H), 4.58 (bt, 
J = 4.9 Hz, 1H), 4.43 (d, J = 15.4 Hz, 1H), 4.34 (bs, 1H), 4.24 (d, J = 15.7 Hz, 1H), 4.11 (bs,1H), 
3.90 (s, 3H), 3.79 (s, 3H), 3.71 (dd, J = 14.2, 5.9 Hz, 1H), 3.24-3.10 (m, 2H), 3.06 (d, J = 15.2Hz, 
1H), 2.92 (dd, J = 16.8, 4.9 Hz, 1H), 2.72 (d, J = 6.0 Hz, 2H), 2.66 (s, 3H), 2.59 (s, 3H), 2.10 (s,3H), 
1.88-1.75 (m, J = 14.3, 7.1 Hz, 2H), 1.61-1.49 (m, 2H), 1.43 (s, 9H), 1.46-1.35 (m, 2H). 13C-NMR 
(101 MHz, CD3OD)  172.4, 171.3, 171.0, 170.8, 168.7, 167.8, 163.0, 162.7, 159.9, 158.1, 139.4, 
137.9, 137.3, 136.6, 134.5, 129.9, 129.8, 129.4, 129.1, 128.8, 128.1, 126.1, 125.7, 112.8, 83.2, 
59.2, 57.7, 56.9, 56.0, 53.9, 51.3, 50.4, 49.8, 48.0, 41.9, 40.7, 38.3, 36.4, 35.8, 30.8, 30.7, 30.5, 
29.6, 28.2, 24.3, 18.8, 12.1; MS (ESI) m/z calcd. for [C47H64N9O12S]+: 978.4 [M+H]+; found:978.7. 
 
Compound 2.81 b: 
MS (ESI) m/z calcd. for [C47H63N9O12SNa]+: 1000.4 [M+Na]+; found: 1000.5. 
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Cyclo[(3R,6S)-DKP-isoAsp(OtBu)-Gly-Arg(Mtr)] (2.82 a) and Cyclo[(3S,6R)-DKP-
isoAsp(OtBu)-Gly-Arg(Mtr)] (2.82 b) 
 
Compound 2.81 a (127 mg, 0.13 mmol, 1 eq) was cyclized in the presence of HATU (198 g, 
0.52mmol, 4 eq), HOAt (71 mg, 0.52 mmol, 4 eq) and DIPEA (136 L, 0.78 mmol, 6 eq) under 
the conditions described in GP9. The crude product was purified by RP-HPLC [gradient: 
90% H2O + 0.1% CF3COOH / 10% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH 
in 10 min; flow: 15 mL/min, tR (product) = 7 min ca.] to afford the desired product 2.82 a as 
a white foam (39 mg, 32%). 
 
Compound 2.82 a: 
1H-NMR (400 MHz, CD3OD) 7.44-7.15 (m, 10H), 6.68 (s, 1H), 5.37 (d, J = 15.1 Hz, 1H), 5.26 (d, 
J = 16.0 Hz, 1H), 5.15 (d, J = 8.0 Hz, 1H), 4.73-4.62 (m, J = 5.4 Hz, 1H), 4.40 (d, J = 16.1 Hz,1H), 
4.29-4.07 (m, 4H), 3.99 (s, 1H), 3.83 (s, 3H), 3.68 (d, J = 16.5 Hz, 1H), 3.47 (d, J = 13.5 Hz,1H), 
3.37 (s, 1H), 3.28-3.15 (m, 2H), 2.86 (dd, J = 14.6, 3.3 Hz, 1H), 2.77 (d, J = 6.6 Hz, 2H), 2.70(s, 
3H), 2.64 (s, 3H), 2.34-2.23 (m, 1H), 2.15 (s, 3H), 1.80-1.55 (m, J = 18.4, 14.0, 5.9 Hz, 3H),1.49 (s, 
9H). 13C-NMR (101 MHz, CD3OD)  175.4, 172.2, 171.7, 171.2, 171.1, 167.8, 167.1, 160.0, 157.9, 
139.5, 138.8, 136.8, 130.1, 129.8, 129.5, 129.2, 128.9, 128.4, 128.1 , 125.8, 112.9, 83.4, 60.0, 
59.4, 56.0, 55.0, 51.8, 51.3, 49.9, 47.7, 42.8, 40.5, 38.8, 29.0, 28.2, 24.3, 18.8, 12.1; MS(ESI) m/z 
calcd. for [C47H62N9O11S]+: 960.4 [M+H]+; found: 960.6. 
 
Compound 2.81 b (40 mg, 0.04 mmol, 1 eq) was cyclized in the presence of HATU (60 mg, 
0.16 mmol,4 eq), HOAt (22 mg, 0.16 mmol, 4 eq) and DIPEA (62 L, 0.24 mmol, 6 eq) under 
the conditions described in GP4. The residue was purified over flash column eluting 
DCM/MeOH (from 97:3 to 9:1) to afford the crude product 2.82 b as a pale yellow foam. 
 
Compound 2.82 b: Rf = 0.16 (9:1 DCM/MeOH); MS (ESI) m/z calcd. for [C47H62N9O11S]+: 
960.4[M+H]+; found: 960.6 [M+H]+. 
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Cyclo[(3R,6S)-DKP-isoDGR] (2.76) and Cyclo[(3S,6R)-DKP-isoDGR] (2.77) 
 
Compound 2.82 a (40 mg, 0.04 mmol, 1 eq) or 2.82 b(15 mg, 0.015 mmol, 1 eq) was 
deprotected under the conditions described in GP10. The crude product was purified by 
RP-HPLC [compound 2.76= gradient: 90% H2O + 0.1% CF3COOH / 10% CH3CN + 0.1% 
CF3COOH to 100% CH3CN + 0.1% CF3COOH in 10 min; flow: 15 mL/min, tR (product) = 4.7 
min; compound 2.77 = gradient: 100% H2O + 0.1% CF3COOH to 50% H2O + 0.1% CF3COOH / 
50% CH3CN + 0.1% CF3COOH in 11 min; flow: 15 mL/min, tR (product) = 9.6 min]. The pure 
fractions were concentrated and freeze-dried, affording 2.76 or 2.77as a white solid (2.76: 
12.5 mg, 37%; 2.77: 3.0 mg, 25%). 
Compound 2.76: 
1H-NMR (400 MHz, D2O)  7.54-7.31 (m, 10H), 5.26 (d, J = 15.3 Hz, 1H), 5.09-5.00 (m, 2H), 
4.79(d , 1H), 4.67 (d, J = 16.4 Hz, 1H), 4.33-4.30 (m, 1H), 4.29-4.17 (m, 3H), 4.11 (dd, J = 14.7, 
3.6Hz, 1H), 3.91 (d, J = 16.8 Hz, 1H), 3.68 (dd, J = 14.6, 1.6 Hz, 1H), 3.25 (t, J = 6.8 Hz, 2H), 3.02 
(dd, J = 14.8, 3.9 Hz, 1H), 2.90 (d, J = 5.9 Hz, 2H), 2.45 (dd, J = 14.8, 11.2 Hz, 1H), 1.88-1.55 (m, 
4H).13C-NMR (101 MHz, D2O)  175.3, 174.2, 172.1, 171.5, 170.5, 156.8, 135.8, 135.1, 
129.2,128.9, 128.3 128.1, 127.7, 126.8, 66.6, 59.1, 57.7, 54.2, 50.1, 49.7, 47.2, 41.6, 40.7, 40.4, 
39.8, 37.3, 27.5, 24.4 
 
Compound 2.77: 
1H-NMR (400 MHz, CD3OD)  7.48-7.15 (m, 10H), 5.20 (d, J = 15.4 Hz, 1H), 4.68-4.56 (m, 
2H),4.50 (dd, J = 9.4, 2.4 Hz, 1H), 4.43-4.37 (m, 1H), 4.27 (d, J = 5.4 Hz, 1H), 4.19 (d, J = 15.4 
Hz,1H), 4.07 (d, J = 8.8 Hz, 1H), 4.03 (d, J = 5.4 Hz, 1H), 3.75-3.65 (m, 2H), 3.13 (dd, J = 11.7, 
6.5Hz, 2H), 2.96 (dd, J = 15.3, 8.6 Hz, 1H), 2.83 (dd, J = 14.5, 2.4 Hz, 1H), 2.67 (dd, J = 15.3, 3.8 
Hz,1H), 2.55 (dd, J = 14.5, 9.5 Hz, 1H), 1.94-1.83 (m, 1H), 1.62-1.48 (m, 3H), 1.32-1.20 (m, 2H); 
13C-NMR (101 MHz, CD3OD, HSQC projection)  135.2, 129.2, 129.0, 128.3, 127.7, 126.7, 59.7, 
56.3, 53.2, 52.2, 47.8, 40.5, 39.4, 36.5, 26.9, 24.4 
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HPLC TRACE OF THE FINAL PRODUCT 2.76 
 
Purity: ≥99% 
 
HPLC TRACE OF THE FINAL PRODUCT 2.77 
 
Purity: 94%   
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CHAPTER 3 
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DKP-RGD MAGNETIC NANOPARTICLES CONJUGATES 
 
3.1 Aim of the project 
The aim of this part of the work was the “active targeting” of MNPs to specific type of 
cells in order to allow hyperthermia therapy. The strategy of “active targeting” consists in 
adding to the surface of MNPs ligands such as small molecules, peptides, antibodies or 
antibodies fragments, and nucleic acids to activate the molecular recognition of the cells 
through the ligand-receptor binding. In particular, we were interested in obtaining 
bioconjugates between MNPs and cyclo-RGD integrin ligand peptidomimetics to target 
V3 overexpressing cells. We planned to obtain the bioconjugation by a Cu(I)-catalyzed 
Azide-Alkyne Click chemistry (CuAAC) reaction between the azide component 
containing the cyclo-RGD integrin ligand peptidomimetics and the alkyne component 
linked to the MNPs. 
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3.2 Hyperthermia and magnetic nanoparticles 
3.2.1 Hyperthermia 
Hyperthermia (also named thermal therapy or thermotherapy) is a cancer treatment in 
which a tissue is exposed to high temperatures (up to 45°C). The use of increased 
temperature for therapeutical purposes has been reported for many centuries: a first 
evidence could be found in the Egyptian Edwin Smith surgical papyrus (dated around 
3000BC). Later (19th and 20th centuries) radiofrequency techniques have been 
investigated as a method to produce heating, as well as fever therapy 170 . High 
temperatures can damage and kill cancer cells without affecting in a relevant manner 
normal tissues.171 The in vivo moderate selectivity for tumor tissues (achieved between 
40°C and 44°C) is reached thanks to a characteristic difference between normal and 
tumor physiology which is present in tumor regions with hypoxia and low pH, while it 
cannot be found in normal healthy tissues.172 These regions are more sensitive to high 
temperatures. Cell death occurs probably by protein denaturation and consequent 
cytoskeleton and membranes alterations. Moreover, changes in enzyme complexes for 
DNA synthesis and repair occur. 173  Hyperthermia has been used as monotherapy 
treatment or, almost always, in association with radiation therapy and chemotherapy.174 
Heating tissues causes an increase blood flow, and a consequent higher sensitivity to 
radiotherapy (because of the improved tissue oxygenation 175 ) or to chemotherapy 
(because of the major amount of cytotoxic agent that reaches the tumor). The supra-
additive effect of the combination hyperthermia-radiotherapy is mediated both by a 
direct action on cells that cannot be damaged by radiations and sensitizing cancer cells 
to radiations.176  In addition, hyperthermia is also able to potentiate radiations effects 
because it interferes with the cellular repair of radiation-induced DNA damage, probably 
acting on cellular proteins.177 
Hyperthermia has also been studied in association with chemotherapy and various 
examples can be found in the literature proving that hyperthermia is able to enhance the 
effects of certain anticancer drugs (if given in close sequence to the drug treatment).178 A 
deep analysis of this application is beyond the scope of this thesis, however an extensive 
                                                          
170 Seegenschmiedt, M. H.; Veron, C.C. in “Thermoradiotherapy and Thermochemotherapy”, 1, (Berlin: Springer Verlag), 1995, 3-4 
171 Van der Zee, J., Annals of Oncology 2002, 13, 1173-1184 
172 Reinhold, H. S.; Endrich, B., Int. J. Hyperthermia 1986, 2, 111-137 
173 (a) Streffer, C. in “Thermoradiotherapy and Thermochemioterapy “, 1 (Berlin: Springer Verlag), 1995, 47-74; (b) Hildebrandt, B.; Wust, P.; Ahlers, O.; Dieing, A.; Sreenivasa, G.; Kerner, T.; Felix, R.; Riess, H., Critical Reviews in Oncology/Hematology 2002, 43(1), 33–56 
174 Wust, P.; Hildebrandt, B.; Sreenivasa, G.; Rau, B.; Gellermann, J.; Riess, H.; Felix, R.; Schlang, P. M., The Lancet Oncology 2002, 3(8), 487–497 
175 Song, C. W. M.; Shakil, A.; Griffin, R. J.; Okajima, K., Semin. Oncol. 1997, 24, 626-632 
176 Raaphorst, G. P. in “An Introduction to the Practical Aspects of Clinical Hyperthermia (London: Taylor and Francis), 1990, 10-54 
177 Kampinga, H. H.; Dikomey, E., Int. J. Radiat. Biol. 2001, 77, 399-408 
178 For example see: (a) Engelhard, R., Recent Results Cancer Res. 1987, 104, 136-203, (b) Hanhn, G. M., Cancer Res. 1979, 39, 2264-2268; (c) Dahl, O.; Mella, O., Anticancer Res.1982, 2, 359-364 
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review on the combination of hyperthermia with chemotherapy was published in 1995.179 
In addition to the enhanced tissue perfusion, guarantee by the increased blood flow, it 
was shown a reduction of the drug resistance and an increase of the intracellular drug 
uptake.171 
 
3.2.2 Magnetic nanoparticles 
Magnetic nanoparticles (MNPs) are interesting in various research fields: magnetic 
fluid, 180  catalysis, 181 biotechnology/biomedicine, 182  data storage, 183  environmental 
remediation.184 The synthesis of MNPs could be performed according to many different 
procedures, however the stability of the particles over a range of different conditions is 
one big limitation to their applications. 
 
3.2.2.1 Application of MNPs in hyperthermia 
MNPs offer some attractive possibilities in biomedicine because of their peculiar 
properties. First, the controllable size. Since the size is ranging from a few nanometers up to 
tens of nanometers, it is smaller than or comparable to cells (10-100 m), viruses (20-450 
nm), proteins (5-50 nm) or genes (2nm wide and 10-100 nm long) size. Because of this, 
MNPs can interact with or bind to a biological entity that can be targeted or addressed in 
such a way. Second, particles can be manipulated by an external magnetic field gradient 
delivering anticancer drugs, or radionuclide atoms, to a targeted region of the body. 
Third, MNPs are responsive to a time-varying magnetic field and for example they can be 
made to heat up thus delivering heat to the surrounding areas.185 As a result, MNPs find 
applications as hyperthermia agents186 , drug delivery carriers187 , and as MRI contrast 
enhancement agents182,188. Among all these applications, hyperthermia will be deepened 
as it was hypothesized as application for Cyclo[RGD-DKPf3]-MNPs conjugates. 
                                                          
179 Dahl, O. in “Thermoradiotherapy and Termochemoterapy”, 1 (Berlin: Springer Verlag) 1995, 103-121 
180 Chikazumi, S.; Taketomi, S.; Ukita, M.; Mizukami, M.; Miyajima, H.; Setogawa, M.; Kurihara, M., J. Magn. Mater. 1987, 65, 245-251 
181 (a) Lu, A.-H.; Schmidt, W.; Matoussevitch, N.; Bӧnnermann, H.; Spliethoff, B.; Tesche, B.; Bill, E.; Kiefer, W.; Schüt, F., Angew. Chem. Int. Ed. 2004, 43, 
4303-4306; (b) Tsang, S. C.; Caps, V.; Paraskevas, I.; Chadwick, D.; Thompsett, D., Angew. Chem. Int. Ed. 2004, 43, 5645-5649 
182 (a) Gupta, A. K.; Gupta, M., Biomaterials 2005, 26, 3995-4021; (b) Mornet, S.; Vasseur, S.; Grasset, F.; Verveka, P.; Goglio, G.; Demourgues, A.; Portier, J.; Pollert, E.; Duguet, E., Prog. Solid State Chem. 2006, 34, 237; (c) Li, Z.; Wei, L.; Gao, M. Y.; Lei, H., Adv. Mater. 2005, 17, 1001-1005 
183 Hyeon, T., Chem. Commun. 2003, 927-934 
184 (a) Elliott, D. W.; Zhang, W.-X., Environ. Sci. Technol.  2001, 35, 4922-4926; (b) Takafuji, M.; Ide, S.; Ihara, H.; Xu, Z., Chem. Mater. 2004, 16, 1977-1983 
185 Pankhurst, Q. A.; Connolly, J.; Jones, S. K.; Dobson, J., J. Phys. D: Appl. Phys. 2003, 36, R167-R181 
186 See references in paragraph 3.1.2.1 
187 For example see: (a) Widder, K. J.; Senyei, A. E.; Scarpelli, D. G., Proc. Soc. Exp. Biol. Med. 1987, 58, 141-146; (b) Senyei, A.; Widder, K.; Czerlinski, C., J. Appl. Phys. 1987, 49, 3578-3583; (c) Mosbach, K.; Schrӧder, U., FEBS Lett. 1979, 102, 112-116; (d) Alexiou, C.; Arnold, W.; Klein R. J.; Parak, F. G.; Hulin, P.; 
Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lübbe, A. S., Cancer Res. 2000, 60, 6641-6648; (e) Lübbe, A. S.; Bergemann, C.; Huhnt, W.; Fricke, T.; Reiss, H.; Brock, J. W.; Huhnt, D., Cancer Res. 1996, 56, 4694-4701; (f) Lübbe, A. S.; Bergemann, C.; Riess, H.; Schriever, F.; Reichardt, P.; Possinger, K.; Matthias, M.; Doerken, B.; Herrmann, F.; Guertler, R., Cancer Res. 1996, 56, 4686-4693 (g) Häfeli, U. O.; Casillas, S.; Dietz, D. W.; Pauer, G. J.; Rybiki, L. A.; Conzone, S. D.; Day, D. E., Int. J. Radiat. Oncol. Biol. Phys. 1999, 44, 189-200; (h) Häfeli, U.; Pauer G.; Failing, F.; Tapolsky, G., J. Magn Mater. 2001, 225, 73-78 
188 For example see: (a) Lawaczeck, R.; Bauer, H.; Frenzel, T.; Hasegawa, M.; Ito, Y.; Kito, K.; Miwa, N.; Tsutsui, H.; Vogler, H.; Weinmann, H. J., Acta Radiol. 1997, 38, 584-597; (b) Weissleder, R.; Elizondo, G.; Wittenburg, J.; Rabito, C. A.; Bengele, H. H.; Josephson, L., Radiol. 1990, 175, 489-493; (c) Ruehm, S. G.; Corot, C.; Vogt, P.; Kolb, S.; Debatin, J. F., Circulation 2001, 103, 415-422; (d) Wacker, F. K.; Reither, K.; Ebert, W.; Wendt, M.; Lewin, J. S.; Wolf, K. J., 
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Ferromagnetic material (FM) are magnetic even without an applied field, while 
superparamgnetic material (SPM) exhibit a magnetic behavior only when inserted into a 
magnetic field. These second class of material has emerged as the best one for 
hyperthermia because it requires lower magnetic field strengths to produce an useful 
amount of heating. The challenge in humans is to generate enough heat using clinical 
safe field conditions (high magnetic fields can have dangerous effects 189 ). When a 
magnetic field is applied, there is a constant flow of energy into the magnetic material 
and this energy will be transferred into thermal energy. This is the physical basis of 
magnetic hyperthermia. Therapeutic efficacy of magnetically mediated hyperthermia 
was proved in animals model190 and different devices were developed to heat selectively 
malignant cells.171,174,191 The first evidences regarding the use of magnetic materials in 
hyperthermia date back to 1957192 and since then many different publications concerning 
that topic have been written.193 Since most of the hyperthermia devices cannot avoid the 
heating of healthy tissues, magnetic particles hyperthermia offers a way to heat only the 
targeted tissue(s) by selective delivery of MNPs. 
 
Figure 3.1 – Magnetic hyperthermia: MNPs are selectively delivered to the tumor tissues and then heated up through the application of an external magnetic field 
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3.2.2.2 Synthesis and coating of MNPs: general methods 
MNPs of different compositions are reported in the literature: oxides (such as Fe3O4 and 
-Fe2O3) 194 , pure metals (such as Fe and Co) 195 , spinel-type ferromagnets (such as 
MgFe2O4, MnFe2O3, and CoFe2O4)196, alloys (such as CoPt3 and FePt)197. Several methods 
directed to the synthesis of high-quality MNPs are reported. Since comprehensiveness is 
not the purpose of this work, only some examples will be taken into account. 
Co-precipitation is an useful protocol to prepare Fe3O4 and -Fe2O3 MNPs starting from 
aqueous Fe2+/Fe3+ salt solutions by addition of a base under inert atmosphere at room 
temperature or at elevated temperature. Depending on the type of salt, the Fe2+/Fe3+ 
ratio, the reaction temperature, the pH value and the ionic strength of the media, MNPs 
with different sizes, shapes and compositions can be produced. However once the 
reaction conditions are set, the quality of MNPs is reproducible even if the particle size 
distribution is not narrow. The resulting MNPs are stabilized by repulsive electrostatic forces 
because of the positive charge.198 The effects of several organic anions were extensively 
studied199: chelation of the metal ions and adsorption of additives on the nuclei act in an 
opposite way. As a matter of facts, chelation leads to the formation of a small number of 
nuclei that then grow up while absorption of additives may inhibit the growth of the 
particles, which favors the formation of small units. A proper organic additive acting as 
stabilizer and reducing agents are useful tools to produce monodisperse Fe3O4 MNPs. The 
best one resulted the oleic acid.200 
Thermal decomposition in non-aqueous media was developed as a method to 
synthesize high quality semiconductor nanocrystals.201 Also MNPs could be obtained by 
thermal decomposition of organometallic compound in high-boiling organic solvents 
containing stabilizing surfactants.196b,202 The ratios of all the starting materials, the reaction 
temperature, and the reaction time are crucial parameters to control the size and the 
morphology of the MNPs. A zerovalent metal in the precursor lead to oxide MNPs but there 
are two-step procedures that give oxide MNPs.201a,203 For example Peng and co-workers 
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developed a general decomposition approach for the synthesis of Fe3O4 nanocrystals204 
that was later generalized to other metal oxides (Cr2O3, MnO, Co3O4, NiO). A similar 
protocol was also used by Hyeon and co-workers to prepare Fe3O4 MNPs with size 
depending on the decomposition temperature and on the aging period. The obtained 
MNPs are dispersible in organic solvent.202 This method was also used to prepare metal 
MNPs, for example Co MNPs205 or nanodisks195,206 or nanorods207. 
A microemulsion is a thermodynamically stable isotropic dispersion of two immiscible 
liquids stabilized by an interfacial film of surfactants molecules.208 The size of the reverse 
micelle is determined by the molar ratio of the co-solvent and surfactants.209 For example 
metallic cobalt, cobalt/platinum alloys, and gold-coated cobalt/platinum nanoparticles 
were synthesized in reverse micelles. 210  Also MnFe2O4 MNPs with controllable sizes 
(depending on the ratio solvent/co-solvent) were synthesized through the formation of 
water-in-toluene inverse micelles with sodium dodecylbenzensulfonate as surfactant.211 
This techniques allows to obtain spheroids or particles with an oblong cross section.212 
However, the particle size is varying over a relative wide range, yields are lower than with 
other methods and large amounts of solvents are required.  
Li and co-workers reported a general hydrothermal methods which allows the synthesis 
of a various range of nanostructured materials.213 At the interfaces of the solid, liquid, and 
solution phases in the reaction mixture, phase transfer and separation mechanisms occur. 
These events are at the basis of the hydrothermal method. 
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In table 3.1 is reported a short summary on the different synthetic techniques. 
Method Synthesis Reaction T (°C) Reaction time Sol. Size distribution Shape control Yield 
Co-precipitation 
Very simple, ambient conditions 20-90 Minutes Water 
Relatively narrow Not good High/ scalable 
Thermal decomposition 
Complicated, inert atmosphere 100-320 Hours-days Organic Very narrow 
Very good High/ scalable 
Microemulsion Complicated, ambient conditions 20-50 Hours Organic 
Relatively narrow Good Low 
Hydrothermal synthesis Simple, high pressure 220 Hours ca. days Water-ethanol Very narrow Very good Medium 
Table 3.1 – Summary comparison on the synthetic methods 
Underlined the best advantage of each technique: co-precipitation is the preferred route in terms of synthesis simplicity, thermal decomposition is the best one in terms of size and morphology and hydrothermal synthesis allows to obtain a very narrow size distribution range. 
Long time stability and suspendibility in solvents without agglomeration of these particle 
are an important requirements for almost any application. Pure metals and their alloys are 
instable towards oxidation in air and this susceptibility becomes higher the smaller the 
particles are. Two main solutions were developed: synthesize nanoparticles with a core-
shell structure (that means naked magnetic nanoparticles as a core and an isolating shell 
coating), or synthesize MNPs dispersed in a solid matrix (that means embedded MNPs, 
fixed in space relative to each other)214. In this latter approach MNPs can be dispersed in a 
continuous matrix, or they can be dispersed in coating/larger particles, or they can 
agglomerate of individual nanoparticles which are connected through their protective 
shells. For what concerns MNPs coating, there are three main options: oxides (created by 
mild oxidation of the MNPs surface205b,215 or additionally deposited216) or organic shell 
(surfactant and polymers217) or inorganic components (mainly silica,218 carbon,219 precious 
metals such as Ag,220 Au221). Moreover, further modifications of the MNPs surface can be 
achieved by anchoring molecules to the shell of the MNPs, creating new materials with 
specific functions.222 
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Since a comprehensive treatment of the topic is beyond the purpose of this thesis, only 
the techniques involved in the Cyclo[DKPf3-RGD] conjugates preparation will be 
considered in the corresponding paragraph. 
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3.3 Polyethylenimine magnetic nanoparticles (PEI MNPs) 
PEI MNPs (Figure 3.2) have a cobalt core, a protective carbon shell and a further 
polyethylenimine coating which confers water dispersibility and the chance of a further 
functionalization.  
 
Figure 3.2 – Co/C PEI MNPs 
Co/C MNPs (Figure 3.3) were successfully produced by Stark and co-workers through a 
flame-spray procedure. 223  The addition of acetylene to the Co-MNPs-forming process 
resulted in the deposition of carbon on the particles.  
 
Figure 3.3 – Co/C MNPs 
TEM pictures revealed that several carbon layers coated the particles in an onion-type 
arrangement. The produced MNPs exhibited excellent magnetic properties with a 
saturation magnetization of 158 Am2/Kg. As a consequence, recovery from a suspension is 
fast and complete (Figure 3.4). 
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Figure 3.4 – Co/c MNPs recovery through an external magnet 
These functionalized MNPs were selected to produce the bioconjugates with the cyclic 
RGD-peptidomimetic because carbon-based materials have many advantages over 
polymer or silica, such as much higher chemical and thermal stability as well as 
biocompatibility. Carbon-coated nanoparticles are usually in the metallic state, and thus 
have a higher magnetic moment than the corresponding oxides. The graphitic carbon 
layers provide an effective barrier against acid leaching and oxidation. 224  The main 
problem of carbon-coated MNPs is related to their synthesis: the formation mechanism is 
usually quite not understood and it often leads to agglomerated clusters instead of single 
units. Various synthetic strategies were developed to lay down the protective shell around 
nanoparticles: for example carbon-encapsulated metal or metal carbide nanocrystallites 
can be generated by the Krätschmer arc-discharge process225 or under laser ablation, 
and electron irradiation. 226  Gedanken and co-workers reported a sonochemical 
procedure that leads to air-stable cobalt nanoparticles in which the high stability arises 
from the formation of the carbon shell. However, MNPs produced in this way are rather 
polydispersed.227 As further example can be mentioned the work of Johnson et al., that 
described the synthesis of Fe and Fe3C nanoparticles by direct pyrolisis of iron stearate at 
900°C under an argon atmosphere228, and the Co/C MNPs of Lu et al.219 
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3.3.1 Co/C MNPs 
The diazonium chemistry was used to covalently functionalize graphene coated 
MNPs.229 The mechanism (Scheme 3.1) involves an electron transfer reaction. A graphene 
electron is transferred to the adsorbed diazonium ion, generated by the thermal 
decomposition of the diazonium salt, and nitrogen is released. As a consequence, a 
phenil radical, more reactive, is formed. This radical reacts with the carbon surface230, 
even if the reaction is rather unspecific (simultaneous polymerization can occur). 
 
Scheme 3.1 – Mechanism for the diazonium reaction with the graphene surface 
Organic chemistry on metal nanoparticles bound graphene has yielded a broad range 
of accessible structures (Figure 3.5). 
 
Figure 3.5 – Diazonium salt chemistry on graphene: accessible structures 
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Co/C MNPs were functionalized by Stark and co
thus obtaining stable suspension 
different procedures: a covalent ligation strategy and a non
were developed for the functionalization of the Co/C MNPs
covalent method the –NO2 intermediate, generated through the diazonium chemistry, 
was converted into an amine
suitable moiety to insert further functionalization throu
On the other hand, polyarenes could be 
stacking interactions with the graphen
hydrophobic effects have resulted useful for this approach, as demonstrated by the 
successful immobilization on MNPs of metal complexes.
Scheme 3.2 – Principal strategies for covalent and non
All these modified MNPs were
ammonium groups confer somehow 
of the covalent ligation strategy
water-dispersible particles showed
that a high loading of polar functional groups is a requirement to obtain stable water
suspensions of the functionalized MNPs.
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-workers with highly charged polymers 
in water. 231  Reiser’s research group developed also 
-covalent ligation strategy 
 (Scheme 3.
 and then into the corresponding azide.232
gh an azide-alkyne cycloa
connected to the carbon shell by attractive 
e-like layers of the MNPs surface.
234 
-covalent functionalization of Co/C MNPsmolecule) 
 tested for the dispersibility in water: positively charged 
higher dispersibility than hydroxy groups
 increases the dispersibility in water. In any case, 
 only a 60 min stable dispersion.222a It was
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3.3.2 Co/C PEI synthesis and characterization
Reiser’s research group 
grafting a polyethyleneimine
highly water-dispersible MNPs
phenylethyleneamine-functionalized particles
produced through the reaction of 
from the aniline 3.3. 
Co HCl, NaNO2
H2N
NH2
3.2 3.3
The loading of amino functionalities was e
and by TGA. The nitrogen loading 
polymeric coating, it is not possible to describe the exact structure
nitrogen groups are primary amines, half are secondary amines and ¼ are tertiary amines. 
Co/C. PEI MNPs 3.1 were characterized by 
discrete particles and no cross
Figure 3.6 – IR spectra of phenylethyleneamine
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developed highly amine-loaded Co/C nanoparticles 
 (PEI) onto the MNPs (Scheme 3.3) with the aim of producing 
. Aziridine (3.5) was polymerized 
 (3.4). These functionalized particles 
Co/C MNPs (3.2) with the diazonium salt generated 
CoCoCo NH2
HN
HClDCM
3.4
3.5
Scheme 3.3 – PEI MNPs synthesis 
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Figure 3.7 – TEM picture of PEI MNPs (3.1) 
The superconducting quantum interference device (SQUID) measurements confirmed 
the high mass proportion of PEI polymer (60% wt by TGA): the magnetic saturation value 
was reduced from 128 emu/g (value for Co/C naked MNPs) to 39 emu/g (value for PEI 
MNPs)(Figure 3.8). 
 
Figure 3.8 – SQUID measurements for naked Co/C MNPs and PEI MNPs (3.1) 
This system proved to form water dispersions stable over days (stability test reported in 
the same paper222a) without any sedimentation or agglomeration even in a biphasic 
system with DCM (Figure 3.9). Because of all their properties, MNPs 3.1 are suitable 
candidates as carrier for bioactive compounds. 
 
Figure 3.9 – PEI MNPs (3.1) dispersibility between water and DCM 
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3.3.3 Co/CPEI further functionalization 
As mentioned in the introduction of this chapter, we planned to obtain the MNPs 
functionalized as alkynes and the biological active compound linked to an azide moiety. 
Different strategies were explored to introduce the alkyne (Scheme 3.4). In table 3.2 is 
presented a brief summary. 
 
Scheme 3.4 – PEI MNPs functionalization, general scheme 
Entry Ligand Reactant(s) Solvent Temperature Reaction time Loading 
1 Succinic anhydride / DCM r.t. 24 h 0.01 mmol/g[a] 
2 Glutaric acid HATU, HOAt, DIPEA DMF r.t. 15 h 0.003 mmol/g[a] 
3 Mono-methyl glutarate HATU, HOAt, DIPEA DMF r.t. 15 h 0.160 mmol/g[a] 
4 4-pentenoic acid NHS, DIC DMF r.t. 15 h <0.01 mmol/g[b] 
5 3-bromopropionic acid K2CO3 DMF 80°C 24 h 0.376 mmol/g[a] 
6 Propargyl bromide K2CO3 DMF 80°C 24 h 1.542 mmol/g[a] 
Table 3.2 – Functionalization strategies on Co/C MNPS ([a] = Initial loading  8.53 mmol N/g; [b] Initial loading 7.28 mmol N/g ) 
All these attempts could be divided into two main classes: direct insertion of the alkyne 
(entry 4 and 6) or insertion of a linker on which a further functionalization would allow to 
put the desired alkyne moiety (entries 1 to 3 and 5). The second strategy gave low 
loadings of the linker, especially taking into account that the first strategy does not require 
a further step. The letter synthetic procedure is represented in Scheme 3.5. Between entry 
4 and 6, the difference is marked: coupling reagents, used to form an amide bond, are 
absolutely less efficient than the bromide. The alkyne functionality was introduced by a 
nucleophilic substitution.235 
                                                          
235 Levy, D. E.; Marlowe, C.; Kane-Mauire, K.; Bao, M.; Cherbavaz, D. B.; Tomlison, J. E.; Sedlock, D. M.; Scarborough, R. M., Bioorg. Med. Chem. Lett. 2002, 12, 3085-3088 
 Page 106    
 
Scheme 3.5 – Synthesis of alkyne-PEI MNPs (3.6) 
MNPs 3.6 were characterized by elemental analysis (alkyne loading of 1.542 mmol/g) 
and by SQUID measurements. SQUID measurements afforded a saturation magnetization 
value of 70.57 emu/g. Interestingly, these MNPs 3.6 are not suspensible in water, thus the 
alkyne functionalization cancels the high water suspendibility of PEI MNPs. 
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3.4 Iron oxide silica coated magnetic nanoparticles 
(Fe3O4@silica MNPs) 
Fe3O4 is an iron oxide that has a cubic inverse spinel structure with oxygen forming a fcc 
closed packing and Fe cations occupying interstitial tetrahedral sites and octahedral 
sites.236 With proper surface coating, these magnetic nanoparticles can be dispersed into 
water. 237 The use of Fe3O4 MNPs (with various coatings) for biological purposes is 
consolidated and a lot of examples are present in the literature.238 In particular Fe3O4 and 
-Fe2O4 MNPs have appropriate magnetic properties and biological compatibility 239 . 
Naked Fe3O4 MNPs usually have a magnetic saturation values in the range of 30-50 emu/g 
but unfortunately they are not very stable under ambient conditions: they are easily 
oxidized to maghemite (that, luckily, is still ferrimagnetic) or dissolved in acid media. 
Fe3O4 MNPs are commonly produced via co-precipitation of ferrous (Fe2+) and ferric 
(Fe3+) ions by a base in aqueous solution,240 or by thermal decomposition of alkaline 
solutions of Fe3+ chelate in presence of hydrazine,241 or by sonochemical decomposition of 
hydrolyzed Fe2+ salts followed by thermal treatment. 242  As an alternative, also the 
microemulsion method has been reported.243 
Among the most used surface coating materials, silica and alkoxysilanes are the 
preferred ones, especially for iron oxide MNPs. 244  Silica has the advantage of being 
biocompatible, hydrophilic244h,l, stabile under aqueous conditions (if the pH value is not 
extremely basic), chemically inert and physically stable.245 The silica shell exercises two 
main functions: the magnetic core protection and the prevention of the contact between 
the MNPs core and additional agents linked to the silica, thus avoiding unwanted 
reactions.246 In addition, silica prevents the aggregation of particles.244h,l Furthermore, the 
silica coating can react with various agents to covalently attach specific ligands allowing 
                                                          
236 Cornell, R. M.; Schwertmann, U. in “ The Iron Oxides: Structure, Properties, Reactions, Occurrence and Uses” (VHC: New York) 1996, 28-29 
237 Fu, L.; Dravid, V. P.; Johnson, D. L., Appl. Surf. Sci. 2001, 181, 173-178 
238 For example see: (a) Lin, R.-Y.; Dayananda, K.; Chen, T.-Y.; Chen, C.-Y.; Liu, G.-C.; Lin, K.-L-.; Wang, Y.-M., Contrast Media Mol. Imaging 2012, 7, 7-18; (b) Zheng, S. W.; Huang, M.; Hong, R. Y.; Deng, S. M.; Cheng, L. F.; Gao, B.; Badami, D., Journal of Biomaterials Applications 2014, 28 (7), 1051-1059; (c) Deng, S.; Zhang, W.; Zhang, B.; Hong, R.; Chen, Q.; Dong, J.; Chen, Y.; Wu, Y., J. Nanopart. Res. 2015, 17, 19; (d) Xie, J.; Chen, K.; Lee, H.-Y.; Xu, C.; Hsu, A. R.; Peng, S.; Chen, X.; Sun, S., J. Am. Chem. Soc. 2008, 130, 7542-7543 
239 (a) Weissleder, R.; Cheng, H. C.; Bogdavova, A.; Bogdanov A., J. Magn. Reson. Imaging 1997, 7, 258-263; (b) Cengelli, F.; Maysinger, D.; Tschudi-Monnet, F.; Montet, X.; Corot, C.; Petri-Fink, A.; Hofmann, H.; Juillerat-Jeanneret, L., J. Pharmacol. Exp. Ther. 2006, 318, 108-116; (c) Brigger, I.; Dubernet, C.; Couvreur, P., Adv. Drug Delivery Rev. 2002, 54, 631-651; (d) Wang, L.; Bao, J.; Wang, L.; Zhang, F.; Li, Y., Chem. Eur. J. 2006, 12, 6341-6347 
240 (a) Kang, Y. S.; Risbud, S.; Rabolt, J. F.; Stroeve, P., Chem. Mater. 1996, 8, 2209-2211; (b) Hong, C.-Y.; Jang, L. J.; Horng, H. E.; Hsu, C. J.; Yao, Y. D.; Yang, H. C., J. Appl. Phys. 1997, 81, 4275-4277; (c) Fried, T.; Shemer, G.; Markovic, G., Adv. Mater. 2001, 13, 1158-1161 
241 Sapieszko, R. S.; Matijevic, E., J. Colloid Interface Sci. 1980, 74, 405-422 
242 Vijayakumar, R.; Koltypin, Y.; Felner, I.; Gedanken, A., Mater. Sci. Eng. 2000, A286, 101-105 
243 Santra, S.; Tapec, R.; Theodoropoulou, N.; Dobson, J.; Hebrad, A.; Tan, W., Langmuir 2001, 17, 2900-2906 
244 (a) Philipse, A. P.; Van Bruggen, M. P.; Pathmamanoharan, C., Langmuir 1994, 10, 92-99; (b) Yang, H. H.; Zhang, S. Q.; Chen, X. L.; Zhuang, Z. X.; Xu, J. G.; Wang, X. R., Anal. Chem. 2004, 76, 1316-1321; (c) Bruce, I. J.; Sen, T., Langmuir 2005, 21, 7029-7035; (d) Kohler, N.; Fryxell, G. E.; Zhang, M., J. Am. Chem. Soc. 2004, 126, 7206-7211; (e) Mikhaylova, M.; Kim, D. K.; Berry, C. C.; Zagorodni, A.; Toprak, M.; Curits, A. S.; Muhammed, M., Chem. Mater. 2004, 16, 2344-2345; (f) Fan, H.; Chen, Z.; Brinker, C. J.; Clawson, J.; Alam, T., J. Am. Chem. Soc. 2005, 127, 13746-13747; (g) Donselaar, L. N.; Philipse, A. P.; Suurmond, J., Langmuir 1997, 13, 6018; (h) Liu, Q.; Xu, Z.; Finch, J. A.; Egerton, R., Chem. Mater. 1998, 10, 3936-3940; (i) Correa-Duarte, M. A.; Giersig, M.; Kotov, N. A.; Liz-Marzan, L. M., Langmuir 1998, 14, 6430-6435 
245 Smith, J. E.; Wang, L.; Tan, W., Trends Anal. Chem. 2006, 25, 848-855 
246 Lu, A.-H; Salabas, E. L.; Schüth, F., Angew. Chem. Int. Ed. 2007, 46, 1222-1244 
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the insertion of various functionalities on the MNPs. 247  Alkoxysilanes are bifunctional 
molecules with the general formula [X(CH2)n]mSiR(OR’)3-m, where X represents the 
headgroup functionality, (CH2)n a flexible spacer, and Si(OR’)the anchor groups by which 
they can attach to free SiOH or FeOH surface groups after hydrolysis of the alkoxy 
group.244c These molecules can be used to directly connect functional groups or bioactive 
molecules on the MNPs. However, silica as two main disadvantages: it is not stable under 
basic conditions and it may contain pores through which oxygen or other species could 
diffuse affecting the core. The silica coating is usually deposited on the MNPs through the 
Stӧber method248 or through sol-gel processes.249 The coating thickness can be tuned by 
varying the concentrations of ammonium and the ratio of tetraethoxysilane (TEOS) to H2O. 
Since the iron oxide surface has a strong affinity towards silica, no primer is required to 
promote the deposition and adhesion of silica.249c 
In the case of the iron oxide MNPs used for our purposes, their synthesis is depicted in 
Scheme 3.6. Alkyne-Fe3O4@silica MNPs 3.7 were conveniently silica coated and 
functionalized with an alkyne in an one-step reaction. In order to introduce the alkyne 
group, reagent 3.8 was synthesized by reaction of equimolar amounts of TEOS and 4-
pentyn-1-ol in dry toluene. The resulting solution was directly used to coat the MNPs.250 
 
Scheme 3.6 - Alkyne-Fe3O4@silica MNPs 
Reagents and conditions: a) dry toluene, 90°C, under N2; b) Na2CO3, H2O, 90°C; c) ultrapure water, citric acid, ultrasonic bath for 1 h, T< 40°C; d) 3.8, acetic acid cat., ultrapure water cat., dry toluene, reflux. 
MNPs 3.7 were analyzed by elemental analysis: the alkyne loading was evaluated 0.519 
mmol/g. The SQUID measurement gave a saturation magnetization value of 52.41 emu/g 
(Figure 3.10).  
                                                          
247 Ulman, A., Chem. Rev.1996, 96, 1533-1554 
248 Stӧber, M.; Fink, A.; Bohn, E. J., J. Colloid Interface Sci. 1968, 26, 62-69 
249 (a) Tago, T.; Hatsuta, T.; Miyajima, K.; Kishida, M.; Tashiro, S.; Wakabayashi, K., J. Am. Ceram. Soc. 2002, 85, 2188-2194; (b) Lu, Y.; Yin, Y.; Mayers, B. T.; Xia, Y., Nano Lett. 2002, 2, 183-186; (c) Graf, C.; Vossen, D. L. J.; Imhof, A.; Van Blaaderen, A., Langmuir 2003, 19, 6693-6700; (d) Philipse, A. P.; Van Bruggen, M. P. B.; Pathmamanoharan, C., Langmuir, 1994, 10, 92-99; (e) Zhao, W.; Gu, J.; Zhang, L.; Chen, H.; Shi, J., J. Am. Chem. Soc. 2005, 127, 8916-8917 
250 Mader, H.; Li, X.; Saleh, S.; Link, M.; Kele, P.; Wolfbeis, O. S., Ann. N. Y. Acad. Sci. 2008, 1130, 218-223 
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Figure 3.10 – SQUID measurements for Fe3O4 MNPs and alkyne-Fe3O4@silica MNPs (light blue: Fe3O4 MNPs 3.9; red: alkyne-Fe3O4@silica MNPs 3.7) 
Since the alkyne loading was low, a different strategy was explored. MNPs were 
functionalized with different commercially available silane-derivatives 3.10 (Figure 3.13), 
bearing a terminal amino group, and 3.11, bearing a terminal chlorine (Figure 3.11) to 
obtain a starting material for a further functionalization.  
 
Figure 3.11 – Silane-derivatives used for MNPs functionalization 
Amino- and chloro-functionalized MNPs were prepared with the same protocol used for 
MNPs 3.7, differing only for the silane used (Scheme 3.7).250 The loading for 3.12 and 3.13 
MNPs are reported in Table 3.3, and compared with MNPs 3.7. 
 
Scheme 3.7 – Coating of Fe3O4 MNPs 3.9 with silane-derivatives 3.10 and 3.11 
Reagents and conditions: a) dry toluene, 90°C, under N2; b) ultrapure water, citric acid, ultrasonic bath for 1 h, T< 40°C; c) 3.10 or 3.11, acetic acid cat., ultrapure water cat., dry toluene, reflux. 
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Ligand Functionlized MNPs Loading (evaluated by EA) 
/ 3.7 0.51mmol alkyne/g 
3.10 3.12 1.76 mmol N/g 
3.11 3.13 1.71 mmol Cl/g 
Table 3.3 – Loading values of different functionalities on Fe3O4 (3.9) MNPs 
Luckily, these loadings resulted quite high. The best value was obtained with the 
aminosilane. Therefore MNPs 3.12 were deemed the best starting material to insert the 
alkyne. The reaction protocol reproduced the one used on PEI MNPs (Scheme 3.8).235 The 
final compound, MNPs 3.14, has an alkyne loading of 1.54 mmol/g (according to EA). 
 
Scheme 3.8 – Fe3O4@silica-NH-alkyne MNPs synthesis 
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3.5 Iron oxide poly(acrylic acid) coated magnetic 
nanoparticles (Fe3O4@PAA-COOH MNPs) 
These MNPs have a Fe3O4 core and a poly(acrylic) acid coating with free carboxylic 
acid groups on the surface (Figure 3.12). 
 
Figure 3.12 – Schematic illustration of the Fe3O4@PAA-COOH nanocrystals 
A ferrofluid is a liquid that becomes strongly magnetized in the presence of a magnetic 
field.251 In the case of ferrofluids, surface charge is very important for their stabilization. For 
example, the MNPs obtained through co-precipitation (starting from Fe2+ and Fe3+) of 
Fe3O4 MNPs in ammonia or NaOH solution are usually negatively charged. This surface 
charge causes agglomeration. Thus, to obtain stable colloids, MNPs have to be treated 
with aqueous tetramethylammonium hydroxide or with aqueous perchloric acid. 252 
Surfactants or polymers can be chemically anchored or physically adsorbed on MNPs to 
form a single or a double layer253 to passivate the surface of MNPs during or after the 
synthesis. These agents create repulsive (mainly as steric repulsion) forces to balance the 
magnetic and the van der Waals attractive forces acting on the nanoparticles thus 
avoiding agglomeration and keeping MNPs in a stable colloidal state. Examples of 
biocompatible polymers-coated MNPs can be found in the literature and they have a 
widespread use.254 The main disadvantage of surfactants/polymer coating is related to 
metallic MNPs: even if they are stabilized by single or double layers of surfactant or 
polymer, they are not air stable and they are easily leached by acidic solution,255 resulting 
in the loss of magnetization. 
  
                                                          
251 Papell, S. S., US Patent 3215572, 1965 
252 Massart, R., IEEE Trans. Magn. 1981, MAG-17, 1247 
253 (a) Shen, L.; Laibinis, P. E.; Hatton, T. A., Langmuir 1999, 83, 217; (b) Sousa, M. H.; Tourinho, F. A.; Depeyrot, J.; Da Silva, G. J.; Lara, M. C. F. L., J. Phys. Chem. B 2001, 105, 1168-1175 
254 (a) Harris, L. A.; Goff, J. D.; Carmichael, A. Y.; Riffle, J. S.; Harburn, J. J.; St. Pierre, T. G.; Saunders, M., Chem. Mater. 2003, 15, 1367-1377; (b) Thunemann, A. F.; Schutt, D.; Kaufner, L.; Pison, U.; Mӧhwald, H., Langmuir 2006, 22, 2351-2357 
255 Farrell, D.; Majetich, S. A.; Wilcoxon, J. P., J. Phys, Chem. B 2003, 107, 11022-11030 
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3.5.1 Fe3O4@PAA-COOH MNPs synthesis 
Yin and co-workers synthesized high quality water-soluble, uniform size nanocrystals with 
a poly(acrylic acid) (PAA) as capping agent.194d These MNPs are highly soluble in water 
and their solutions show a ferrofluidic behavior when subjected to an external magnetic 
field. It was shown that a low reaction temperature causes a low degree of control over 
the size, the distribution, the crystallinity and a narrow size distribution of the coated 
MNPs.256 Not all the capping agents are stable at high temperatures and are able to 
maintain hydrophilicity after binding to electron-poor Fe atoms. Short-chain PAA satisfies 
both these requirements.194d MNPs were prepared through the hydrolysis of Fe3Cl with 
NaOH solution at temperature higher than 200°C in diethylene glycol in the presence of 
PAA. The reaction proceeds through hydrolysis (favored by the NaOH addition which 
increases the alkalinity) under reductive atmosphere (provided by DEG) at high 
temperature. 257  Under these conditions, Fe(OH)3 partially transforms to Fe(OH)2, finally 
leading to the formation of Fe3O4 particles through dehydratation. For these MNPs, the 
solubility in water is guaranteed by the large number of uncoordinated carboxylate 
groups on the polymer chains that extend into the aqueous solution. These same groups 
could also be employed to link biomolecules or for further electrostatic functionalization. 
The other carboxylate groups on PAA chains strongly coordinate the Fe cations on the 
surface of MNPs forming a robust coating. Every polymer chain has multiple anchor points. 
These MNPs are soluble in water at basic and neutral pH values. As the pH decreases, also 
the solubility of the nanocrystal decreases because the carboxylate groups are 
progressively less ionized. At pH values < 4, the carboxylate groups are protonated and so 
less hydrophilic thus creating aggregates and precipitating out from the solution. On the 
other hand, the higher is the pH, the higher is the solubility (Figure 3.13). 
 
Figure 3.13 – Water solubility of Fe3O4@PAA-COOH at different pH 
                                                          
256 (a) Babes, L.; Denizot, B.; Tanguy, G.; Le Jeune, J. J.; Jallet, P., J. Colloid Interface Sci. 1999, 212, 474; (b) Jeong, J.-R.; Shin, S.-C.; Lee, S.-J.; Kim, J.-D., J. Magn. Magn. Mater. 2005, 286, 5; (c) Pileni, M. P., J. Phys. Chem. B 2001, 105, 3358 
257 (a) Sun, Y.; Xia, Y., Science 2002, 298, 2176-2179; (b) Deng, H.; Li, X. L.; Peng, Q.; Wang, X.; Chen, J. P.; Li, Y. D., Angew. Chem. Int. Ed. 2005, 44, 2782-2785 
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These magnetic nanocrystals resulted superparamagnetic, biocompatible, with small 
and uniform particle size (Figure 3.14). Thanks to the high temperature annealing that 
occurs during the synthesis, particles have an high crystalline character and each particles 
is a well-ordered single crystal.194d 
 
Figure 3.14 – TEM images and corresponding measured size distributions of Fe3O4@PAA nanocrystals 
A) Average diameter of 2.9 Å; B) Average diameter of 6.6 nm, individual nanocrystal shown in the insert (HRTEM picture); C) Average diameter of 11.3 nm, individual nanocrystal shown in the insert (HRTEM picture). 
The amount of NaOH added allows the control of the nanocrystal size if all the other 
parameters are fixed: the larger is the amount of NaOH, the bigger are the crystals. 
Probably this happens because of the alkalinity variation and the difference in H2O 
concentration. As a matter of fact, only when Fe3+ is fully hydrolyzed both nucleation and 
growth can be relatively quick, otherwise the crystal growth is very slow. The full hydrolysis 
of Fe3+ can take place when the amount of H2O, the alkalinity and the NaOH are 
sufficient. Thanks to the high reaction temperature, a relatively rapid nucleation occurs 
shortly after the injection of NaOH, leading to magnetite nanocrystals with narrow size 
distribution.258 
                                                          
258 Yin, Y.; Alivisators, A. P., Nature 2005, 437, 664-670 
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3.5.2 Fe3O4@PAA-COOH functionalization 
PAA-capped nanocrystals can be conveniently conjugated to biological molecules 
through an appropriate bifunctional linker and one of the well-established techniques.259 
An alkyne functionality is required to click 3.25 on them. As first attempt, a classical 
protocol for esterification was employed (Scheme 3.9). The C5-alkyne was selected in 
analogy to the alkyne used for MNPs 3.7. and the loading, evaluated by elemental 
analysis, was 0.115 mmol/g. These particles resulted extremely dispersible in water and their 
suspension is stable over weeks (dispersibility test according to procedure in the reference 
222a). 
 
Scheme 3.9 – Functionalization of Fe3O4-@PAA MNPs with 4-pentyn-1-ol 
However the alkyne loading was not really satisfying. Looking deeply in the literature, a 
protocol for the alkyne functionalization of the very same 3.15 MNPs had already been 
developed.260 Thus alkyne-Fe3O4@PAA-COOH MNPs 3.17 were synthesized following the 
exact reported procedure (Scheme 3.10) with the same C3-alkyne. Unfortunately, it was 
impossible to reproduce this procedures and according to the elemental analysis nitrogen 
was present in the final product even after various washing steps with water and with 
organic solvents. 
 
Scheme 3.10 – Functionalization of Fe3O4-@PAA MNPs with propargyl alcohol, 1st procedure 
Since alkyne-MNPs 3.16 had been successfully obtained with a different protocol, I 
applied the same procedure261 changing only the alkyne (propargyl bromide instead of 4-
penty-1-ol) to prepare the same MNPs of reference 260 (Scheme 3.11). Fe3O4@PAA-alkyne 
3.18 were successfully obtained and the alkyne loading evaluated by elemental analysis 
was 3.8 mmol/g, higher than the literature value of reference 260. These particles resulted 
                                                          
259 Hermanson, G. T., Bioconjugate Techniques, Academic Press, 1996 
260 He, H.; Zhang, Y.; Gao, C.; Wu, J., Chem. Commun. 2009, 1655-1657 
261 Wang, H.; Negretti, S.; Knauff, A. R.; Montgomery, J., Org. Lett. 2015, 17, 1493-1496 
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extremely dispersible in water and their suspension is stable over weeks (dispersibility test 
according to procedure in the reference 222a). 
 
Scheme 3.11 – Functionalization of Fe3O4-@PAA MNPs with propargyl alcohol, 2nd procedure 
SQUID (Figure 3.15) confirmed the MNPs functionalization. A magnetization saturation 
value of 17.89 emu/g was measured for 3.18 while the value for naked MNPs was 37.93 
emu/g. 
 
Figure 3.15 – SQUID measurements for Fe3O4@PAA MNPs and alkyne-Fe3O4@PAA MNPs (light blue: Fe3O4@PAA MNPs 3.15; red: alkyne-Fe3O4@PAA MNPs 3.18) 
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3.6 [DKPf3-RGD]-MNPs conjugates 
A huge number of RGD-containing-MNPs conjugates has been developed for cancer-
cell targeting and therapy.238b,238c,262 For example, USPIOs (ultrasmall iron oxide magnetic 
nanoparticles) coated with different RGD-peptides were used as MRI and/or PET or SPECT 
contrast agents.263 The physiochemical properties of the core provide the therapeutic 
effect and, in addition, passive targeting while the compound on the MNPs surface offers 
an higher level of specific targeting (active cell targeting). 
 
3.6.1 Cyclo[DKPf3-RGD]-PEG 
3.6.1.1 Cyclo[DKPf-RGD] library: short overview and synthesis 
Our group has already synthesized a small collection of Cyclo[DKPsf-RGD]-Paclitaxel 
conjugates (Figure 3.16) containing the DKPf library (Figure 2.23, Chapter 2) as scaffolds.148 
 
Figure 3.16 – Cyclo[DKPf-RGD] library 
  
                                                          
262 For example see: (a) Xie, J.; Chen, K.; Lee, H.-Y.; Xu, C.; Hsu, A. R.; Peng, S.; Chen, X.; Sun, S., J. Am. Chem. Soc. 2008, 130, 7542-7543; (b) Lin, R.-Y.; Dayananda, K.; Chen, T.-J.; Chen, C.-Y.; Liu, G.-C.; Lin, K.-L.; Wang, Y.-M., Contrast Media Mol. Imaging 2012, 7, 7-18 
263 For example see: (a) Bouziotis, P.; Psimadas, D.; Tsotakos, T.; Stamopoulos, D.; Tsoukalas, C., Curr. Top Med. Chem. 2012, 12, 2694-2702; (b) Lee, H. Y.; Li, Z.; Chen, K.; Hsu, A. R.; Xu, C.; Xie, J.; Sun, S.; Chen, X., J. Nucl. Med. 2008, 49, 1371-1379; (c) Zhang, C.; Jugold, M.; Woenne, E. C.; Lammers, T.; Morgenstern, B.; Mueller, M. M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; Kiessling, F., Cancer Res. 2007, 67, 1555-1562; (d) Zhang, F.; Huang, X.; Zhu, L.; Guo, N.; Niu, G.; Swierczewska, M.; Lee, S.; Xu, H.; Wang, A. Y.; Mohamedali, K. A.; Rosenblum, M. G.; Lu, G.; Chen, X., Biomaterials 2012, 33, 5414-5422 
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Among these, the derivative containing the DKPf3 (3.20), was already conjugated also 
to a peptidic sequence to produce a dual-action ligand targeting V3 integrin and VEGF 
receptors149 and, through lysosomally cleavable linkers, again to Paclitaxel264. 3.20 seemed 
also suitable for the link to MNPs both Co/C and Fe3O4. The solution synthesis pathway 
employed to prepare the library, is the same that was used for the Cyclo[DKPs-
RGD]ligands, differing only for the DKP scaffolds (Scheme 3.12). 
 
Scheme 3.12 - Cyclo[DKPf-RGD] ligands synthesis 
Reagents and conditions: a) 1) CsCO3, MeOH; 2) BnBr, DMF; b) 1) TFA/DCM 1:2; 2) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2; c) 1) TFA/DCM 1:2; 2) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2; d) 1) TFA/DCM 1:2; 2)Cbz-Asp(OtBu)-OH, HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2 e) 1) TFA/DCM 1:2; 2) H2, Pd/C, THF/H2O 1:1, r.t.; f) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2; g) TFA/thianisole/ethanedithiol/anisole 90:5:3:2. 
 
  
                                                          
264 Dal Corso, A.; Caruso, M.; Belvisi, L.; Arosio, D.; Piarulli, U.; Albanese, C.; Gasparri, F.; Marsiglio, A.; Sola, F.; Troiani, S.; Valsasina, B.; Pignataro, L.; Donati, D.; Gennari, C., Chem. Eur. J. 2015, 21, 6921-6929 
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3.6.1.2 Cyclo[DKPf3-RGD]-(PEG)8-N3 
A bifunctional linker is necessary to connect the biological active compound and the 
functionalized MNPs. Poly(ethylene glycol) (PEG) is a highly hydrophilic, biocompatible, 
non-toxic and non-immunogenic polymer.265 Pegylation is known in the literature as a 
method to increase functionality, biocompatibility and water solubility.266 Moreover, also 
the blood circulation times of pegylated compounds is increased compared to the non-
pegylated ones, because pegylation reduces clearance via reticuloendothelial system 
(RES)267, protein adsorption, platelet adhesion, and cell adhesion.268 An average molecular 
weight of 2000 g/mol is enough for this cell repellent effect269. 
Because of these properties, a commercially available PEG-linker was considered the 
best choice for our purposes. The commercial available compound N3-(PEG)8-NH2 (3.23) 
bears an amino functionality thus it is unsuitable to be directly connected to 3.20. Since in 
our group a PEG-linker had already successfully been conjugated to 3.20,149 a similar 
approach was followed (Scheme 3.13). 3.24 was synthesized through the direct opening of 
the succinic anhydride. This derivative is suitable for the further coupling with 3.20 on the 
amino-moiety. The final compound 3.25 has an azido moiety appropriate for a 
conjugation to MNPs via click chemistry reaction. 
 
Scheme 3.13 – Cyclo[DKPf3-RGD]-(PEG)8 (3.25) synthesis 
Reagents and conditions: a) dry DCM, under N2, r.t.; b) NHS, DIC, DCM, under N2, r.t.; c) buffer (pH=7), CH3CN. 
                                                          
265 (a) Amiji, M.; Park, K., J. Biomater. Sci., Polym. Ed. 1993, 4, 217-234; (b) Fuerteges, F.; Abuchowski, A., J. Controlled Release 1990, 11, 139 
266 (a) Adams, M. L.; Lavasanifar, A.; Kwon, G. S., J. Pharm. Sci. 2003, 92 (7), 1343-1355; (b) Yang, S. T.; Fernando, K. A. S.; Liu, J. H.; Wang, J.; Sun, H. F.; Liu, Y. F.; Chen, M.; Huang, Y. P.; Wang, X.; Wang, H. F.; Sun, Y. P., Small 2008, 4 (7), 940-944; (c) Xiaoming Sun, Z. L.; Welsher, K.; Robinson, J. T.; Goodwin, A.; Zaric, S.; Dai, A. H., Nano Res. 2008, 1, 203-212; (d) Lin Wang, W. Z., Nano Res. 2008, 1, 99-115 
267 (a) Xie, J.; Huang, J.; Li, X.; Sun, S.; Chen, X., Curr. Med. Chem. 2009, 16 (10), 1278-1294; (b) Chen, K.; Xie, J.; Xu, H.; Behera, D.; Michalski, M. H.; Biswal, S.; Wang, A.; Chen, X., Biomaterials 2009, 30 (36), 6912-6919; (c) Sunderland, C. J.; Steiert, M.; Talmadge, J. E.; Derfus, A. M.; Barry, S. E., Drug Dev. Res. 2006, 67 (1), 70-93; (d) Veiseh, O.; Sun, C.; Gunn, J.; Kohler, N.; Gabikian, P.; Lee, D.; Bhattarai, N.; Ellenbogen, R.; Sze, R.; Hallahan, A.; Olson, J.; Zhang, M., Nano Lett. 2005, 5 (6), 1003-1008 
268 (a) Shin, H.-S.; Park, K.; Kim, J. H.; Kim, J.-J.; Han, D. K., J. Bioact. Compat. Polym., 2009, 24, 316-328; (b) Zhang, F.; Kang, E. T.; Neoh, K. G.; Huang, W., J. Biomater. Sci., Polym. Ed. 2001, 12, 515-531; (c) Han D. K.; Hubbell, J. A., Macromolecules, 1997, 30, 6077-6083 
269 Bozukova, D.; Pagnoulle, C.; De Pauw-Gillet, M.-C.; Desbief, S.; Lazzaroni, R.; Ruth, N.; Jérôme R.; Jérôme, C., Biomacromolecules 2007, 8, 2379-2387 
  
3.6.2 Cyclo[DKPf3-RGD]
Cu(I)-catalyzed Azide-Alkyne Click c
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experimental conditions. The discovery 
alkyne and an azide can be catalyzed by Cu(I) species under mild conditions dates back 
to 2002, when the groups of Sharpless
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In the past years, great progress 
catalytic procedures for CuAAC and a large amount of similar 
literature.149, 273 To conjugate 
developed for solid phase reactions was
the most appropriate since MNPs could be compared to a solid support on which the 
bioactive compound is linked. First attempts 
identify the most promising conjugate among 
3.14), the Fe3O4@silica MNPs conjugate
conjugate (Scheme 3.16). 
 
                                                          
270 Huisgen, R. in: “1,3-Dipolar Cycloaddition Chemistry” (New York: Wiley) 
271 Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., 
272 TornØe, C.; Christensen, C.; Meldal, M., J. Org. Chem. 
273 For example see: (a) Shao, C.; Cheng, G.; Su, D.; Xu, J.; Wang, X.; Hu, Y., H.; Finn, M. G., J. Am. Chem. Soc. 2010, 132, 14570
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Scheme 3.14 – Synthesis of the conjugate with Co/C PEI MNPs 3.26 
The conjugate 3.26 (Scheme 3.14) was characterized through elemental analysis and 
SQUID measurement (Figure 3.18). The magnetization saturation value of the conjugate is 
50.83 emu/g, as expected lower than the value of the MNPs 3.6 (70.57 emu/g). 
 
Figure 3.18 – SQUID measurements for alkyne-Co/C PEI MNPs and the for the conjugate (light blue: alkyne-Co/C PEI MNPs 3.6; red: conjugate 3.26) 
The loading of 3.25 resulted very low (0.054 mmol/g). In any case it was enough to 
evaluate if the conjugation of an hydrophilic moiety changed the water dispersibility of 
MNPs 3.6. The same test was performed in water at different pH values (pH = 8.0, pH = 6.9, 
pH = 7.4, pH = 6.0) following the procedure reported in reference 222a. The lightly basic pH 
was chosen to see if avoiding the protonation of the free amino groups on the MNPs 
surface would favor the dispersibility. The lightly acid pH (pH = 8.0) was selected to see the 
effect on the protonation of the free amino groups on the MNPs surface. Finally the 
physiological pH was selected because it is a common pH in a biological environment. 
Unfortunately, as presented in the pictures (Figure 3.19), the conjugate did not give a 
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Figure 3.20 – SQUID measurements for Fealkyne
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3.7 Conclusions and outlooks 
MNPs 3.1 were generated for biological purposes,222a but unfortunately the alkyne 
functionalization prevented their dispersion in water. As a matter of facts, different 
conjugations strategies directly performed on the –NH2 group, might afford a conjugate 
able to produce stabile suspensions in water. 
For what concerns the Fe3O4@silica MNPs, the most promising derivative is compound 
3.14 which presents a good alkyne loading. Unfortunately, they do not produce stable 
suspensions in water so a different functionalization has to be developed to guarantee 
water-stable suspensions of the MNPs. 
Since MNPs 3.16 and 3.18 are very similar and they generate extremely stable water 
suspensions, they are both suitable substrate for the conjugation with 3.25. Up to now, only 
MNPs 3.16 were conjugated to 3.25.  
Among the three different kind of conjugates synthesized, only the conjugate 3.28 
resulted appropriate for biological tests because of the water dispersibility. Unfortunately, 
the loading value of the bioactive compound 3.25 is extremely low. However, in all the 
conjugation reactions the yield was very low. 
Since in the literature there are a lot of different protocols to perform click reactions 
and since in CuAAC the optimal conditions are known to be strictly depending on the 
substrates, the best strategy has to be selected according to the 3.25 and to the alkyne-
MNPs. The conditions have to be optimize thus leading to higher loading value for the 
biological active compound. As an alternative, different synthetic conjugation 
methodologies, not considering CuAAC reactions, could be explored. 
The final conjugated hopefully would show enhanced ability to inhibit the binding of 
biotinylated vitronectin to immobilized V3 integrin if compared with unconjugated 
compound because of the contemporary presentation of several ligands on the MNPs 
(displaying a cooperative effect). 
Since preliminary studies performed on the Fe3O4@PAA-COOH MNPs194d suggested a 
possible application in hyperthermia, the conjugate would be a candidate to be tested 
for selective hyperthermia therapy thanks to its ability of targeted delivery of MNPs to cell 
overexpressing the integrin V3. 
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3.8 Experimental section 
3.8.1 Materials and methods 
All manipulations requiring anhydrous conditions were carried out in flame-dried 
glassware, with magnetic stirring and under a nitrogen atmosphere. All commercially 
available reagents were used as received. Carbon coated cobalt nanoparticles (Co/C, 
20.5 m2/g, mean particle size ≈ 25 nm) were obtained from Turbobeads Llc, Switzerland. 
Anhydrous solvents were purchased from commercial sources and withdrawn from the 
container by syringe, under a slight positive pressure of nitrogen. The reactions were 
monitored by analytical TLC using silica gel 60 F254 pre-coated glass plates (0.25 mm 
thickness). Visualization was accomplished by irradiation with a UV lamp and/or staining 
with a potassium permanganate alkaline solution or ninhydrin. Proton NMR spectra of 
compound 3.20 (and of all the intermediates in its synthetic pathway) were recorded on a 
spectrometer operating at 400.16 MHz while NMR spectra of compound 3.8, 3.24, 3.25 
were recorded on a spectrometer operating at 300 MHz. Proton chemical shifts are 
reported in ppm () with the solvent reference relative to TMS. The following abbreviations 
are used to describe spin multiplicity s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, bs = broad signal, dd = doublet of doublet, ddd = doublet of doublet of doublet, 
ddt = doublet of doublet of triplet. Carbon NMR spectra were recorded on a 
spectrometer operating at 100.63 MHz, with complete proton decoupling. Carbon 
chemical shifts are reported in ppm () relative to TMS. ESI-MS spectra were recorded on 
the ion trap mass spectrometer Finnigan LCQ Advantage. 
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3.8.2 Synthesis 
Co/C PEI MNPs (3.1) were synthesized according to literature procedure (Kainz, Q. M.; 
Fernandes, S.; Eichenseer, C. M.; Besostri, F.; Kӧrner, H.; Müller, R.; Reiser, O., Faraday 
Discuss. 2014, 175, 27-39); EA: N loading = 7.28 mmol N/g 
3.8 was synthesized according to literature procedure (Mader, H.; Li, X.; Saleh, S.; Link, 
M.; Kele, P.; Wolfbeis, O. S., Ann. N. Y. Acad. Sci. 2008, 1130, 218-223) and its analytical 
data were in agreement with those already published.  
Fe3O4 @PAA-COOH MNPs (3.15) were synthesized according to literature procedure 
(Ge, J.; Hu, Y.; Biasini, M.; Dong, C.; Guo, J.; Beyermann, W. P.; Yin, Y., Chem. Eur. J. 2007, 
13, 7153-7161) 
3.20 was synthesized according to literature procedure (Wang, H.; Negretti, S.; Knauff, 
A. R.; Montgomery J., Org. Lett. 2015, 17, 1493-1496) and its analytical data were in 
agreement with those already published.  
Co/C PEI-alkyne MNPs 3.6 
 
MNPs 3.1 (loading 7.28 mmol N/g-statistically 1.82 mmol NH2/g, 100 mg) were 
suspended in dry DMF (3.0 mL) at room temperature under N2. K2CO3 (0.728 mmol, 4.0 eq), 
previously milled, and propargyl bromide (80% in toluene, 3.640 mmol, 20.0 eq.) were 
sequentially added in one portion. The mixture was stirred heating at 80°C under N2 for 24 
hours, then it was allowed to reach rt. MNPs were collected thanks to an external 
magnetic field and liquids were removed. MNPs were sequentially washed with DCM (3 x 2 
mL), water (3 x 2 mL), acetone (3 x 2 mL) and dried under vacuum. 95 mg of alkyne-MNPs 
3.6 were recovered. 
EA: alkyne loading = 1.542 mmol/g 
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Fe3O4 MNPs (3.9) 
 
Na2CO3 (5.29 g) was dissolved in water (200 mL) and the mixture was heated up to 
90°C under argon atmosphere. In a second flask, FeCl3.6H2O (6.75 g) and FeCl2.4H2O 
(2.485 g) were dissolved in 50 mL of water; the mixture was added drop wise in the first flask 
when the temperature reached 90°C. The mixture was stirred for 1h under these conditions 
and then it was allowed to reach r.t.. MNPs were washed three times with water and then 
dried under vacuum. 
 
Fe3O4@silica-alkyne MNPs (3.7) 
 
Fe3O4 MNPs (100 mg) were suspended in ultrapure water (44 mL) and sonicated for 10 
min. Citric acid (244 mg) in ultrapure water (44 mL) was added to the suspension and the 
mixture was sonicated for 1 h keeping the temperature under 40°C. Particles were 
collected and liquids were eliminated. Particles were washed with ultrapure water (1 x 30 
mL). A small portion of MNPs was dried under high vacuum and submitted to EA (%C = 
0.895%); the remaining particles were stored in ethanol solution. MNPs were collected and 
EtOH was removed; MNPs were washed with toluene (to eliminate completely EtOH) and 
toluene was removed. MNPs were transferred into a flame-dried flask under N2. 3.8 (1.13 
mmol, directly used in toluene solution), acetic acid (24 L) and ultrapure water (33 L) 
were sequentially added at r.t. under N2. The mixture was stirred heating to reflux for 24h, 
then it was allowed to reach r.t.. MNPs were collected thanks to an external magnetic field 
and liquids were removed. MNPs were sequentially washed with methanol (3 x 3 mL), 
hexane (3 x 3 mL) and acetone (3 x 3 mL); then they were dried under vacuum. 115 mg of 
alkyne-MNPs 3.7 were recovered. 
EA: alkyne loading = 0.519 mmol/g 
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Fe3O4@silica-NH2 MNPs (3.12) 
 
Fe3O4 MNPs (100 mg) were suspended in ultrapure water (44 mL) and sonicated for 10 
min. Citric acid (244 mg) in ultrapure water (44 mL) was added to the suspension and the 
mixture was sonicated for 1 h keeping the temperature under 40°C. Particles were 
collected and liquids were eliminated. Particles were washed with ultrapure water (1 x 30 
mL). MNPs were transferred into a flame-dried flask under N2 and suspended in dry toluene 
(2 mL). 3.10 (1.76 mmol, 412 L), acetic acid (24 L) and ultrapure water (33 L) were 
sequentially added at r.t. under N2. The mixture was stirred heating to reflux for 24h, then it 
was allowed to reach r.t.. MNPs were collected and liquids were removed. MNPs were 
sequentially washed with methanol (3 x 3 mL), hexane (3 x 3 mL) and acetone (3 x 3 mL); 
then they were dried under vacuum. 95 mg of MNPs 3.12 were recovered. 
EA: 3.10 loading = 1.76 mmol N/g 
 
Fe3O4@silica-Cl MNPs (3.13) 
 
Fe3O4 MNPs (100 mg) were suspended in ultrapure water (44 mL) and sonicated for 10 
min. Citric acid (244 mg) in ultrapure water (44 mL) was added to the suspension and the 
mixture was sonicated for 1 h keeping the temperature under 40°C. Particles were 
collected thanks to an external magnetic field and liquids were eliminated. Particles were 
washed with ultrapure water (1 x 30 mL). MNPs were transferred into a flame-dried flask 
under N2 and suspended in dry toluene (2 mL). 3.11 (1.76 mmol, 424 L), acetic acid (24 L) 
and ultrapure water (33 L) were sequentially added at r.t. under N2. The mixture was 
stirred heating to reflux for 24h, then it was allowed to reach r.t.. MNPs were collected 
thanks to an external magnetic field and liquids were removed. MNPs were sequentially 
washed with methanol (3 x 3 mL), hexane (3 x 3 mL) and acetone (3 x 3 mL); then they 
were dried under vacuum. 90 mg of MNPs 3.13 were recovered. 
EA: 3.11 loading = 1.71 mmol/g 
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Fe3O4@silica-NH-alkyne MNPs (3.14) 
 
MNPs 3.12 (loading 1.76 mmol N/g, 77 mg) were suspended in dry DMF (3.0 mL) at room 
temperature under N2. K2CO3 (0.135 mmol, 1.0 eq), previously milled, and propargyl 
bromide (80% in toluene, 0.675 mmol, 5.0 eq.) were sequentially added in one portion. The 
mixture was stirred heating at 80°C under N2 for 24 hours, then it was allowed to reach rt. 
MNPs were collected thanks to an external magnetic field and liquids were removed. 
MNPs were sequentially washed with DCM (3 x 2 mL), water (3 x 2 mL), aceton (3 x 2 mL) 
and dried under vacuum. 83 mg of alkyne-MNPs 3.14 were recovered. 
EA: alkyne loading = 1.54 mmol/g 
 
Fe3O4@PAA-alkyne MNPs (3.16) 
 
MNPs 3.15 (100 mg) were suspended in DCM (2 mL) at r.t. under N2. 4-pentyn-1-ol (4.5 
eq., 3.00 mmol), DCC (1.0 eq., 0.67 mmol) and DMAP (0.18 eq., 0.12 mmol), previously 
dissolved in DCM (1.5 mL and 0.5 mL respectively), were sequentially added. The mixture 
was stirred under these conditions for 24 h, then MNPs were collected thanks to an 
external magnetic field and liquids were removed. MNPs were washed with DCM (6 x 3 
mL), then dried under vacuum and submitted to EA. 98 mg of alkyne-MNPs 3.16 were 
recovered. 
EA: alkyne loading = 0.115 mmol/g 
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Fe3O4@PAA-alkyne MNPs (3.18) 
 
MNPs 3.15 (700 mg) were suspended in DCM (50.0 mL) at r.t. under N2. propargyl 
alcohol (1.8 eq., 21.04 mmol), DCC (1.0 eq., 11.69 mmol) and DMAP (0.2 eq., 21.04 mmol), 
were sequentially added. The mixture was stirred under these conditions for 24 h, then 
MNPs were collected thanks to an external magnetic field and liquids were removed. 
MNPs were washed with DCM (6 x 3 mL), then dried under vacuum and submitted to EA. 
517 mg of alkyne-MNPs 3.18  were recovered. 
EA: alkyne loading = 3.8 mmol/g 
 
N3-(PEG)8-(CH2)2-COOH (3.24) 
 
The reaction was performed in a flame-dried flask. N3-(PEG)8- NH2 3.23(0.11 mmol, 50 
mg) was dissolved in dry DCM (1.1 mL) at r.t. under N2. Succinic anhydride (5.0 eq., 0.55 
mmol) was added in one portion and the mixture was stirred over night under these 
conditions. In the morning the reaction was complete. The excess of succinic anhydride 
was eliminated by sublimation at 30°C and 0.1mbar. The final compound 3.24 was used 
without further purification.  
Compound 3.24: 
1H-NMR (300 MHz, CDCl3)  6.78 (s, 1H), 3.88 – 3.79 (m, 1H), 3.60 (dt, J = 4.9, 3.8 Hz, 32H), 3.53 
– 3.46 (m, 2H), 3.41 – 3.36 (m, 2H), 3.35 – 3.29 (m, 2H), 2.59 (dd, J = 12.6, 6.2 Hz, 2H), 2.52 – 
2.45 (m, 1H); 13C-NMR (151 MHz, CDCl3)  172.97, 70.73 – 69.33, 69.42 – 69.33, 52.79 – 50.57, 
39.52, 30.95, 30.52; MS (ESI) m/z calcd. for [C22H41N4O11]-: 537.2777 [M-H]-; found: 537.2788; 
IR 2870 cm-1, 2102 cm-1, 1729 cm-1, 1651cm-1 
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Cyclo[DKPf3-RGD]-(PEG)8-(CH2)2-COOH (3.25) 
 
3.24 (1.25 eq., 39.6 mol) was dissolved under N2 in dry DCM (1.4 mL) at room 
temperature. NHS (1.8 eq., 57.1 mol) and DIC (2.42 eq., 76.7 mol) were added in one 
portion under these conditions. The solution was stirred for 2 h then the solvent was 
removed under reduced pressure and the resulting solid was taken-up with acetonitrile 
(1.4 mL). 3.20 (20 mg, 31.7 mol), previously dissolved in a pH 7 buffer (0.7 mL), was cooled 
to 0°C and added in one portion to the mixture. The mixture was stirred overnight under 
these conditions. The pH was monitored for the first 2 h and it was kept between 7.3 and 
7.6 by correction with a 0.2 M aqueous NaOH solution. In the morning volatiles were 
removed under reduced pressure and then dried under high vacuum. The crude, 80 mg, 
was checked by LR-Mass [(M + 2H)2+ = 576.28] and used as crude in the following step. 
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Cyclo[DKPf3-RGD]-(PEG)8-(CH2)2-COOH-Co/C PEI MNPs (3.26) 
 
3.5 (18 mol, 1.25 eq., crude*) was dissolved in DMF under N2 at room temperature and 
the mixture was added to 3.6 (alkyne loading 1.542 mmol/g, 14 mol of alkyne, 50 mg) at 
r.t. under N2. CuI (18 mol, 1.25 eq) and DIPEA (180 mol, 12.5 eq) were added in one 
portion. The mixture was stirred at r.t. under N2 over weekend. MNPs were collected, liquids 
were removed and MNPs were sequentially washed with DMF (3 x 3 mL) and DCM (3 x 3 
mL). MNPs were dried under vacuum. 10 mg of MNPs were recovered and a portion was 
submitted to EA.  
* calculation done considering a reaction yield of 50% 
EA: 3.25 loading = 0.054 mmol/g; SQUID = 50.72 emu/g 
  
 Page 133    
Cyclo[DKPf3-RGD]-(PEG)8-(CH2)2-COOH-Fe3O4@silica MNPs (3.27) 
 
3.5 (3.13 mol, 1.25 eq., crude*) was dissolved in DMF under N2 at r.t. and the mixture 
was added to 3.7 (alkyne loading 0.519 mmol/g, 2.5 mol of alkyne, 50 mg) at r.t. under 
N2. CuI (13.25 mol, 5.3 eq) and DIPEA (132.5 mol, 53 eq) were added in one portion. The 
mixture was stirred at room temperature under N2 over weekend. MNPs were collected, 
liquids were removed and MNPs were sequentially washed with DMF (3 x 3 mL) and DCM 
(3 x 3 mL). MNPs were dried under vacuum and a portion was submitted to EA.  
* calculation done considering  a reaction yield of 50% 
EA: 3.25 loading = 0.04 mmol/g 
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Cyclo[DKPf3-RGD]-(PEG)8-(CH2)2-COOH-Fe3O4@PAA MNPs (3.28) 
 
3.25 (mol, 1.25 eq., crude*) was dissolved in DMF under N2 at r.t. and the mixture was 
added to 3.16 (alkyne loading 0.115 mmol/g, 2.5 µmol of alkyne, 50 mg) at r.t. under N2. 
CuI (mol, 5.3 eq) and DIPEA (mol, 53 eq) were added in one portion. The mixture was 
stirred at room temperature under N2 over weekend. MNPs were collected, liquids were 
removed and MNPs were sequentially washed with DMF (3 x 3 mL) and DCM (3 x 3 mL). 
MNPs were dried under vacuum and a portion was submitted to EA. 
* calculation done considering  a reaction yield of 50% 
EA: 3.25 loading =  0.00257 mmol/g 
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RGD- AND isoDGR--ACPC INTEGRIN LIGANDS 
 
4.1 Aim of the project 
The aim of this project was the synthesis of a small collection of RGD- and isoDGR-
containing peptidomimetics constrained by a five member ring scaffold. The cyclic 
derivatives obtained should be tested for activity and selectivity on integrins. The synthesis 
was planned in a mixed solid phase/solution phase approach. 
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4.2 -ACC-containing peptidomimetics 
4.2.1 -amino acids 
Four -aminocarboxylic acids naturally occur in mammals: -Alanine (a), (S)--
aminoisobutyrate (b), (R)--aminoisobutyrate (c), and -Leucine (d) (Figure 4.1). -amino 
acids do not generally occur in mammalian proteins.274 On the other hand many -amino 
acids were isolated from plants and microorganisms as free molecules and components of 
peptides and antibiotics.275 
 
Figure 4.1 – -amino acids occurring in mammals 
-amino acids received considerable attention as constituents of -peptides276 , as 
analogues of the common protein amino acids and they were used as alternative 
substrates, to probe the structural specificity of -amino acid binding-sites or as inhibitors of 
enzymes, or they were incorporated into synthetic peptides in combination with -amino 
acids277. In addition, their incorporation into peptides of pharmacological interest was 
sometimes advantageous in terms of biological activity, metabolic stability or both 
because of their limited normal metabolism (and consequently, extended biological half-
lives compared to the correspondent -amino acid-containing peptides).274 Early studies 
by Abderhalden 278 , tempered by later studies 279  on enzymatic hydrolysis stability of 
peptide bonds involving -amino acids, arose interest in their synthesis, hydrolytic stability, 
and conformational characteristics. -amino acids stabilize distinct overall conformations 
of cyclopeptides and they act as -turn mimetics: if a single -amino acid is incorporated 
into a cyclic pentapeptide, it preferably occupies the central position of a -turn. As a 
                                                          
274 Griffith, O. W., Ann. Rev. Biochem. 1986, 55, 855-878 
275 For reviews see: (a) Dery, C. N. C in “The Chemistry and Biochemistry of Amino Acids” (ed. B Weinstein, New York: Dekker), 1976, 4, 241-299; (b) Dery, C. N. C in “The Chemistry and Biochemistry of Amino Acids” (ed. G. C. Barrett, London: Chapman & Hall) 1976, 25-54 
276 Leading reviews: (a) Seebach, D.; Matthews, J. L., Chem. Commun.1997, 2015-2022; (b) Gellman, S. H., Acc. Chem. Res.1998, 31, 173-180 
277 (a) Juaristi, E. in “Synthesis of -amino acids” (Wiley-VHC: New York), 1997; (b) Cole, D. C., Tetrahedron 1994, 50, 9517-9582; (c) Palomo, C.; Oiarbide, M.; González-Rego, M. C.; Sharma, A. K.; Garcia, J. M.; González, A.; Landa, C.; Linden, A., Angew. Chem. 2000, 112, 1105-1107; (d) Tang, T. P.; Ellman, J. A., J. Org. Chem. 1999, 64, 12-13, (e) Miyabe, H.; Fujii, K.; Naito, T., Org. Lett. 1999, 1, 569-572; (f) Marcotte, S.; Pannecoucke, X.; Feasson, C.; Quiron, J.-C.; J. Org. Chem. 1999, 64, 8461-8464; (g) Nocioni, A., M.; Papa, C.; Tomasini, C., Tetrahedron Lett. 1999, 40, 8453-8456; (h) Davies, S. G.; Ichihara, O., Tetrahedron Lett. 1999, 40, 9313-9316; (i) Enders, D.; Wahl, H.; Bettray, W., Angew. Chem. 1995, 107, 527-529; (j) Es-Sayed, M.; Gratkowski, C.; Krass, N.; Meyers, A. I.; De Meijere, A., Tetrahedron Lett. 1993, 34, 289-292; (k) Jefford, C. W.; Wang, J., Tetrahedron Lett. 1993, 34, 1111-1114; (l) Juaristi, E.; Quintana, D.; Escalante, J., Aldrichimica Acta 1994, 27, 3-11; (m) Burgess, K.; Liu, L. T.; Pal, B., J. Org. Chem. 1993, 58, 4758-4763; (n) Lombardi, A.; Saviano, M.; Nastri, F.; Maglio, O.; Mazzeo, M.; Isernia, C.; Paolillo, L.; Pavone, V., Biopolymers 1996, 38, 693-703; (o) Pavone, V.; Lombardi, A.; Yang, X.; Pedone, C.; Blasio, B. D., Biopolymers 1990, 30, 189-196; (p) Blasio, B. D.; Lombardi, A.; Yang, X.; Pedone, C.; Pavone, V., Biopolymers 1991, 31, 1181-1188; (q) Pavone, V.; Lombardi, A.; D’Auria, G.; Saviano, M.; Nastri F.; Paolillo, L.; Blasio, B. D.; Pedone, C., Biopolymers 1992, 32, 173-183; (r) Pavone, V.; Lombardi, A.; Maggi, C. A.; Quartara, L.; Pedone, C. J., J, Pept. Sci. 1995, 1, 236-240; (s) Dado, G. P.; Gellman, S. H., J. Am. Chem. Soc. 1994, 116, 1054-1062 
278 (a) Abderhalden, E.; Reich, F., Fermentforschung, 1928, 10, 173-194; (b) Adberhalden, E.; Fleischmann, R., Fermenforschung 1928, 10, 195-206 
279 Hanson, H. T.; Smith, E. L., J. Biol. Chem. 1948, 175, 833-848 
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consequence, the turn is extended by one CH2 group and hence it is called a pseudo--
turn (Ψ).64 
Since only -alanine and a few racemic -aminocarboxylic acids are available 
commercially, most -amino acids (both racemic and pure) must be synthesized or 
isolated from natural sources. A review on these aspect was written by Balenovic280 and 
Drey and procedures of general utility are described in Griffith review281. However, -amino 
acids synthesis is a research field always in evolution. -amino acid racemates are 
generally resolved by the same methods used with -amino acids282 even if less easily by 
HPLC chiral solvent systems (presumably because of the increased separation between 
the amino and the carboxyl groups that allows greater flexibility in the complex with the 
solvent component). 
 
4.2.2 Cyclo[-ACC-RGD] peptidomimetics  
4.2.2.1 -ACC scaffolds 
The use of rigid amino acids is a powerful tool to investigate the bioactive structure of 
peptides283 and to build constrained peptides. Among the various rigid amino acids, in this 
paragraph -aminocyclopropane carboxylic acids (-ACCs, Figure 4.2)284 will be treated in 
particular for what concerns the synthesis of cyclic peptides.285 These cyclic -amino acids 
are among the most restricted -alanine derivatives. The rigidity is conferred by the 
bridging of the carbons bearing the amino and the carboxylic acid functionality by a 
methylene group.286 
  
                                                          
280 Balenovic, K. in “CibaFound. Symp. Amino Acids and Peptides with Antimetabolic Activity” (ed. G. E. W. Wolstenholme, Boston: Little Brown), 1958, 5-16 
281 (a) Kupiecki, F. P.; Coon, M. J., J. Biol. Chem. 1957, 229, 743-754; (b) Kakimoto, Y.; Armstrong, M. D., J. Biol. Chem. 1961, 236, 3283-3286; (c) Bohme, H.; Broese, R.; Eiden, F., Chem. Ber. 1959, 92, 1258-1262; (d) Bauce, L. G.; Goren, H. J., Int. J. Peptide Protein Res. 1979, 14, 216-226; (e) Sekura, R.; Hochreiter, M.; Meister A., J. Biol. Chem. 1976, 251, 2263-2270; (f) Birkofer, L.; Storch, I., Chem. Ber. 1953, 86, 529-534; (g) Dietriche, R. F.; Sakurai, T.; Kenyon, G. L., J. Org. Chem. 1979, 44, 1894-1895; (h) Shimohigashi, Y.; Waki, M.; Izumiya, N., Mem. Fac. Sci. Kyushu, Univ., Ser. C 1979, 11, 217-224; (i) Shimohigashi, Y.; Waki, M.; Izumiya, N., Bull. Chem. Soc. Jpn. 1979, 52, 949-950; (j) Wingo, W. J.; Lewis, H. B., J. Biol. Chem. 1946, 165, 339-346; (k) Gundermann, K. D., Ann. Chem. 1954, 588, 167-181 
282 For example see: (a) Rossi, D.; Lucente, G.; Romeo, A., Experientia, 33, 1557-1559; (b) Khedouri, E.; Meister, A., J. Biol. Chem. 1965, 240, 3357-3360; (c) Cohen, S. G.; Khedouri, E., J. Am. Chem. Soc. 1961, 83, 1093-1096; (d) Kotani, H.; Kuze, Y.; Uchida, S.; Miyabe, T.; Iimori, T.; Okano, K., Kobayashi, S.; Ohno, M., Agric. Biol. Chem. 1983, 47, 1363-1365; (e) Winnacker, E. L.; Herbst, M. M.; Barker, H. A., Biochim. Biophys. Acta 1971, 237, 280-283; (f) Pollock, G., Anal. Biochem. 1974, 57, 82-88; (g) Solem, E., Clin. Chim. Acta 1974, 53, 183-190; chiral solvents: (h) Gil-Av, E.; Tishbee, A.; Hare, P. E., J. Am. Chem. Soc. 1980, 102, 5115-5117; (i) Lam, S. K., J. Chromatogr. 1982, 234, 485-488; (j) Gilon, C.; Leshem, R.; Grushka, E., Anal. Chem. 1980, 52, 1206-1209; (d) Weinstein, S.; Engel, M. H.; Hare, P. E., Anal. Biochem. 1982, 121, 370-377; chiral stationary phase: (k) Pirkle, W. H.; Hyun, M. H.; Tsipouras, A. Hamper, B. C.; Banks, B., J. Pharmacol. Biomed. Anal. 1984, 2, 173-181; (l) Gubitz, G.; Jellenz, W.; Santi, W., J. Chromatogr. 1981, 203, 377-384; (m) Pirkle, W. H.; Finn, J. M.; Schreiner, J. L.; Hamper, B. C., J. Am. Chem. Soc. 1981, 103, 3964-3966 
283 (a) Jakubke, H.-D. in “Peptide” (Spektrum: Heidelberg), 1996; (b) Jones, J. in “Amino Acid and Peptide Synthesis” (Oxford University Press: Oxford, UK,) 1992 
284 For a review see: Gnad, F.; Reiser, O., Chem. Rev. 2003, 103, 1603-1624 
285 (a) Paulini, K.; Reissing, H.-U., Liebigs Ann. Chem. 1994, 549-554; (b) Beck-Sickinger, A. G.; Hoffmann, E.; Paulini, K.; Reissing, H.-U.; Willim, K.-D.; Wieland, H. A.; Jung, G., Biochem. Soc. Trans. 1994, 22, 145-149; (c) Hibbs, D. E.; Hursthouse, M. B.; Jones, I. G.; Jones, W.; Malik, K. M. A.; North, M., Tetrahedron 1997, 53, 17417-17424; (d) North, M., J. Pept. Sci. 2000, 6, 301-313; (e) Voigt, J.; Noltemeyer, M.; Reiser, O., Synlett 1997, 202-204; (f) Bubert, C.; Cabrele, C.; Reiser, O., Synlett 1997, 827-829 
286 Beumer, R.; Reiser, O., Tetrahedron 2001, 57, 6497-6503 
  Page 140    
 
 
Figure 4.2 – -aminocylopropanecarboxylic acid 
Reiser and co-workers synthesized short / peptides alternating -amino acids (L-Ala 
residues) with 3-substituted-cis--ACCs. The product (Figure 4.3) showed a high affinity to 
the Y1 receptor of neuropeptide Y.287 In addition, -ACCs improved the stabilization of the 
secondary structure of peptides288 and have been embedded into cyclic RGD peptides as 
constraining scaffolds (as presented in paragraph 4.2.2.2).289 
 
Figure 4.3 - / peptides alternating -amino acids (L-Ala residues) with 3-substituted-cis--ACCs 
However their synthesis and utilization as building blocks in peptide synthesis is not 
simple because the two new stereocenters created require a control of 
diastereoselectivity (cis- or trans--ACC) and enantioselectivity.286 A further problem is 
related to the -ACCs nature of vicinally donor-acceptor 1,2-substituted cyclopropanes, 
which are extremely prone to ring opening.290 These aspect could be useful for some 
synthetic applications but on the other hand it means that these derivatives are only 
stable if the amino group is protected by at least one electron withdrawing group.291 
However a lot of effort was done to improve their synthesis and a number of different 
approaches towards the synthesis292 of -ACCs and their incorporation into peptides285 are 
present in the literature. An efficient synthesis of both cis- and trans--ACC (4.1 and 4.2 
respectively, Figure 4.4) diastereo- and enantiomerically pure was developed.285f,286,292f 
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Figure 4.4 - 4.1 and 4.2 
Since these constrained molecules are often difficult to prepare as amine-free or they 
are unstable in the unprotected form, coupling through the classical carboxylic acid 
activation pathway could be difficult. Reiser and co-workers developed a procedure for a 
one-pot amine deprotection-coupling of a Boc--ACC285f or an Alloc--ACC293 with an 
amine-protected amino acid. Thus, (+)--ACC 4.1 a and (-)--ACC 4.1 b were introduced 
into the cyclic peptides already coupled to Fmoc-Asp(OtBu)-OH (respectively 4.2 and 4.3, 
Figure 4.5). 
 
Figure 4.5 – Dipeptide building blocks containing the -ACC scaffold and Fmoc-Asp(OtBu)-OH 
 
4.2.2.2 Conformational and biological evaluation of the cyclic peptidomimetics 
The chemistry and biology of RGD-containing peptides were already illustrated in 
Chapter 1. The conformation has an important role in this class of peptides, thus -ACCs-
seemed interesting constraining moieties to produce cyclic RGD-containing peptides. 
Reiser group synthesized Cyclo-[Arg-Gly-Asp-(+)--ACC-Val] 4.4 and Cyclo[Arg-Gly-Asp-(-)-
-ACC-Val] 4.5 containing enantiomeric (+)- or (-)- -ACC adjacent to the RGD sequence 
(Figure 4.6). 
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Figure 4.6 – Cyclic peptides containing the -ACC scaffolds 
The biological activity of peptides 4.4 and 4.5 was evaluated and compared to 
Cyclo[Arg-Gly-Asp-D-Phe-Val] 4.654,294 and Cyclo[Arg-Gly-Asp-D-Phe-Val--Ala] 4.7295 in 
cell-adhesion assays on K562 and WM115. K562 is a myelogenous leukemia cell line in 
which adhesion to ECM proteins is mediated predominantly by integrin 51 while 
WM115 is a human skin melanoma cell line in which adhesion to ECM proteins is 
mediated predominantly by integrin V3. The inhibition of the adhesion of the cells was 
evaluated establishing the IC50 value of the various compounds (Table 4.1). 
Compound WM115, V3 IC50 M 
K562, 51 
IC50 M Ratio IC50 K562/WM115 
4.6 0.2 ± 0.06 18.5 ± 6.4 92.5 
4.7 1.4 ± 0.40 9.1 ± 5.3 6.5 
4.4 0.02 ± 0.002 1.5 ± 0.5 75.0 
4.5 0.6 ± 0.23 1.8 ± 0.7 3.0 
Table 4.1 – IC50 values of the cyclic peptides as determined by cell-adhesion assays 
The value measured on WM115 cells for the reference compound 4.6294b (IC50 = 0.2 M) 
is in good agreement with literature data as estimated by Aumailley et al.54. Peptide 4.4, 
(containing the (+)--ACC), displayed a tenfold higher affinity (IC50 = 20 nM) than 4.6. 
Peptides 4.4 and 4.5 were proved to nearly equally inhibit integrin 51 mediated adhesion 
of K562 cells to fibronectin with IC50 values of 1.5 M and 1.8 M respectively. This means 
that they are five- to sixfold more active than 4.7, which was twice as active as peptide 
4.6. Peptides 4.4 and 4.5 had a larger influence on the interaction between vitronectin 
and integrin V3 than on the interaction between fibronectin and integrin 51. As shown 
in Table 4.1, peptides 4.6296 and 4.4 showed a higher selectivity towards integrins V3.  
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Distance geometry calculations were performed applying the distance restrains 
derived from the NOESY spectra. For both peptides, one major cluster (comprising more 
than 95% of the structures) was obtained and used as starting structure for restrained 
molecular dynamics calculations (Figure 4.7). For peptide 4.4 only one major torsion-angle 
cluster was observed (more than 87% of the observed conformation were contained) 
while for peptide 4.5 two clusters were observed (the major one was populated during the 
80% of the trajectories). 
 
Figure 4.7 – Schematic representation of the structure of peptides 4.4 and 4.5 
The representations were obtained by restrained MD calculations based on experimental distance information. Ψ indicates a pseudo--turn and the arrows indicate the hydrogen bonds. 
In both peptides, the backbone remained rigid around the -ACC residue. However a 
high dynamics in the RGD sequence was observed, as known for RGD peptides 296 . 
According to Kessler and co-workers, the RGD motif should adopt a non-stretched 
conformation to interact with V3 integrins, whit a C(Arg)-C(Asp) distance of about 650 
pm.57c For example, reference compound 4.7, presents an elongated conformation of the 
RGD motif with a C(Arg)-C(Asp) distance of 930 pm which correlates well with the lower 
affinity toward integrin V357c. According to the torsion angles, the Gly residue in peptide 
4.4 is in the central position of a -turn while (+)--ACC occupies the i+1 position of a 
pseudo--turn and the C(Arg)-C(Asp) distance lies between 600 pm and 800 pm for the 
majority of the structures (706 pm in the central structure of the major cluster). For peptide 
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4.5 this distance is between 700 pm and 900 pm for the majority of the structures (although 
it fluctuates during the trajectory). These data indicate a more stretched conformation of 
the RGD sequence for peptide 4.5 than for peptide 4.4, as confirmed also by the C(Arg)-
C(Asp) distance. In 4.4 the  and  turns are at the same positions as in 4.6 (even if the 
type of -turn is different) while 4.5 displays a more stretched RGD sequence like 4.7. All 
these data in combination with the biological results indicates that the more active cyclic 
-ACC-RGD-containing V3 integrin ligand is 4.4, which showed a bent RGD sequence. 
 
4.2.2.3 Synthesis of the cyclic ligands 
Reiser and co-workers were able to couple Boc--ACC with amino acids via their 
ammonium chloride salt through a protocol which employs saturated HCl gas ethyl 
acetate.294a The procedure was employed to synthesize the building blocks 4.8 and 4.9 
(Scheme 4.1). 
 
Scheme 4.1 – Synthesis of 4.2 and 4.3 
Reagents and conditions: a) HCl/Ethyl acetate, under N2, 0°C; b) Fmoc-Asp(OtBu)-OH, EDC, HOBt, Py DCM, r.t.; c) 1,4-cyclohexadiene in pentane, Pd/C 5%, MeOH, r.t., under N2. 
The linear precursors 4.10 and 4.11 were assembled by SPPS with a Fmoc/tBu protection 
protocol (Scheme 4.2). O-chlorotritylchloride resin (loading: 1.51 mmol/g) was selected as 
solid support. Each coupling step consisted in: 
i) activation of the Fmoc-protected amino acid, 
ii) addition of the activated amino acid to the resin to effect the coupling 
reaction, 
iii) capping and Fmoc- deprotection 
The cleavage of the linear precursor from the resin was accomplished in weakly acidic 
conditions. 
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Scheme 4.2 – Linear precursors (4.10 and 4.11) synthesis 
Reagents and conditions: a) Fmoc-Gly-OH, DIPEA, DCM; b) 1) 2%DBU in DMF, 2% piperidine DMF; 2) Fmoc-Arg(Pbf)-OH, TBTU, DIPEA; c) 1) 2% DBU in DMF, 2% piperidine DMF; 2) Fmoc-Val-OH, DIPEA, DCM; d) 1) 2% DBU in DMF, 2% piperidine DMF; 2) 4.2 or 4.3 HATU, DIPEA; e) 1) 2% DBU in DMF, 2% piperidine DMF; 2) TFA/DCM. 
The linear cleaved precursors (4.10 and 4.11) were cyclised under pseudo-high dilution 
conditions to give derivatives 4.12 and 4.13.297 Fmoc-ortogonal PGs were selected for the 
lateral chains of the amino acids (Pbf for Arg and tBu for Asp). The cyclic derivatives 4.12 
and 4.13 were deprotected (by treatment with TFA/Et3SiH/water, 95%/2.5%/2.5%) and 
purified by preparative HPLC (Scheme 4.2) to give the final peptidomimetics 4.14 and 4.15. 
 
Scheme 4.3 – Cyclic derivatives synthesis 
Reagents and conditions: a) HATU, DIPEA, r.t.; b) TFA/Et3SiH/water 95%/2.5%/2.5% 
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4.3 -ACPC-containing peptidomimetics 
4.3.1 -ACPC scaffolds 
A wide variety of natural products contain -alkyl--amino acids,274a,298 many of which 
exhibit interesting biological properties. For example, cis-(1R,2S)-2-aminocyclopentane-1-
carboxylate 4.16 (Cispentacin, Figure 4.8) is a potent antifungal agent.299 However, the 
incorporation of an oxygen or a sulfur heteroatom within the carbocyclic skeleton, 
generates heterocyclic -amino acid derivatives 4.17 (Figure 4.8) and 4.18 (Figure 4.8) with 
a significant reduced biological activity.300 The cis-N-heterocyclic compound 4.19 (Figure 
4.8) and its Boc-protected derivative 4.20 (Figure 4.8) has also found application in 
medicinal chemistry as probe to test the structure of the GABA receptor 301  and as 
bioactive compound respectively. 4.20 has resulted a modestly active influenza 
neuramidase inhibitor.302 
 
Figure 4.8 – Cispentacin and its heterocyclic analogues 
Furthermore these kind of derivatives were embedded also in longer structures, such as 
the water soluble short chain peptides 4.22 (Figure 4.9) containing both transpentacin and 
the trans-derivative 4.21 residues (Figure 4.9). It adopted a distinct helical secondary 
structures in solution.303 
 
Figure 4.9 – Derivatives 4.21 and 4.22 
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301 Thorbeck, P.; Hjeds, H.; Schaumburg, K., Acta Chem. Scand. 1981, B35, 473-478 
302 Bunnage, M. E.; Davies, S. G.; Roberts, P. M.; Smith A. D.; Withey J. M., Biomol. Chem. 2004, 2, 2763-2776 
303 Wang, X.; Espinosa, J. F.; Gellman, S. H., J. Am. Chem. Soc. 2000, 122, 4821-4822 
  Page 147    
Also 2:1 and 1:2 /-backbone patterns (Figure 4.10) were found to promote helix 
formation in short oligomers.304 
 
Figure 4.10 – Short oligomers containing 2:1 and 1:2 /-backbone patterns 
Reiser and co-workers presented helical peptides foldamers (Figure 4.11) containing -
cis-aminocyclopentanecarboxylic (-cis-ACPC, 4.16 and 4.23, Figure 4.12) acids.305 These 
molecules have been combined following the stereochemical patterning approach by 
Fülӧp and co-workers.306 They have shown a defined spatial distributions of their functional 
groups in polar solvents including water. 
 
Figure 4.11 – Reiser’s foldamers 
                                                          
304 Schmidt, M. A.; Choi, S. H.; Guzzi, I. A.; Gellmann, S. H., J. Am. Chem. Soc. 2006, 128, 4538-4539 
305 Berlicki, Ł.; Pilsl, L.; Wéber, E.; Mándity, I.; Cabrele, C.; Martinek, T. A.; Fülӧp, F.; Reiser, O., Angew. Chem. Int. Ed. 2012, 51, 2208-2212 
306 Mándity, I. M.; Wéber, E.; Martinek, T. A.; Olajos, G.; Tóth, G. K.; Vass, E.; Fülӧp, F., Angew. Chem. Int. Ed. 2009, 48, 2171-2175 
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Figure 4.12 - -ACPC scaffolds 4.16 and 4.23 
All the foldamers were successfully obtained by SPPS using the Fmoc-chemistry. As a 
consequence, the correspondent Fmoc-protected 4.24 (Figure 4.13) and 4.25 (Figure 4.13) 
derivatives were synthesized. Differing from the 3-membered rings, these derivatives are 
stable and they can be used as this in the SPPS, the one-pot deprotection-coupling 
procedure is not required. 
 
Figure 4.13 - -ACPC scaffolds 4.24 and 4.25 
 
4.3.2 Cyclo RGD- and isoDGR-peptidomimetics 
The work carried out has at the moment produced four compounds containing the -
ACPC scaffold, two RGD-peptidomimetics (4.26 and 4.27, Figure 4.14), one isoDGR-
peptidomimetic (4.28, Figure 4.14), and the compound 4.29 (characterization ongoing at 
the moment, Figure 4.14). Since the isoDGR-peptidomimetics contain the isoAsp instead of 
the Asp, the RGD-peptidomimetics are 17-membered ring cyclic compounds while the 
isoDGR feature16-membered rings having one more carbon in the isoAsp amino acid 
skeleton (which is a -amino acid as well). 
  
Figure 4.14 - -ACPC-containing peptides 4.26, 4.27, 4.28 and 4.29 
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This small collection of molecules is under investigation as integrin ligand class to 
evaluate whether the 5-membered ring scaffold changes preferred conformations of the 
cyclic peptidomimetics, affinity and/or selectivity against V3, V5, and 51 compared to 
the 3-membered ring scaffolds. In order to evaluate these aspects, the synthesized 
compounds will be tested for the ability to inhibit biotinylated vitronectin binding to the 
purified V3 and V5 receptors. Biological tests on 4.26, 4.27, 4.28 and 4.29 are ongoing as 
well as their conformational analysis. 
 
 
4.3.3 Synthesis 
Only a limited number of methods for the asymmetric synthesis of these heterocyclic -
amino acid derivatives in enantiomerically pure form exist. However Cispentacin was 
isolated from Streptomyces setonii299c and Bacillus cereus299a or, in the homochiral form, it 
was prepared by classical299a,d and kinetic307 resolution methods. However, for instance, 
cis-4-amino-pyrrolidine-3-carboxylic acid was diastereoselectively synthesized via 
enantioselective hydrogenation308  and 1,3-dipolar cycloaddition of nitrones309 . On the 
other hand, trans-4-aminoppyrrolidine-3-carboxylic acid was diastereoselectively obtained 
through radical addition310 and through reductive amination.311 However, there is no single 
methodology that allows the selective asymmetric synthesis of both cis- and trans-
diastereoisomers. 
In Davies’ work it was shown that conjugate addition of homochiral lithium 4.30 to 
compound 4.31 and subsequent N-deprotection and ester hydrolysis allows an efficient 
synthesis of Cispentacin 4.16 (Scheme 4.4).312 An extension of this methodology envisaged 
that the conjugate addition of homochiral lithium (S)-N-benzyl-N-α-methylbenzylamide 
4.30 to a range of dihydrofuran-, N-protected dihydropyrrole-and dihydrothiophene--
unsaturated esters would facilitate the asymmetric synthesis of both cis- and trans-
stereoisomers of the corresponding -amino acid derivatives.303 
                                                          
307 (a) Konosu, T.; Oida, S., Chem. Pharm. Bull. 1993, 42, 1012; (b) Evans, C.; McCague, R.; Roberts, S. M.; Sutherland, A. G.; Wisdom, R., J. Chem. Soc., Perkin Trans. 1 1991, 2276-2277 
308 Tang, W.; Wu, S.; Zhang, X., J. Am. Chem. Soc. 2003, 125, 9570-9571 
309 (a) Hanselmann, R.; Zhou, J.; Ma, P.; Confalone, P. N., J. Org. Chem. 2003, 68, 8739-8741; (b) Aggareal, V. K.; Roseblade, S.; Alexander, R., Org. Biomol. Chem. 2003, 1, 684-691 
310 Miyata, O.; Muroya, K.; Kobayashi, T.; Yamanaka, R.; Kajisa, S.; Koide, J.; Naito, T., Tetrahedron 2002, 58, 4459-4479 
311 Lee, H.-S.; LePlae, P. R.; Porter, E. A.; Gellman, S. H., J. Org. Chem. 2001, 66, 3597-3599 
312 (a) Davies, S. G.; Ichihara, O.; Walters, A. S., Synlett 1993, 461-462; (b) Davies, S. G.; Ichihara, O.; Lenoir, I.; Walters, A. S., J. Chem. Soc. Perkin Trans. 1 1994, 1411-1415; for the asymmetric synthesis of derivatives of Cispentacin using kinetic resolution methodology see: (c) Bailey, S.; Davies, S. G.; Smith, A. D.; Withey, J. M., Chem. Commun. 2002, 2910-2911; (d) Davies, S. G.; Diez, D.; El Hammouni, M. M.; Garrido, N. M.; Garner, A. C.; Long, M. J. C.; Morrison, R. M.; Smith, A. D.; Sweet, M. J.; Withey, J. M., Chem. Commun. 2003, 2410-2411 
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Scheme 4.4 – Synthesis of Cispentacin 
Reagents and conditions: a) 1) 2-methylpropene, H2SO4; 2) LDA, I2; 3) DBU; b) 1) 4.30 in THF, 2) 4.32; c) H2, Pd/C; d) TFA then Dowex 50X8-200. 
The scaffold 4.24 was synthesized according to this procedure (Scheme 4.5) and the 
derivative 4.16 was converted in the building block 4.24 via Fmoc-protection of the amino 
group. In analogy to the scaffold 4.24, the synthesis of scaffold 4.25 was accomplished 
through the synthetic pathway represented in Scheme 4.5 using the correspondent (R)-
litum derivative. 
 
Scheme 4.5 – Synthesis of scaffolds 4.24 and 4.25 
Reagents and conditions: a) Isobutylene, conc. H2SO4, DCM, -78°C to r.t.; b) 1) LDA, THF, -78°C; 2) I2, THF, -78°C; 3) DBU, THF, -78°C; c) 1) 4.33, THF, -95°C to -78°C; 2) 4.34, THF, -95°C; d) 1) H2 (20 atm), Pd(OH)2 (20%), AcOH, MeOH, r.t.; 2) TFA, DCM; e) FmocOSu, NaHCO3, 1,4-dioxane:water (1:1), 0°C to r.t.. 
Cyclic peptidomimetics were synthesized through a mixed solid-phase/solution-phase 
approach (Scheme 4.6) following the example of cyclic compounds 4.14 and 4.15 
(presented in chapter 4.2). The linear precursors 4.32 and 4.33 were assembled by SPPS on 
O-chlorotritylchloride resin as solid support using a Fmoc/tBu protection strategy. The linear 
cleaved precursors (4.32 and 4.33) were cyclised under pseudo-high dilution conditions297 
to give derivatives 4.34 and 4.35. Referring to the synthesis of 4.14 and 4.15, the same 
Fmoc-ortogonal PGs were selected for the lateral chains of the amino acids. The cyclic 
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derivatives 4.34 and 4.35 were deprotected and purified by preparative HPLC (Scheme 
4.2) to give the final peptidomimetics 4.26 and 4.27. 
 
Scheme 4.6 – Synthesis of RGD-containing peptidomimetics 4.26 and 4.27 
Reagents and conditions: a) Fmoc-Gly-OH, DIPEA, DCM; b) 2% DBU, 2% piperidine, DMF; c) Fmoc-Arg(Pbf)-OH, TBTU, DIPEA, DMF; d) 2% DBU, 2% piperidine, DMF; e) Fmoc-Val-OH, TBTU, DIPEA, DMF; f) 2% DBU, 2% piperidine, DMF; g) 4.24 or 4.25, HATU, DIPEA, DMF; h) 2% DBU, 2% piperidine, DMF; i) Fmoc-Asp(OtBu)-OH, DIPEA, DCM; j) 2% DBU, 2% piperidine, DMF; k) TFA in DCM; l) TFA/Et3SiH/H2O (95%:2.5%:2.5%). 
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The attributions of 1H-NMR and 13C-NMR signals for 4.26 are reported in Table 4.2. 
 1H ( ppm) 13C ( ppm) 
NH1 7.59  
2 4.21 53.4 
3 2.09 -1.98 27.1 
4 1.80 – 1.69 21.4 
5 1.88 – 1.83 27.4 
6 2.92 47.4 
NH Val 7.59  
H Val 3.80 61.8 
H Val 2.08 28.9 
H Val 0.94 19.0 
NH Arg 8.31  
H Arg 4.22 53.4 
H Arg 1.86 – 1.80 31.1 
H Arg 1.60 25.1 
H Arg 3.18 40.8 
NH Arg 7.18  
NH Gly 8.62  
H Gly 3.86 – 3.78 44.1 
NH Asp 8.38  
H Asp 4.59 50.7 
H Asp 2.93 – 2.86 35.4 
Table 4.2 
The attributions of 1H-NMR and 13C-NMR signals for 4.27 are reported in Table 4.3. 
 1H ( ppm) 13C ( ppm) 
NH1 7.33  
2 4.29 53.4 
3 1.91 – 1.60 31.3 
4 1.78 – 1.56 22.1 
5 1.90 – 1.85 27.4 
6 3.08 46.7 
NH Val 7.92  
H Val 4.12 59.2 
H Val 2.05 30.4 
H Val 0.91 18.1 
NH Arg 9.11  
H Arg 3.86 54.4 
H Arg 1.98 – 1.81 26.4 
H Arg 1.79 – 1.58 25.9 
H Arg 3.23 – 3.17 40.6 
NH Arg 7.21  
NH Gly 8.37  
H Gly 4.14 – 3.68 43.1 
NH Asp 7.73  
H Asp 4.89 49.6 
H Asp 2.91 – 2.58 36.3 
Table 4.3 
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Also the isoDGR-containing peptidomimetics 4.28 and 4.29 were synthesized via a 
similar synthetic pathway (Scheme 4.7). Obviously, the isoDGR derivatives present some 
differences compared to the RGD-containing ones because of the use of isoAsp and 
because of the different order of linking the amino acids. The linear precursors 4.36 and 
4.37 were cyclized to give derivatives 4.38 and 4.39 and then deprotected on the lateral 
chains. Final HPLC purification gave the compounds 4.28 and 4.29 (the characterization of 
4.29 is ongoing at the moment). 
 
Scheme 4.7 – Synthesis of RGD-containing peptidomimetics 4.28 and 4.29 
Reagents and conditions: a) Fmoc-Gly-OH, DIPEA, DCM; b) 2% DBU, 2% piperidine, DMF; c) Fmoc-isoAsp(OH)-OtBu, TBTU, DIPEA, DMF; d) 2% DBU, 2% piperidine, DMF; e) Fmoc-Val-OH, TBTU, DIPEA, DMF; f) 2% DBU, 2% piperidine, DMF; g) 4.24 or 4.25, HATU, DIPEA, DMF; h) 2% DBU, 2% piperidine, DMF; i) Fmoc-Arg(Pbf)-OH, DIPEA, DCM; j) 2% DBU, 2% piperidine, DMF; k) TFA in DCM; l) TFA/Et3SiH/H2O (95% : 2.5% : 2.5%). 
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The attributions of 1H-NMR and 13C-NMR signals for 4.28 are reported in Table 4.4. 
 1H (d ppm) 13C (d ppm) 
NH1 7.92  
2 4.22 53.5 
3 1.93 – 1.82 27.1 
4 1.72 – 1.63 21.9 
5 1.72 – 1.67 27.5 
6 2.87 46.9 
NH Val 7.74  
H Val 3.75 60.7 
H Val 1.94 29.4 
H Val 0.96 – 0.91 18.9 
NH Arg 8.44  
H Arg 4.19 53.8 
H Arg 1.88 27.3 
H Arg 1.66 – 1.58 24.7 
H Arg 3.15 40.2 
NH Arg 7.14  
NH Gly 8.04  
Ha Gly 4.13 – 3.98 42.7 
NH isoAsp 8.42  
H isoAsp 4.74 50.2 
H isoAsp 2.85 – 2.73 37.7 
Table 4.4 
 
4.4 Conclusions and outlooks 
According to the biological tests, the activity and selectivity on integrins V3, V5 and 
V1 of 4.26, 4.27, 4.28 and 4.29 will be evaluated. A further conformational analysis will 
allow to better understand these binding data and, possibly, the disposition of the 
compound in the integrin binding pocket. With all these data in our hands, a comparison 
will be done with the two -ACC-RGD-containing compounds. If the results will be 
interesting, in cell studies could be performed to evaluate the agonist/antagonist activity 
of these molecule. Since the scaffold has no points suitable for a further functionalization, 
a correspondent moiety containing a N-protected group (Figure 4.15) could be inserted to 
get a cyclic peptide suitable for a conjugation step. 
 
Figure 4.15 – Cis-scaffold containing a N-protected moiety 
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4.5 Experimental section 
4.5.1 Materials and methods 
All commercially available reagents were used as received; DMF was anhydrify according 
to GP0. Non solid-phase reactions were monitored by analytical thin layer 
chromatography (TLC) using silica gel 60 F254 pre-coated glass plates (0.20 mm thickness). 
Visualization was accomplished by irradiation with a UV lamp and/or staining with a 
ninhydrin; solid phase steps was followed by LR-Mass. Visualization was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline 
solution or ninhydrin. Flash column chromatography was performed according to the 
method of Still and co-workers169 using Chromagel 60 ACC (40-63 m) silica gel. Proton 
NMR spectra were recorded on a spectrometer operating at 500 MHz. Carbon NMR 
spectra were recorded on a spectrometer operating at 125 MHz, with complete proton 
decoupling. The following abbreviations are used to describe spin multiplicity s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of doublet, 
ddd = doublet of doublet of doublet, ddt = doublet of doublet of triplet. Carbon chemical 
shifts are reported in ppm () relative to TMS with the respective solvent resonance as the 
internal standard. ESI-MS spectra were recorded on the ion trap mass spectrometer 
Finnigan LCQ Advantage. 
RP-HPLC purification 
HPLC purifications were performed on a Dionex Ultimate 3000 instrument equipped with a 
Dionex RS Variable Wavelenght Detector (column: Atlantis Prep T3 OBDTM 5 TM 19 x 100 
mm). The crude reaction mixture was dissolved in water and the solution was filtered 
(polypropylene, 0.45 m, 13 mm ø, PK/100) and injected in the HPLC, affording purified 
products. 
RP-HPLC analysis 
Purity analysis for each of the compounds was carried out on a Dionex Ultimate 3000 
instrument equipped with a Dionex RS Variable Wavelenght Detector (column: Atlantis 
Prep T3 OBDTM 5 TM 19 x 100 mm). 0.8 mg of purified product was dissolved in 0.5 mL of 
H2O and 0.3 mL of acetonitrile and was injected using gradient: 100% H2O + 0.1% 
CF3COOH/0% CH3CN + 0.1% CF3COOH to 50% H2O + 0.1% CF3COOH/50% CH3CN + 0.1% 
CF3COOH in 11 min. The analysis of the integrals and the relative percentage of purity was 
performed with the software Cromeleon 6.80 SR11 Build 3161.  
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Freeze-drying 
The product was dissolved in water and frozen with dry ice: the freeze-drying was carried 
out at least for 48 h at -50 °C using the instrument 5Pascal Lio5P DGT. 
 
4.5.2 General procedures for SPPS 
DMF anhydrification 
GP0: A flask was charged with CaH2 (around 5g/L) and DMF. The mixture was stirred at r.t. 
over night. DMF was subsequently transferred into a flask under N2 and distilled under 
reduced pressure (around 20 mBar). DMF was stored under N2 in a dark brown flask over 
molecular sieves (3Å).  
 
SPPS was manually accomplished using a shaker. Fmoc strategy and 2-chlorotritylchloride 
resin (100-200 mesh, 1% DVB; loading: 1.51 mmol/g resin) were used. Each coupling step 
consisted in: 
i) activation of the Fmoc-protected amino acid, 
ii) addition of the activated amino acid to the resin at the shaker to  
effect the coupling reaction; 
iii) following steps of capping, deprotection and washing. 
 
Resin preparation and storage 
The resin was weighted in a 10 mL vial and swelled (GP1); at the end of this operation the 
resin was ready for the SPPS. When necessary, beads were stored at 4 °C under nitrogen 
after being washed several times with DCM and dried at the high vacuum pump. 
Swelling of the resin 
GP1: The resin was weighted in a vial, suspended in DCM (approximately 10 mL per gram 
of resin) and shaken for 30 minutes. The solvent was dried from the resin and, at the end of 
this operation, the resin was ready for the SPPS. This step is repeated every times before 
starting procedures on the resin if it was previously dried under vacuum and stored at 4°C. 
 
Loading of the first amino acid and capping of the resin 
GP2: The resin was suspended in DCM (approximately 14 mL per gram of resin); Fmoc-AA-
OH (2.0 eq.) and DIPEA (0.3 eq.) were sequentially added. The resin was shaken for 10 
minutes then DIPEA (0.5 eq.) was added and the resin was shaken for 1h 30min; after this 
time the solvent was removed. The resin was washed with DCM (3 x 2 mL), then methanol 
was added (approximately 1.5 mL per gram of resin) and the resin was shaken for 15 
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minutes. The solvent was removed and the resin was washed with DCM (3 x 2 mL), DMF (3 x 
2 mL), DCM again (3 x 2 mL), and methanol (1 x 2 mL). 
 
Amino acid activation and coupling 
GP3: To a 0.14 M solution of the amino acid (1.5 eq.) in dry DMF under N2 at 0°C, TBTU (1.5 
eq. in DMF) and DIPEA (3.0 eq. in DMF) were added. The mixture was stirred under these 
conditions for 30-40 minutes and then the solution was added to the resin. The resin was 
shaken at r.t. for 3 hours then the solvent was removed. Each coupling step was performed 
twice times. After the second coupling, the resin was washed with DCM (3 x 2 mL), DMF (3 
x 2 mL), and DCM again (3 x 2 mL). 
 
Scaffold activation and coupling 
GP4: To a solution of the scaffold (1.5 eq.) in dry DMF (solution 0.14 M) under N2 at 0°C, 
HATU (1.5 eq. in DMF) and DIPEA (3.0 eq. in DMF) were added. The mixture was stirred 
under these conditions for 45 minutes and then the solution was added to the resin. The 
resin was shaken at r.t. for 7 hours then the solvent was removed. After the coupling, the 
resin was washed with DCM (3 x 2 mL), DMF (3 x 2 mL), and DCM again (3 x 2 mL). 
 
Capping procedure 
GP5: A 1M solution of Ac2O (50 eq.) and pyridine (50 eq.) in DMF (approximately 30 mL per 
gram of unsubstituted resin) was added to the resin. The mixture was shaken at r.t. for 40 
minutes then solution was removed and beads were washed with DMF (3 x 2 mL).  
 
Fmoc removal procedure 
GP6: Deprotection of the N-terminal Fmoc group was achieved using a solution of 2% DBU 
and 2% piperidine (v/v) in DMF (approximately 30 mL per gram of the unsusbstituted resin). 
The solution was added to the resin which was shaken for 15 minutes then the solution was 
removed. Two deprotection steps were carried out. At the end of each step, the solvent 
was removed. At the end of the second step, beads were sequentially washed with DMF 
(6 x 2 mL) and DCM (3 x 2 mL). 
Peptide cleavage: 
GP7: The resin was washed with DCM (3 x 2 mL) and then treated with 1% TFA in DCM (15.0 
mL for gram of the not substituted resin) for 5 minutes each time. Treatment was repeated 
as long as the peptide was cleaved from the resin (approximately 10 times), checking by 
TLC. Combined solutions were evaporated under reduced pressure and then in vacuum. 
The crude obtained was used without purification in the macrolactamization step. 
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4.5.3 General procedures for solution-phase synthesis 
Macrolactamization 
GP8: The linear precursor (1 eq.) was dissolved in dry DMF (5 mM solution) and transferred 
into a syringe. HATU (3.0 eq.) was dissolved in the same volume of dry DMF and transferred 
into a second syringe. These two solutions were added slowly using two syringe pumps to a 
stirred solution of DIPEA (6.0 eq.) and HATU (0.1 eq.) in half of the previous volume of dry 
DMF at a rate of 0.7mL/h. Once the addition was complete, the mixture was stirred for 
another 30 minutes. The solvent was evaporated under reduced pressure at a 
temperature lower than 35°C. Crude was taken up with ethyl acetate (25 mL), sequentially 
washed with a solution 1M of KHSO4, a saturated solution of NaHCO3 and brine. The 
organic layer was dried over Na2SO4 anhydrous and volatiles were removed under 
reduced pressure. The mixture was taken-up dissolved in DCM:MeOH (9:1) and filtered 
over silica gel. 
 
Side chain deprotection 
GP9: Crude fully protected macrolactam was treated for 8 h with a solution (around 21 
mL/mg of protected peptide) of TFA (95%) at room temperature in the presence of water 
(2.5%) and triisopropylsilane (2.5%). After TFA removal under reduced pressure, the residue 
was taken up with a 1:1 mixture of diethyl ether/water. Phases were separated and the 
aqueous layer was washed several times with diethyl ether. The aqueous phase was 
concentrated under reduced pressure and then the solution was freeze-dried. The crude 
was purified by preparative HPLC. 
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4.5.4 Synthesis 
4.24 and 4.25 were synthesized according to literature procedure ((a) Bunnage, M. E.; 
Davies, S. G.; Roberts, P. M.; Smith, A. D.; Withey, J. M. Org. Biomol. Chem. 2004, 2, 2763; (b) 
Davies, S. G.; Ichihara, O.; Lenoir, I.; Walters, I. A. S. J. Chem. Soc., Perkin Trans. 1 1994, 11, 
1411) and their analytical data were in agreement with those already published.  
Asp(OtBu)-(1R,2S)--ACPC-Val-Arg(Pbf)-Gly-OH (4.32) and Asp(OtBu)-(1S,2R)--ACPC-
Val-Arg(Pbf)-Gly-OH (4.33) 
 
The resin was weighed in a solid phase syringe and swelled (GP1) and Fmoc-Gly-OH was 
activated and coupled to the resin (GP2). After a capping step (GP5) and a Fmoc 
deprotection step (GP6), Fmoc-Arg(Pbf)-OH was activated and coupled to the Gly-resin 
(GP3). Then a capping a capping step (GP5) and a Fmoc deprotection step (GP6) were 
performed. Fmoc-Val-OH was activated and coupled to the Arg(Pbf)-Gly-resin (GP3); the 
coupling was followed by a capping step (GP5) and a Fmoc deprotection step (GP6). 4.24 
and 4.25 were activated and coupled to the Val-Arg(Pbf)-Gly-resin (GP4), then a capping 
step (GP5) and a Fmoc deprotection step (GP6) were performed. Fmoc-Asp(OtBu)-OH 
was activated and coupled to the 4.24-Val-Arg(Pbf)-Gly-resin (GP3) and 4.25-Val-Arg(Pbf)-
Gly-resin (GP3), then Fmoc deprotection step (GP6) was performed. The linear precursor 
was cleaved from the resin (GP7), checked by LR-Mass and used in the following steps as 
crude. The crude 4.32 (140 mg) and 4.33 (185 mg) were obtained as brown oils. 
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Exact amounts of the amino acids and coupling reagents used for SPPS are reported in 
Table 4.5 for 4.32 and in Table 4.6 for 4.33. 
Table 4.5 
Reagents Eq. or concentration mmol Amounts 
Chlorotritylchloride resin (1.51 mmol/g) 1.0 eq 0.190 130 mg 
Fmoc-Gly-OH* 2.0 eq 0.380 113 mg 
DIPEA 0.3 eq 0.057 10 µL 
DIPEA 0.5 eq 0.095 17 µL 
DCM / / 2.0 mL 
Fmoc-Arg(Pbf)-OH* 1.5 eq 0.285 185 mg 
TBTU 1.5 eq 0.285 92 mg 
DIPEA 3.0 eq 0.570 99 µL 
DMF 0.14 M / 2 mL 
Fmoc-Val-OH* 1.5 eq 0.285 97 mg 
TBTU 1.5 eq 0.285 92 mg 
DIPEA 3.0 eq 0.570 99 µL 
DMF 0.14 M / 2 mL 
4.24 1.5 eq 0.285 100 
HATU 1.5 eq 0.285 108 
DIPEA 4.0 eq 0.760 132 µL 
DMF 0.14 M / 2 mL 
Fmoc-Asp(OtBu)-OH* 1.5 eq 0.285 117 mg 
TBTU 1.5 eq 0.285 92 mg 
DIPEA 3.0 eq 0.570 99 µL 
DMF 0.14 M / 2 mL 
* a double coupling step is performed. 
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Table 4.6 
Reagents Eq. or concentration mmol Amounts 
Chlorotritylchloride resin (1.51 mmol/g) 1.0 eq 0.190 130 mg 
Fmoc-Gly-OH* 2.0 eq 0.380 113 mg 
DIPEA 0.3 eq 0.057 10 µL 
DIPEA 0.5 eq 0.095 17 µL 
DCM / / 2.0 mL 
Fmoc-Arg(Pbf)-OH* 1.5 eq 0.285 185 mg 
TBTU 1.5 eq 0.285 92 mg 
DIPEA 3.0 eq 0.570 99 µL 
DMF 0.14 M / 2 mL 
Fmoc-Val-OH* 1.5 eq 0.285 97 mg 
TBTU 1.5 eq 0.285 92 mg 
DIPEA 3.0 eq 0.570 99 µL 
DMF 0.14 M / 2 mL 
4.25 1.5 eq 0.285 100 mg 
HATU 1.5 eq 0.285 108 mg 
DIPEA 4.0 eq 0.760 132 µL 
DMF 0.14 M / 2 mL 
Fmoc-Asp(OtBu)-OH* 1.5 eq 0.285 117 mg 
TBTU 1.5 eq 0.285 92 mg 
DIPEA 3.0 eq 0.570 99 µL 
DMF 0.14 M / 2 mL 
* a double coupling step was performed. 
 Cyclo[Asp(OtBu)-(1R,2S)--ACPC-Val-Arg(Pbf)-Gly] (4.34) and Cyclo[Asp(OtBu)-(1S,2R)--
ACPC-Val-Arg(Pbf)-Gly] (4.35) 
 
Compound 4.32 or 4.33 (4.32: 140 mg crude, 0.163 mmol, considered 1.0 eq for 
stoichiometric calculations; 4.33: 185 mg crude, 0.217 mmol, considered 1.0 eq for 
stoichiometric calculations) was treated with HATU (4.32: 193, 0.489 mmol, 3.1 eq; 4.33: 252 
mg, 0.662 mmol, 3.1 eq) and DIPEA (4.32: 170 µL, 0.979 mmol, 6.0 eq; 4.33: 226 µL, 1.299 
mmol, 6.0 eq) under the conditions described in GP8. The product was obtained as pale 
yellow solid (4.34: 61 mg, crude; 4.35: 94 mg, crude). 
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Cyclo[Asp-(1R,2S)--ACPC-Val-Arg-Gly] (4.26) and Cyclo[Asp-(1S,2R)--ACPC-Val-Arg-
Gly]  (4.27) 
 
Compound 4.34 (61 mg, crude) or 4.35 (94 mg, crude) was deprotected under the 
conditions described in GP9. The crude product was purified by RP-HPLC [compound 4.26 
= gradient: 100% H2O + 0.1% CF3COOH/0% CH3CN + 0.1% CF3COOH to 50% H2O + 0.1% 
CF3COOH/50% CH3CN + 0.1% CF3COOH in 11 min; flow: 15 mL/min; compound 4.27 = 
gradient: 100% H2O + 0.1% CF3COOH/0% CH3CN + 0.1% CF3COOH to 50% H2O + 0.1% 
CF3COOH/50% CH3CN + 0.1% CF3COOH in 11 min; flow: 15 mL/min]. Pure fractions were 
concentrated and freeze-dried, affording 4.26 or 4.27 as a white solid (4.26: 11 mg, 0.017 
mmol, overall yield 9%; 4.27: 13 mg, 0.020 mmol, overall yield 10%). 
Compound 4.26: 
1H-NMR (500 MHz, D2O)  8.62 (1H), 8.38 (1H), 8.31 (1H), 7.59 (2H), 7.18 (4H), 4.59 (1H), 4.22 
(1H), 4.21 (1H), 3.86-3.78 (2H), 3.80 (1H), 3.18 (2H), 2.93-2.86 (2H), 2.92 (1H), 2.09-1.98 (2H), 
2.08 (1H), 1.88-1.83 (2H), 1.86-1.80 (2H), 1.80-1.69 (2H), 1.60 (2H), 0.94 (6H). 13C-NMR (125 
MHz, D2O)  61.8, 53.4, 53.4, 50.7, 47.4, 44.1, 40.8, 35.4, 31.1, 28.9, 27.4, 27.1, 25.1, 21.4, 19.0; 
MS (ESI) m/z calcd. for [C38H38N8O7]+: 538.2863 [M+H]+; found: 539.2944. 
 
Compound 4.27: 
1H-NMR (500 MHz, D2O)  9.11 (1H), 8.37 (1H), 7.92 (1H), 7.73 (1H), 7.33 (1H), 7.21 (4H), 4.89 
(1H), 4.29 (1H), 4.14-3.68 (2H), 4.12 (1H), 3.86 (1H), 3.23-3.17 (2H), 3.08 (1H), 2.91-2.58 (2H), 
2.05 (1H), 1.98-1.81 (2H), 1.91-1.60 (2H), 1.90-1.85 (2H), 1.79-1.58 (2H), 1.78-1.56 (2H), 0.91 
(6H). 13C-NMR (125 MHz, D2O)  59.2, 54.4, 53.4, 49.6, 46.7, 43.1, 40.6, 36.3, 31.3, 30.4, 27.4, 
26.4, 25.9, 22.1, 18.1; MS (ESI) m/z calcd. for [C38H38N8O7]+: 538.2863 [M+H]+; found: 
539.2935. 
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HPLC trace of compound 4.26 
 
HPLC purity = 99% 
 
HPLC trace of compound 4.27 
 
HPLC purity = 96% 
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Arg(Pbf)-(1R,2S)--ACPC-Val-isoAsp(OtBu)-Gly-OH (4.36) and Arg(Pbf)-(1S,2R)--ACPC-Val-isoAsp(OtBu)-Gly-OH (4.37) 
 
The resin was weighed in a solid phase syringe and swelled (GP1) and Fmoc-Gly-OH was 
activated and coupled to the resin (GP2). After a capping step (GP5) and a Fmoc 
deprotection step (GP6), Fmoc-Asp(OH)-OtBu was activated and coupled to the Gly-resin 
(GP3). Then a capping step (GP5) and a Fmoc deprotection step (GP6) were performed. 
Fmoc-Val-OH was activated and coupled to the Asp(OtBu)-Gly-resin (GP3); the coupling 
was followed by a capping step (GP5) and a Fmoc deprotection step (GP6). 4.24 and 4.25 
were activated and coupled to Val-Asp(OtBu)-Gly-resin (GP4), then a capping step (GP5) 
and a Fmoc deprotection step (GP6) were performed. Fmoc-Arg(Pbf)-OH was activated 
and coupled to 4.24-Val-Asp(OtBu)-Gly-resin (GP3) and to 4.25-Val-Asp(OtBu)-Gly-resin 
(GP3), then Fmoc deprotection step (GP6) was performed. The linear precursor was 
cleaved from the resin (GP7), checked by LR-Mass and used in the following steps as 
crude. The crude 4.36 (114 mg) and 4.37 (80 mg) was obtained as a yellow solid. 
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Exact amounts of the amino acids and coupling reagents used for SPPS are reported in 
Table 4.7 for 4.36 and in Table 4.8 for 4.37. 
Table 4.7 
Reagents Eq. or concentration mmol Amounts 
Chlorotritylchloride resin (1.51 mmol/g) 1.0 eq 0.095 65 mg 
Fmoc-Gly-OH* 2.0 eq 0.190 56 mg 
DIPEA 0.3 eq 0.029 5 µL 
DIPEA 0.5 eq 0.048 8 µL 
DCM / / 1.0 mL 
Fmoc-Asp(OH)-OtBu* 1.5 eq 0.142 58 mg 
TBTU 1.5 eq 0.142 46 mg 
DIPEA 3.0 eq 0.285 50 µL 
DMF 0.14 M / 1.0 mL 
Fmoc-Val-OH* 1.5 0.142 48 mg 
TBTU 1.5 0.142 46 mg 
DIPEA 3.0 0.142 50 µL 
DMF / / 1.0 mL 
4.24 1.5 eq 0.142 50 mg 
HATU 1.5 eq 0.142 54 mg 
DIPEA 4.0 eq 0.380 66 µL 
DMF 0.14 M / 1.0 mL 
Fmoc-Arg(Pbf)-OH* 1.5 0.142 92 mg 
TBTU 1.5 0.142 46 mg 
DIPEA 3.0 0.285 50 µL 
DMF / / 1.0 mL 
* a double coupling step is performed. 
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Table 4.8 
Reagents Eq. or concentration mmol Amounts  
Chlorotritylchloride resin (1.51 mmol/g) 1.0 eq 0.095 65 mg 
Fmoc-Gly-OH* 2.0 eq 0.190 56 mg 
DIPEA 0.3 eq 0.029 5 µL 
DIPEA 0.5 eq 0.048 8 µL 
DCM / / 1.0 mL 
Fmoc-Asp(OH)-OtBu* 1.5 eq 0.142 58 mg 
TBTU 1.5 eq 0.142 46 mg 
DIPEA 3.0 eq 0.285 50 µL 
DMF 0.14 M / 1.0 mL 
Fmoc-Val-OH* 1.5 eq 0.142 48 mg 
TBTU 1.5 eq 0.142 46 mg 
DIPEA 3.0 eq 0.285 50 µL 
DMF 0.14 M / 1.0 mL 
4.25 1.5 eq 0.142 50 mg 
HATU 1.5 eq 0.142 54 mg 
DIPEA 4.0 eq 0.380 66 µL 
DMF 0.14 M / 1.0 mL 
Fmoc-Arg(Pbf)-OH* 1.5 0.142 92 mg 
TBTU 1.5 0.142 46 mg 
DIPEA 3.0 0.285 50 µL 
DMF 0.14 M / 1.0 mL 
* a double coupling step was performed. 
 
Cyclo[Arg(Pbf)-(1R,2S)--ACPC-Val-isoAsp(OtBu)-Gly] (4.38) and Cyclo[Arg(Pbf)-(1S,2R)--
ACPC-Val-isoAsp(OtBu)-Gly] (4.39) 
 
Compound 4.36 and 4.37 (4.36: 114 mg, 0.13 mmol, considered 1.0 eq for stoichiometric 
calculations; 4.37: 80 mg, 0.093 mmol, considered 1.0 eq for stoichiometric calculations) 
were treated with HATU (4.36: 154 mg, 0.41 mmol, 3.1 eq; 4.37: 110 mg, 0.29 mmol, 3.1 eq) 
and DIPEA (4.36: 136 µL, 0.78 mmol, 6.0 eq; 4.37: 98 µL, 0.55 mmol, 6.0 eq) under the 
conditions described in GP8. The product was obtained as pale yellow solid (4.38: 70 mg, 
0.08 mmol, 0.1 eq; 4.39: 73 mg, 0.09 mmol) and it was used without purification. 
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Cyclo[Arg-(1R,2S)--ACPC-Val-isoAsp-Gly] (4.28) 
 
Compound 4.38 (70 mg, crude) was deprotected under the conditions described in GP9. 
The crude product was purified by RP-HPLC [gradient: 100% H2O + 0.1% CF3COOH/0% 
CH3CN + 0.1% CF3COOH to 50% H2O + 0.1% CF3COOH/50% CH3CN + 0.1% CF3COOH in 11 
min; flow: 15 mL/min]. Pure fractions were concentrated and freeze-dried, affording 4.28 
as a white solid (9.97 mg, 0.015 mmol, 16% overall yield). 
Compound 4.28: 
1H-NMR (500 MHz, D2O)  8.44 (1H), 8.42 (1H), 8.04 (1H), 7.92 (1H), 7.74 (1H), 7.14 (4H), 4.74 
(1H), 4.22 (1H), 4.19 (1H), 4.13-3.98 (2H), 3.75 (1H), 3.15 (2H), 2.87 (1H), 2.85-2.73 (2H), 1.94 
(1H), 1.93-1.82 (2H), 1.88 (2H), 1.72-1.67 (2H), 1.72-1.63 (2H), 1.66-1.58 (2H), 0.96-0.91 (6H). 
13C-NMR (125 MHz, D2O)  60.7, 53.8, 53.5, 50.2, 46.9, 42.7, 40.2, 37.7, 29.4, 27.5, 27.3, 27.1, 
24.7, 21.9, 18.9; MS (ESI) m/z calcd. for [C38H38N8O7]+: 538.2863 [M+H]+; found: 539.2543. 
 
HPLC trace of compound 4.28 
 
HPLC purity > 99% 
  Page 168    
Cyclo[Arg-(1R,2S)--ACPC-Val-isoAsp-Gly] (4.29) 
 
Compound 4.39 (73 mg, crude) was deprotected under the conditions described in GP9. 
The crude product was purified by RP-HPLC [gradient: 100% H2O + 0.1% CF3COOH/0% 
CH3CN + 0.1% CF3COOH to 50% H2O + 0.1% CF3COOH/50% CH3CN + 0.1% CF3COOH in 11 
min; flow: 15 mL/min]. Pure fractions were concentrated and freeze-dried, affording 6.92 
mg of a white solid. The characterization is ongoing. 
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List of abbreviations: 
AA    Amino acid 
Ac   Acetyl 
AcCN    Acetonitrile 
Ac2O   Acetic anhydride 
All    Allyl 
Amp   4-amino proline 
aq.    Aqueous solution 
Ar    Aril 
Bn    Benzyl 
Boc    tert-butoxycarbonyl 
Boc2O    di-tert-butyldicarbonate 
BOC-ON   2-(tert-buttyloxycarbonyloxymino)-2-phenylacetonitrile 
Bu   Butyl 
c-   Cyclo 
Cbz    Carboxybenzyl 
CD   Circular Dichroism 
Col.   Collagens 
calcd.   Calculated 
conc.    Concentrated 
COSY    Correlation Spectroscopy 
Co/C   Carbon-coated cobalt nanoparticles   
CuAAC  Cu(I)-catalyzed Azide-Alkyne Click chemistry 
DCC    N,N-Dicyclohexylcarbodiimide 
DCM    Dicloromethane 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene  
DEG   Diethylene glycol 
DIAD   diisopropylazadicarboxylate 
DIC    N,N'-Diisopropylcarbodiimide 
DIPEA    N,N-Diisopropylethylamine  
DKP   Diketopiperazine 
DMAP    4-Dimethylaminopyridine 
DMF    N,N-Dimethylformamide 
DMSO   Dimethylsulfoxide 
EA    Elemental analysis 
ECM   Extracellular matrix 
EDC.HCl  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
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EDT   1,2-ethanedithiol 
EGF   Epidermal growth factor 
eq.    Equivalents 
ESI    Electrospray ionization 
EtOAc   Ethyl acetate 
Fbg   Fibrinogen 
FBS   Fetal bovine serum 
Fmoc    9-Fluorenylmethyloxycarbonyl 
Fn   Fibronectin 
h    hours 
HATU  O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-hetramethyluronium 
exafluorphosphate 
HBTU    O-benzotriazole-N,N,N',N'-tetramethyl-uronium hexafluorphosphate 
HMBC   Heteronuclear multiple bond correlation 
HPLC   High performance liquid chromatography 
HR-Ms   High resolution mass 
HRTEM   High resolution transmission electron microscopy 
HSQC   Heteronuclear single quantum correlation 
HOAt    1-Hydroxy-7-azabenzotriazole 
KHMDS   Potassium hexamethyldisilazane 
LN   Laminin 
LR-Ms   Low resolution mass 
IC    Inhibitory Capacity 
iPrOH   Propan-2-ol 
IR   Infrared spectroscopy 
J    Scalar coupling constant 
KHMDS   Potassium hexamethyldisilazane 
MC   Monte Carlo statistical mechanics 
MD   Molecular dynamics 
Me    Methyl 
MeOH    Methanol 
MIDAS   Metal ion dependent site 
min    Minutes 
MNPs    Magnetic nanoparticles 
MRI    Magnetic resonance imaging 
MS   Mass spectroscopy  
Mtr   4-methoxy-2,3,6-trimethylbenzensulfonyl 
MW   Molecular weight/Microwave 
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NMR   Nuclear magnetic resonance 
NOE   Nuclear overhauser effect 
Pbf   2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PAA   Poly(acrylic acid)  
PEG   Polyethylene glycol 
PEI   Polyethyleneimine 
PET   Positron Emission Tomography 
PG   Protecting group 
Ph    Phenyl 
ppm    Part per million 
Py    Pyridine 
quant.   Quantitative 
Rf   Retention factor 
ROESY   Rotating frame NOE spectroscopy 
r.t.    Room temperature 
s   Seconds 
SD   Stochastic dynamics 
SPECT   Single-photon Emission Computed Tomography 
SPPS    Solid phase peptide synthesis 
SQUID   Superconducting quantum interference device 
TEA    Triethyl amine 
TIS    Triisopropylsilane 
TBTU    O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 
tBu   tert-butyl 
TFA    Trifluoroacetic acid 
THF   Tatrahydrofurane 
TOCSY   Total correlation spectroscopy 
tol   Toluene 
TEM   Transmission electron microscopy  
TLC   Thin-layer chromatography 
TMS   Tetramethylsilane 
UV   Ultraviolet spectroscopy 
VN   Vitronectin 
vWf   von Willebrand factor 
XRD   X-ray diffraction 
-Acc   -aminocyclopropanecarboxylic acid 
-ACPC  -aminocyclopentanecarboxylic acid 
   Chemical shift 
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Amino acids 
Amino acid Three-letter code One-letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
isoAspartic acid isoAsp iD 
 
D-amino acids are described by D-Xaa in the three-letter code and with the small letter in 
the one-letter code. Where no indication is present, amino acids have to be intended as 
L-amino acids. 
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